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ABSTRACT 
The thesis entitled "Analysis of Antihypertensive Drugs in 
Commercial Dosage Forms" is comprised of five chapters. The first 
chapter describes a general introduction of the subject matter. The 
very relevant matters include: 
• a brief discussion on drug discovery and drug development. 
• the discussion on possible impurities present in active 
pharmaceutical ingredients. 
• a brief description of various types of analytical techniques used in 
the analysis of drugs. 
• the discussion on validation strategy. The parameters required for 
validation of analytical methods are selectivity / specificity, 
linearity, range, accuracy, precision, limits of detection and 
quantitation, and robustness / ruggedness. These parameters 
have been discussed briefly. 
• a description of the classification of drugs based on 
pharmacological action on human organs and a brief discussion 
mainly on antihypertensive drugs. Finally a brief literature and 
chemical structures of the four drugs, i.e., metoprolo! tartrate, 
labetalol hydrochloride, ramipril and perindopril erbumine are 
presented. An abundant and well-composed list of references is 
given at the end of this chapter, comprises 259 citations, taken 
from the world's leading scientific journals in the field. 
The second chapter describes a simple and sensitive kinetic 
spectrophotometric method based on the oxidation of the metoproiol 
tartrate with alkaline potassium permanganate. The reaction was 
followed spectrophotometrically by measuring the rate of change of 
absorbance at 610 nm. The initial rate and fixed time (at 3 min) 
methods are utilized for constructing the calibration graphs to 
determine the concentration of the drug. The calibration graphs were 
linear in the concentration range of 1.0-6.0 ^g ml'^ for both initial 
rate and fixed time methods. The regression analysis of calibration 
data yielded the regression equations: 
log (rate) = 3.634 + 0.999 log C 
and A = 6.300 x 10"^ + 6.491 x 10"^ C 
for initial-rate and fixed time (at 3 min) methods, respectively. The 
detection limits of initial-rate and fixed time methods have been 
calculated and found to be 0.04 [ig ml"^ and 0.1 |ag m r \ respectively. 
The activation parameters such as Eg, AH*, AS* and AG* were also 
evaluated for the reaction and found to be 90.73 KJ nrior\ 88.20 KJ 
n)o\'\ 84.54 JK"^  mol'^ and -63.01 KJ mol'S respectively. 
The results were validated statistically and through recovery 
studies. The method has been successfully applied to the 
determination of metoprolol tartrate in commercial dosage forms. 
Statistical comparison of the results with the reference method 
showed excellent agreement and indicated no significant difference in 
accuracy and precision. 
In Chapter three, a validated, selective and sensitive 
spectrophotonnetric method has been developed for the determination 
of labetalol hydrochloride in commercial dosage forms. The method is 
based on the coupling reaction of positive diazonium ion of 4-
aminobenzenesulphonic acid with phenolate ion of labetalol to form a 
coloured azo compound which absorbs maximally at 395 nm. Under 
the optimized experimental conditions, the colour was stable up to 2 
h and Beer's law is obeyed in the concentration range of 0.8 - 17.6 i^ g 
ml'^ with linear regression equation of A = 4.84 xlO'^^^- 7.864 x 10'^ 
C and coefficient of correlation, r = 0.9999. The molar absorptivity 
and Sandell's sensitivity were found to be 2.87 x 10'* I mol'^ cm'^and 
0.013 i^ g cm'^ per 0.001-absorbance unit, respectively. The limits of 
detection and quantitation of the proposed method are 0,08 and 0.23 
^g m\'^, respectively. The intra day and inter day precision variation 
and accuracy of the proposed method was acceptable with low values 
of standard analytical error. The recovery results obtained by the 
proposed method in drug formulations are acceptable with mean 
percent recovery ± RSD of 99.97 ± 0.52% - 100.03 ± 0.63 %. The 
results of the proposed method are compared with those of Bilal's 
spectrophotometric method which indicated excellent agreement with 
acceptable true bias of all samples within ± 2 . 0 % . 
The fourth chapter describes a simple and sensitive 
spectrophotometric method for the determination of ramipril. The 
method is based on the reaction of the drug with l-chloro-2, 4-
dinitrobenzene (CDNB) in dimethylsulphoxide (DI^SO) at 100 ± 1°C. 
The absorbance at 420 nm was recorded as a function of time. Fixed-
time (AA) and equilibrium methods were adopted for constructing the 
calibration curves. Both the calibration curves were found to be linear 
over the concentration range of 20 - 220 |ig m l ' ^ The regression 
analysis of calibration data yielded the linear equations; A A = 6.30 
X 10'^ + 1.54 X 10"^ C and A = 3.62 xlO"^ + 6.35 x 10'^ C for fixed 
time (A A) and equilibrium methods, respectively. The limit of 
detection (LOD) for fixed time and equilibrium methods were 1.47 
and 1.05 ^g m r \ respectively. The method has been successfully 
applied to the determination of ramipril in commercial dosage forms. 
Statistical comparison of the results showed that there is no 
significant difference between the proposed methods and Abdellatef's 
spectrophotometric method. 
The last chapter describes two simple, sensitive and accurate 
spectrophotometric methods for the determination of perindopril in 
pharmaceutical preparations. Method A is based on the formation of 
ternary complex between Zn (II), eosin and the perindopril, which is 
extractable with chloroform. The absorption spectrum exhibits a band 
peaking at 510 nm. Method B is based on the interaction of drug with 
iodine in dichioromethane resulting in the formation of charge 
transfer complex which absorbs maximally at 365 nm. Beer's law was 
obeyed in the concentration range 10-200 pg ml'-^  and 10-180 pg ml'-^  
with molar absorptivity of 2.25 xlO^ and 3.71x10^ lit mol'^cm'^ for 
methods A and B, respectively. The detection limits for methods A 
and B were 0.49 and 0.90 pg mT^ respectively. The proposed 
methods have been successfully applied to the determination of 
perindopril in commercial dosage forms. The results of the proposed 
methods were compared statistically with those obtained by 
Abdellatef's spectrophotometric method. The statistical comparision 
of these results indicated that there is no significant difference 
between the methods compared in terms of accuracy and precision. 
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GENERAL INTRODUCTION 
Discovery and development of a new drug is a long, labour-demanding 
process. Recent studies [1] revealed that the average time to discover, develop and 
approve a new drug in the United States has steadily increased from 8.1 years in the 
1960s, to 14.2 years by the 1990s. The actual time may be even longer as the above 
calculation considered the starting point from chemical synthesis, thereby not 
including the time for target identification and lead finding/selection process, which 
in general takes a minimum of two more years. Typically, the whole process is 
fragmented 'Discovery', 'Development' and 'Registration' phases. 
The 'Discovery' phase, routinely three to four years, involves identification of 
new therapeutic targets, lead finding and prioritization, lead optimization and 
nomination of new chemical entities (NCEs). The 'Development' phase, the drug 
candidates are subject to preclinical testing in animals (also known as 'Phase I') for 
about two years. In addition, preliminary clinical trials in man and the subsequent 
full clinical trials (known as Phase II and III) will take a much longer time (-8.6 
years). According to DiMasi [1], the 'Registration' phase averaged around 1.8 years 
in the late 1990s. Each pharmaceutical firm has their own collection of drug 
candidates which are being allocated to different phases of the discovery and 
development process, often referred to as the 'pipeline'. Discovery scientists 
primarily focus on 'hunting' for drug candidates, whereas in Development one is 
trying to 'promote' NCEs as novel and safer commercial medicines. To ensure 
scientific and commercial success, it is critical to understand drug development 
process, (Fig 1.1) the myriad task and milestones that are vital to a comprehensive 
development plan. 
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In recent years, the International Conference on Harmonization of technical 
requirement for registration of pharmaceuticals for human use (ICH) has adopted 
scientific standards for quality control monitoring [2]. These standards are the basis 
for most regulatory guidelines, including those published by the Food and Drug 
Administration [3]. Key steps on the path include pharmaceutical analysis and 
stability studies that are required to determine and assure the identity, potency and 
purity of ingredients, as well as those formulated products. Stability testing 
facilitates the establishment of recommended storage conditions, determination of 
retest periods and definition of acceptable shelf life. These data play a key role in 
determining labeling requirements, as well as in the development and monitoring 
process. 
Stability testing is performed on drug substances and products at various 
stages of product development (Tabic 1.1). In early stages, accelerated stability 
testing (at relatively high temperatures and /or humidities) is used as a "worst ca.se" 
evaluation to determine what types of degradation products may be found after long-
term storage. In preformulation studies, interactions between excipients and the drug 
substance are studied under stress conditions to access compatibility. 
The design of a complete stability-testing programme for a drug or 
nutraceutical product is based upon an understanding of the behaviour, properties 
and stability of the drug substance or active ingredient and the experience gained 
from preformulation studies and early clinical formulations. Products are analysed at 
specific intervals to evaluate a variety of parameters, such as the identity of the 
active ingredient, potency, measurement of degradation products, dissolution time, 
physical properties and appearance. Samples from production lots of approved 
products are retained for stability testing and for comparison testing in the case of 
Table 1.1 
Chemistry, manufacturing and controls testing conducted in the drug 
development pathway 
Discovery to Phase J 
• Active pharmaceutical ingredient (API) solubility studies 
• API identification by spectroscopic analysis 
• Chromatographic purity 
• pKa determination 
• Moisture determination 
• Partitioning studies 
• Characterization studies 
• Development of chromatographic analysis of API 
• Residual solvents indentification and quantitation 
• Short-term stability of API 
• Reference standard certification 
Phase I 
• Validation of analytical methods for API and Phase 1 product 
• Stability of Phase 1 product 
• Release of Phase I clinical test materials 
Phases II and III 
• Continued analytical method refinements and validations as 
per product and process improvements 
• Release of Phase II and III clinical test materials 
• Release of product for long-term toxicology studies 
• Long-term stability programme 
• Cleaning validation support 
• Analysis of manufacturing process validation samples 
• Container/closure extractable/leachable studies 
Post Approval 
• QC release of product 
• QC release of API 
• QC release of excipients 
• Post approval stability programmes 
• Scale-up and post approval changes (SUPAC) 
product failure. Testing of retained samples alongside returned samples is the key to 
ascertaining whether the product failure was manufacturing or storage related. 
The objective of analytical testing during preclinical evaluation and Phase I 
clinical development is to evaluate the stability of the investigational formulations 
used in initial clinical trials, to obtain information needed to develop a final 
formulation and to select the most appropriate container and closure (e.g., 
compatibility studies of potential interactive effects between a drug substance and 
other components). Information from the experiments listed in Table 1.1 under 
discovery to Phase I is summarized in the investigational new drug application 
(IND) with the initiation of Phase I clinical trials. When the delivery mechanism of 
the drug is an integral part of creating the therapeutic effect and must be used in the 
Phase I trials, formulation data, container closure data and corresponding short-term 
accelerated stability data should be included in the IND prior to Phase I trials. 
Analysis studies on formulations should be underway by the end of Phase II 
and the stability protocol for study of both the drug substance and drug product 
should be defined. This will help assure that analytical chemistry data generated 
during Phase 111 are appropriate for submission. Prior to Phase I, stability of the drug 
substance and the formulation to be used must be evaluated. Impurities from the 
manufacturing and degradants that form are quantitated and tracked to ensure safety 
prior to moving into the Phase I clinical trials and continuity of material used for 
laboratory safety testing and clinical trials. 
Stability testing done during Phase 111 studies focuses on testing final 
formulations in the proposed packaging produced at the manufacturing site. It is 
recommended that the stability protocol is defined prior to the initiation of Phase III 
studies. In this regard, consideration should be given to establish appropriate linkage 
between the non-clinical and clinical batches of the drug substance and drug product 
and those of the primary stability batches in support of the proposed expiration-
dating period. Factors to be considered include the source, quality and purity of 
various components of the drug product, manufacturing process and production 
facility for the drug substance and the drug product, as well as use of same 
containers. Data obtained on tests done under controlled conditions replicating 
conditions recommended for long-term storage and slightly elevated temperatures 
are used to determine a product's shelf life and expiration dates. 
Stability testing focuses on the chemical (i.e., integrity, potency, 
degradation) and physical properties (e.g., appearance, hardness, particle size, 
solubility) of active pharmaceutical ingredients (APIs) and products. In addition, 
microbiological testing is done to ensure the substance and products maintain their 
resistance to microbial and bacterial growth. Assuring the physical/chemical 
properties and effectiveness properties of a pharmaceutical is critical for labeling 
and marketing purposes. A wide range of testing is used to evaluate and verify the 
identity, potency and availability of the API in the product (Table 1.2). Stability 
testing is done at all phases of the development, production and marketing process 
for quality control and monitoring purposes. Early in the development of the drug 
product, purposeful degradation studies are done as a means to predict possible 
degradation pathways of an API. This information is used in the validation of 
.stability indicating analytical methods and in pre-formulation studies. Degradation 
studies include stress conditions such as heat, oxidative, light, acidic conditions, 
basic conditions and heat/humidity. Testing to assure that products meet 
specifications for the presence of degradation products and impurities are usually 
intensive chromatographic separations with detection down to the 0.01% levels. 
Table 1.2 
Components of stability testing protocol 
Technical grade and manuFacturcr of drug substance and excipients 
Type. size, and number of balclies 
Type, size, and source of containers and closures 
Test parameters 
Test methods 
Acceptance criteria 
Test time points 
Test storage conditions 
Container storage orientations 
Sampling plan 
Statistical analysis approaches and evaluations 
Data presentation 
Retest or expiration dating period 
Stability commitment 
Typically, impurities and degradation products tliat are 0.1% and above need to be 
evaluated for identity and chemical structure. The level of the impurities allowed 
depends on the toxicity of the impurity and the daily dose levels of the drug. Identity 
information on the stability of a drug substance under defmed storage conditions is 
an integral part of the systematic approach to stability evaluation. Stress testing 
helps to determine the intrinsic .stability characteristics of a molecule by establishing 
degradation pathways to identify the likely degradation products and to validate the 
stability indicating power of the analytical procedures used. 
Testing is carried out on a single batch of a drug substance and includes the 
effects of temperatures in 10°C increments above the accelerated temperature test 
condition and humidity, where appropriate (e.g.. 75% or greater). In addition, one 
must evaluate oxidation and photolysis on the drug substance, plus its susceptibility 
to hydrolysis across a wide range of pll values when in solution or suspension. 
Photostability (i.e. light) testing is an integral part of stress testing. Some 
degradation pathways can be complex and, under forced conditions, decomposition 
products may be observed that are unlikely to be formed under accelerated or loiig-
term testing. This information is useftil in developing and validating suitable 
analytical methods, but may not be necessary to examine specifically for all 
degradation products if it has been demonstrated that in practice these are not 
formed. Information obtained from photostability is the key in choosing appropriate 
container/ closure system. 
In general, all dosage forms are evaluated for appearance, assay and 
degradation products. Additional tests (i.e., potency) are needed for specific dosage 
forms. For example, sterility is needed for sterile products but not for tablets or 
capsules. In addition, not every test will be performed at each time point. 
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Safety and efficacy are two fundamental issues of importance in drug therapy. 
The safety of drug is determined by its pharmacological-toxicological profile as well 
as the adverse effects caused by the impurities in bulk and dosage forms. 
Impurities in pharmaceuticals are the unwanted chemicals that remain with the 
active pharmaceutical ingredients (APIs), or develop during formulation, or upon 
aging of both API and formulated APIs to medicines. The presence of these 
unwanted chemicals even in small amounts may influence the efficacy and safety of 
the pharmaceutical products. Impurity profiling (i.e. the identity as well as the 
quantity of impurity in the pharmaceuticals) is now getting important critical 
attention from regulatory authorities. 
Medicines are the formulated forms of active pharmaceutical ingredients. 
There are two types of impurities in medicines: 
(1) Impurities associated with active pharmaceutical ingredients and 
(2) Impurities that are created during formulation and or with aging or that are 
related to the formulated forms. 
Impurities associated with APIs 
According to ICH guidelines [4], impurities associated with APIs are classified into 
the following categories: 
• Organic impurities (Process and drug-related) 
• Inorganic impurities 
• Residual solvents 
Organic impurities 
Organic impurities may arise during the manufacturing process and/ or storage 
of the drug substances. They may be identified or unidentified, volatile or non-
volatile, and include the following: 
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Starting materials or intermediates - These are the most common impurities found in 
every APIs unless a proper care is taken in every step involved throughout the multi-
step synthesis. Although the end products are always washed with solvents, there are 
always chances of having the residual unreacted starting materials may remain 
unless the manufacturers are very careful about the impurities. 
By-products - In synthetic organic chemistry, getting a single end product with 100% 
yield is very rare; there is always a chance of having by-products. 
Degradation products - Impurities can also be formed by degradation of the end 
product during manufacturing of bulk drugs. However, degradation products 
resulting from storage or formulation to different dosage forms or aging are common 
impurities in the medicines. 
Reagents, ligands, and catalysts - These chemicals are less commonly found in APIs; 
however, in some cases they may pose a problem as impurities. 
In general, an individual API may contain all of the above- mentioned types of 
organic impurities at levels varying from negligible to significant. 
Enantiomeric impurities - The single enantiomeric form of a chiral drug is now 
considered as an improved chemical entity that may offer a better pharmacological 
profile and an increased therapeutic index with more favourable adverse reaction 
profile [5]. In any case, cost benefits as well as the patient's compliance need to be 
considered in selecting drugs. For the manufacturers of single enantiomeric drug 
(eutomer), the undesirable stereoisomers in drug control are considered in the same 
manner as other organic impurities. 
Inorganic impurities 
Inorganic impurities may also derive from the manufacturing processes used 
for bulk drugs, They are normally known and identified and include the following: 
Reagents, ligands, and catalysts - The chances of having these impurities are rare; 
however in some processes, this could create a problem unless the manufactures take 
proper care during production. 
Heavy metals - The main sources of heavy metals are the water in the processes and 
the reactors (if stainless steel reactors are used), where acidification or acid 
hydrolysis takes place. These impurities of heavy metals can easily be avoided using 
demineralized water and glass- lined reactors. 
Other materials (e.g. filter aids, charcoal) - The filters or filtering aids such as 
centrifuge bags are routinely used in the bulk drugs manufacturing plants, and, in 
many cases, activated carbon is also used. The regular monitoring of fibers and 
black particles in the bulk drugs is essential to avoid these contaminafions. 
Solvent residues 
Residua! solvents are organic volatile chemicals used during manufacturing 
process or generated during the production. It is very difficult to remove these 
solvents completely by the work- up process; however, efforts should be taken to the 
extent possible to meet the safety data. Some solvents that are known to cause 
toxicity should be avoided in the production of bulk drugs. Depending on the 
possible risk to human health, residual solvents are divided into three classes [6]. 
Solvents such as benzene (Class I, 2 ppm limit) and carbon tetrachloride (Class I, 4 
ppm limit) are to be avoided. On the other hand, the most commonly used solvents 
such as methylene chloride (600 ppm), N, N- dimethyl formamide (880 ppm limit) 
and acetonitrile (410 ppm limit) are of Class II. Class III solvents (acetic acid, 
acetone, isopropyl alcohol, butanol, ethanol and ethyl acetate) have permitted daily 
exposures of 50 mg or less per day. In this regard, ICH guidelines [6] for limits 
should be strictly followed. 
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Control is more important today than ever. Until the beginning of the 20"^  
century drug products were produced and sold having no imposed control. Quality 
was generally poor. Many products were patent medicines of dubious value. Some 
were harmful and addictive. In 1937, elhyicnc glycol was used as vehicle for an 
elixir of sulphanilamide, which caused more than 100 deaths [7]. Thereupon the 
Food, Drug and Cosmetic act was revised requiring advance proofs of safety and 
various other controls for new drugs. The impurities to be considered for new drugs 
are listed in regulatory documents of the Food and Drug Administration (FDA) [8], 
International Conference on Harmonization of technical requirement for registration 
of pharmaceuticals for human use (ICH) [9, 10] and United States Pharmacopoeia 
(USP) [11]. Nevertheless, there are many drugs in existence, which have not studied 
in such detail. The USP and National Formulary (NF) are the recognized standards 
for potency and purity of new drugs. These compendia have become official upon 
adoption of first food and drug act. They formulate legal standards of quality, purity 
and strength of new drugs. The good manufacturing practices provide minimum 
quality standards for production of pharmaceutical as well as their ingredients [12]. 
The ICH, which took place in Yokohoma, Japan in 1995, has released new 
guidelines on impurities in new drug products [13]. These guidelines have number 
of advantages., both for industry and regulators. The most critical aspects of the 
elaboration of the guidelines were the definition of the levels of the impurities for 
identification and qualification (Table 1.3). 
Qualification is the process of acquiring and evaluating data for establishing the 
biological safety of an individual impurity or a given impurity profile at the levels 
specified. The level of any impurity present in a new drug substance that has been 
adequately tested in safety and clinical studies is considered qualified. A rationale 
14 
Table 1.3 
ICH guidelines for identification and qualification of impurities in bulk drugs 
and formulations 
Dose 
< 1 mg 
1- lOing 
10- 100 mj 
100-2 g 
>2g 
Threshold for 
Identification (%) 
1.0 
0.5 
0.2 
0.1 
0.1 
Qualification (%) 
1.0 
1.0 
0,5 
0.2 
0,1 
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for selecting impurity limits based on safety consideration has to be provided. The 
"Decision tree for safety studies" (Fig. 1,2) describes the considerations for the 
qualification of impurities when threshold are exceeded. This has some consequence 
for method development. 
The monitoring of in-process impurities was an obscure and unidentified about 20 
years ago. Now it has become a major factor in modern pharmaceutical industry. 
This is mainly the pressure of product quality and the demand for higher standards 
of process reliability. Toxicological issues have also brought about a greater 
sensitivity to the significance of impurities at trace levels [14]. New attention has 
been given to the various classes of toxicants present as impurities in pharmaceutical 
products. In view of these changes it has become necessary to pay more attention to 
the origins and pathways of a host of impurities within the process. Frequently, 
impurities are formed as isomers of the desired reaction products and a critical 
impurity can often enter with the feed. Analytical recognition of the problematic 
16 
Decrease 
degradation 
products level below 
threshold 
Yes Above threshold 
No 
No Oualified 
Yes 
Structure elucidated ? 
Yes 
Yes 
Toxicity documented and 
sufficient? 
No 
Related to others with 
known toxicity Yes Acceptable justification? 
No 
No 
Consider patient 
population and 
duration of use 
Yes 
Oualified 
Consider need for: 
1- Genotoxicity studies (point mutation, chromosomal aberration) 
2- General toxicity studies (one species, min.14 days, max. 90 days) 
3- Other specific toxicity end point, as appropriate 
Adverse effects 
Yes, 
Consider additional 
testing or removal / 
lowering level of 
degradation 
products 
Fig. 1.2. ICH decision tree for safety studies 
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ANALYTICAL TECHNIQUES 
From the beginnings of official pharmaceutical analysis, the aim of including 
assay methods in compendial monographs has been to characterise the quality of 
bulk drug materials by setting limits for their active ingredient content. The 
analytical techniques used in drug analysis are given in Table 1.4, based on the 
recent editions of European [17] and US [18] Pharmacopoeias. 
Titrimetric methods 
It is apparent from Table 1.4 that in the majority of cases the titrimetric 
methods are still used, especially in European Pharmacopoeia. Advantages of these 
methods are saving time and labour, high precision and the fact that there is no need 
of using reference standards. Non- aquous titration methods are frequently used in 
drug analysis, which can be extended to weak acids and bases. In majority of the 
cases, the end point is detected potentiometrically and thus, improving the precision 
of the method. In the case of titrimetric methods the lower and upper limhs of assay 
are usually 98.0 - 99.0% and 100.5 - 102.0%, respectively (most typically 99.0-
101.0%)). Recently, titrimetric methods have been used for the determination of 
captopril [19], gatifloxacin [20], promethazine theodate [21] and nizatidine [22] in 
commercial dosage forms. 
High performance liquid chromatography 
High performance liquid chromatography (HPLC) is widely used both in drug 
research and development and also pharmaceutical manufacture. Applications in 
research and development include purity control of new drug syntheses, separation 
of products during stability testing of drugs and formulations, and pharmacokinetics, 
i.e. the determination of drugs and metabolites in biological fluids during 
metabolism and clinical investigations. In pharmaceutical manufacture, HPLC is 
Table 1.4 
Proportion of various analytical methods prescribed for the assay of bulk drug 
materials in Ph. Eur. 4 [17] and USP XXVII [18] 
Method Ph. Eur. 4 USP 27 
_!%) (%) 
HPLC 15.5% 44% 
GC 2 % 2.5 % 
Titration 69.5 % 40.5 % 
Acid-base 57.5 % 29.5 % 
Aqueous mixtures 2 1 % 5.5% 
Indicator 6.5 % 4.5 % 
Potentiometric 14.5 % 1 % 
Non-aqueous 36.5 % 24 % 
Indicator 9.5% 14% 
Potentiometric 27% 10% 
Redox (lodometry, Nitritometry, etc.) 6.5 % 5.5 % 
Other (complexometry, argentometry, etc.) 5.5 % 5.5 % 
UV-vis spectrophotometry 9.5 % 8.5 % 
Microbiological assay (antibiotics) 3 % 2.5 % 
Others (IR, NMR, polaremetry, fluorimetry, atomic 0.5%) 2 % 
absorption spectroscopy, polarography, gravimetry etc.) 
widely used in the quality control of both raw materials and finished dosage forms, 
with pharmacopoeial monographs now containing several HPLC assay procedures. 
It is evident from Table 1.4; HPLC has become the predominant method in US? 
XXVII [18] and- although to a lesser extent - it is one of the most widely used 
methods also in European Pharmacopoeia [17]. 
The problematic points of using specific HPLC methods for the assay of bulk 
drug materials were probably taken into consideration by the European 
Pharmacopoeia Commission when they summarized their approach regarding this 
matter as follows: " Specificity of assays: For elaboration of monographs on 
chemical substances, the approach generally preferred by the Commission is to 
provide control of impurities via a well designed Test section rather than by 
inclusion of an assay that is specific for the active moiety. It is, therefore, the full set 
of requirements of monograph that is designed to ensure that the product is of 
suitable quality" [17]. Table 1.4 reflects the differences between the approaches of 
the European and US Pharmacopoeias: while in USP XXVII the proportion of 
specific HPLC (+GC) methods is 46.5%, the same figure in European 
Pharmacopoeia is only 17.5%. 
Methods based on gradient reversed- phase conditions are found to be very 
popular for analyzing cardiovascular and antihypertensive agents. However, the 
isocratic conditions for separation of nitrendipine and its impurities of reaction 
partners and by-products (methyl-3-amino crotonate, 2-ethyl-2- (nitro-benzylidene) 
acetoacetate, l,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic 
acid diethyl ester and l,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-
pyridinedicarboxylic acid dimethyl ester) on a Lichrosorb RP-185 [im (25 cm x 4 
mm i.d.) methanol- water (70:30) as adjusted to pH 3 with H3PO4 and detection at 
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238 nm were also reported [23]. Ramipril [CAS No.8733-19-5] is one of the several 
angiotensin-converting enzyme inhibitors, which is used as a prodrug for regulating 
of hypertension. The structure of ramipril is similar to that of a proline containing 
natural peptide. Till 1999, methods describing the determination of related 
substances of ramipril are not listed in USP or Eur Ph. Quite recently, Hogan et al. 
have developed and validated a reversed-phase HPLC method for separation of 
related substances of ramipril in Altace capsules using an ion-pairing reagent and a 
simple two step gradient in a 40 min run time [24]. 
The usefulness of HPLC is enhanced when it is coupled with mass 
spectrometry: a HPLC / time of flight MS method was developed for screening 
anabolic steroids in illegal cocktails [25]. A rapid and sensitive HPLC-MS method 
was used for the determination of ramipril and ramiprilat in human serum using 
enalapril as an internal standard [26]. The assay linearities of ramipril and ramiprilat 
were found over the range 0.10 - 100.0 ng ml"' and 0.25 - 100 ng ml"', respectively. 
The hyphenated techniques [27] such as LC-MS and LC-NMR have been employed 
to identify drug degradation products in pharmaceutical development. Barret et. al. 
[28] have reported a validated HPLC-MS/MS method for simultaneous 
determination of simvastatin and simvastatin hydroxy acid in human plasma. HPLC-
MS is an excellent tool for estimating minor components under overlapping peaks, 
e.g. the identification and quantitation of as low as 0.01% prednisolone in 
hydrocortisone [29]. On- line HPLC-NMR, although only few data are available for 
its use in pharmaceutical anaysis, is certainly the method for the future even in this 
field. For example, using this technique estradiol and norethisterone acetate was 
detected in a galenic emulsion [30]. The structure elucidation of impurities in 
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fluticasone propionate is a good example for the application of on-line HPLC-NMR 
[31]. 
Gas chromatography 
Gas chromatography (GC) is based on the volatilized sample transported by 
the carrier gas as the moving phase through the stationary phase of the column 
where separation takes place by the sorption/desorption process. Samples for gas 
chromatographic analysis are normally low molecular weight compounds that are 
volatile and stable at high temperature. In this respect, residual solvents in drug 
substances and drug products are suitable for gas chromatographic analysis. 
Chemical derivatives can also be formed to achieve volatility and thermal stability. 
Due to insufficient volatility and thermal stability of the majority of drug 
materials, gas chromatography can also be used for their assay in a limited number 
of cases only, as reflected by the figures in Table 1.4. 
The main application of GC [32] in the determination of impurities in drugs is 
the determination of solvent residues [33]. GC is the method of choice for the 
determination of volatile, toxic impurities such as N,N- dimethylaniline in 
antibiotics [34], 4-chlorophenol in clofibrate [34], and 2,3,7,8- tetrachlorodibenzo-p-
dioxin (down to 2 ppb) in hexachlorophene [34]. GC can be used for the 
determination of the synthesis-related impurity dicyclohexylurea in peptides [35]. Of 
the limited number of drugs for which GC is prescribed in the pharmacopoeias to 
determine their related impurities, biperiden hydrochloride [36], captopril and 
griseofulvin [36] clioquinol [37] are mentioned. The case of the purity tests of 
desogestrel (13 (3- ethyl-11-methylene-18,19-dinor-17 a-pregen-4-en-20-yn-17-ol) 
merits a special mention. 
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In addition to these, a number of papers have been published on the 
applications of gas chromatography in pharmaceutical analysis both in dosage forms 
and biologicalfluids [38-41]. 
GC-MS is an ideal tool for screening purposes. The perindopril and its active 
free metabolite have been determined after derivatization [42]. GC-MS has been 
utilized for simultaneous determination of formic acid and formaldehyde in 
pharmaceutical excipients [43]. GC-MS method [44] was also developed for the 
determination of 21 different neutral and weakly basic drugs belonging to several 
different medicinal classes like antiphlogistics, beta- blockers, P2-
sympathomimetics, lipid regulators, antiepileptic agents, psychiatric drugs and 
vasodialators. The possibility to enhance the applicability of GC and GC-MS in 
some of the thermally labile compounds is "supersonic GC-MS" using shorter 
capillaries with lower film thickness, an increased carrier gas flow rate and a 
decreased temperature. This technique was used to determine several steroids [45]. 
Thin layer chromatography 
The invention and rapid spread of thin layer chromatography (TLC) in the 
1960s created an entirely new situation in the field of drug analysis. The reasons for 
this are as follows; 
(1) The method enables the detection, separation, identification and quantitative 
determination of organic impurities, which were up to that time not measurable. 
(2) The selective chromatographic method was found to be suitable for the reliable 
determination of also the main component. 
TLC has been used for screening unknown materials in bulk drugs [46]. It 
provides a relatively high degree of assurance that all possible components of drug 
are separated. However, its application to bulk drugs is limited owing to the 
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problems involved in detection systems. This technique has also been used to 
analyse polymyxin B, framycetin, and dexamethasone in an ointment [47] and the 
contents of drotaverine and nifuroxazide in capsules [48]. 
High performance thin layer chromatography 
Now a days high performance thin layer chromatography (HPTLC) is 
becoming a routine analytical technique due to its advantages of low operating cost, 
high sample throughput and need for minimum sample clean up. The major 
advantage of HPTLC is that several samples can be run simultaneously using a small 
quantity of mobile phase unlike HPLC, thus lowering analysis time and cost per 
analysis. 
HPTLC has been used for the determination of a number of drugs in 
pharmaceutical preparations [49-52]. However, the impurities detected by HPTLC 
are limited to 0.1%. 
Capillary electrophoresis 
The advent of fully automated commercially available capillary 
electrophoresis (CE) systems has presented the pharmaceutical analyst with a new 
and viable analytical alternative to HPLC and TLC. The modern CE instruments are 
capable of the required sensitivity and precision, approaching that of HPLC. 
Autosamplers and on-line detection allow simultaneous assay of the main 
component and related impurities by CE, which is not a feature of TLC. 
As in HPLC, there are distinct operational modes for CE and these are 
appropriate to specific drugs and drug classes. For instance free- solution CE 
(FSCE) using low pH electrolytes is appropriate for water- soluble basic drugs 
whilst FSCE with high pH (pH 7-10) electrolytes is appropriate for water-soluble 
acidic compounds. The chromatographic-type CE technique of micellar 
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electrokinetic capillary chromatography (MECC) is applicable to all drug types 
including neutral and v/ater- insoluble drugs. 
A number of papers have appeared on the use of CE for the determination of 
drug impurities due to the advent of highly automated and sensitive capillary 
electrophoresis systems. Many pharmaceutical companies are investing heavily in 
capillary electrophoresis as this is viewed as a highly complementary technique to 
HPLC and the two techniques are often used in combination when assessing drug 
purity. The separation mechanisms are widely different in HPLC and CE; being 
partitioning and mobility differences, respectively. Therefore, a good agreement 
between HPLC and CE results strongly supports a comprehensive evaluation of 
sample's purity, 
CE can have considerable benefits for analysis of related impurities. Table 1.5 
shows a comparison of CE, HPLC and TLC. Specific points from the table are 
discussed below. 
Combination of HPLC, TLC and CE give widely differing selectivities and 
present a good overall assessment of product purity. Preconditioning of CE 
capillaries is relatively rapid and is in the order of 2 - 3 min. Often a single capillary 
can be used to analyse a range of different compounds, which are separated using 
similar electrolytes. Preparation of mobile phase for TLC and HPLC can be a time-
consuming daily task whilst CE electrolyte can be pre-prepared and stored for three 
months in many cases. As in HPLC, the use of short columns can considerably 
reduce analysis time. The typical CE capillary length is 40 - 60 cm. Reducing this to 
20 - 25 cm dramatically reduces analysis time as the field strength (V / cm) is 
increased whilst the distance along the capillary to the detector is considerably 
shortened. Some resolution is lost [53] but the short capillary gives a good 
Table 1.5 
Comparison of HPLC, CE and TLC 
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Sensitivity 
Precision at low levels 
Low UV wavelength detection 
Indirect UV detection 
Preparative isolation 
Running cost 
Sample preparation needs 
Main peak assay 
Automation 
Robustness 
Analysis time (1-5 samples) 
Analysis time (5-50 samples) 
Column etc. costs 
Experience 
Selectivity 
HPLC 
+++ 
+++ 
+ 
-
++ 
+ 
++ 
+++ 
+++ 
++ 
+ 
++ 
+ 
+++ 
++ 
CE 
++ 
++ 
+++ 
++ 
-
+++ 
++ 
++ 
++ 
++ 
++ 
++ 
+++ 
+ 
++ 
TLC 
++ 
+ 
+ 
-
++ 
+ 
++ 
-
+ 
++ 
+ 
++ 
+ 
+ 
++ 
Key: - poor, + acceptable; ++ good; +++ excellent 
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indication of purity and would be useful as a quality control type analysis or an in-
process check. 
The capillary format makes operation robust to the nature of the sample matrix 
and composition. The capillary can be rinsed with acid and / or base between 
injections to remove unquantified sample components. Strongly retained sample 
constituents on HPLC may require use of gradients or extensive analysis times. For 
example, ranitidine impurities have been determined [54] in syrup formulations 
where the samples are simply diluted with water and analysed at low pH. Under 
acidic conditions ranitidine and its impurities are protonated and migrate along the 
capillary, the excipients are uncharged and are removed from the capillary by 
incorporating a rinse step between injections. Also, operation at low UV 
wavelengths allows direct monitoring of compounds and impurities having only 
limited chromophores. This possibility can eliminate [55] the time-consuming need 
to derivatise samples. 
The methods generally employ aqueous buffer systems with daily buffer 
requirements of ca. 20 ml. This compares very favourably [56] to the cost of 
purchase and disposal of the quantities of organic solvents employed in HPLC. 
Capillaries are generally plain fused silica and cost a fraction of that of an HPLC 
column. Since the selectivity is independent of the capillary, method transfer is 
easier as highlighted by a series of successful inter-company method transfer 
exercises [57-59]. 
A recent survey [60] of a number of pharmaceutical companies in both the UK 
and US showed that determination of drug impurities constituted 24% of the 
workload of CE within pharmaceutical companies. The survey also indicated [60] 
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that CE method had been successfully included in the marketing submissions to 
regulatory authorities. 
The majority of attention within the literature has been paid to the purity 
testing of batches of drug substances such as domperidone [61], hydrochlorothiazide 
[62] and salbutamol [63]. Levels of related impurities have also been established in 
pharmaceutical formulations containing various drugs including atenolol [64], 
codeine [65], diltiazem [66] and sumatriptan [67]. 
Analysis of both stored drug substances and formulations constitute a 
considerable workload within pharmaceutical analysis laboratories. A number of 
stability indicating CE methods have been reported and applied [62, 68] to both 
stored drug substance and various formulations. 
Capillary electrochromatography 
Capillary electrochromatography (CEC), which can be considered to be the 
combination of RP-HPLC and CE, has been successfully applied to separation and 
quantitation of drugs. The performance of HPLC and CEC was compared using six 
steroids (androst-4-ene-3, 17- dione, testosterone, progesterone and the 11 -OH and 
20 -OH derivative of the latter). Higher peak efficiencies were obtainable by CEC 
[69]. The very promising possibilities of the new technique CEC-MS have been 
reviewed with several examples from steroid drugs [70]. The identification of 
impurities in fluticasone propionate [71] and the combination of CEC with 
nanospray MS with detection limits of 50 fg for corticosteroids merit special 
attention [72]. 
Flow injection analysis 
Laboratory automation was initiated in the second half of the XX century. 
Steward in the US as well as Ruzicka and Hansen in Denmark, created the flow 
28 
injection analysis (FIA) technique for the automation of chemical procedures [73, 
74]. 
The flov^ injection analysis (FIA) involves injection of a measured amount of 
liquid sample into a moving, nonsegmented stream of reagent. As the injected 
sample plus reagent carrier proceeds down a narrow tube, propelled by a constant 
flow pump, the sample develops a coloured species, which is detected by a flow-
through photodetector or a spectrophotometer equipped with tlow-through cells. The 
signal generated by a coloured species is a sharp peak with a trailing edge. The 
height of the peak is proportional to the concentration of analyte. 
Following the general application of computers in the routine laboratory, a 
second generation of flow analysis was proposed by Ruzicka and Marshall in 1990, 
designated sequential injection analysis (SIA) [75]. As with the FIA, this is a non-
segmented continuous flow technique based on the same principles of controlled 
dispersion and reproducible manipulation of the FIA concept, but whose mode of 
functioning is based on the concept of programmable flow. 
The FIA technique has lent an important contribution to the development of 
automation in pharmaceutical analysis and its advantages are well documented in 
several review articles [76 - 81] as well as in a specialized monograph [82]. 
The introduction of SIA has awakened the interest of the scientific community 
for automation in the pharmaceutical area [83]. Table 1.6 [84 - 97] shows that many 
articles dedicated to pharmaceutical analysis have been published, applying 
sequential analysis to a wide variety of matrices, such as solid matrices (tablets, 
capsules), pastes (ointments, creams), liquids (emulsions, suspensions, solutions) 
and covering various active ingredients with different therapeutic activities. By 
benefiting from the advantages in the economy of reagents and the elevated 
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sampling rates, the majority of the applications are dedicated to the determination of 
active ingredients for quality control in pharmaceutical formulations. 
Electrochemical methods 
Voltammetry can be carried out using commercially available polarographic 
instruments employing the classical polagraphic method (DC polarography) as well 
as pusle methods (e.g. DPP). Modern voltammetric instruments with automatic 
timing of the individual operations are useful for controlling the individual steps in 
adsorptive stripping voltammetry measurements (accumulation time, solution 
stirring, rest period, initiation of polarization); a computerized instrument is useful 
for this purpose. Square- wave voltammetry (SWV) has become more widely 
accessible. Applications of polarography and/or voltammetry in analysis of drugs 
have been reviewed in many citations [98 - 102]. In drug analysis, adsorptive 
stripping voltammetry (Ad SV) is popular because of the low limit of determination 
(reaching few ppb concentration), its accuracy and precision, as well as the low cost 
of instrumentation relative to other analytical methods of analysis. Table 1.7 [103-
111] shows the use of voltammetric methods for the determination of drugs. 
UV-Visible spectrophotometry 
Another group of methods in pharmacopoeias are spectrophotometric methods 
based on natural UV-VIS absorption and visual (VIS) spectrophotometric methods 
based on chemical reactions such as: 
• complex-formation reaction 
• oxidation-reduction process 
• a catalytic effect 
The advantages associated with these methods are low time and labour 
consumption as well as good precision. It is worth mentioning that colorimetric 
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Table 1.7 
Voltammetric 
Drugs 
Nifidipine 
Isoxsuprine, 
Fenoterol 
Doxazosin 
Lacidipine 
Indapamide 
Dopamine 
Dopamine 
Dopamine 
Dopamine 
: analysis of drugs 
Medium 
pHl.5 
BR, buffer 
pH 6.8 
BR buffer, 
pH6.0 
pH4.0 
-
pH7.4 
Physiologi 
cal buffer 
-
Method 
LSV, CV 
DCP, 
DPP, ACP 
AdSV, 
SWV 
DPV 
DPV,ASV 
CV, FIA 
AdSV 
AdSV 
LSV 
Working 
electrode 
GCE 
Hg 
MCPE 
GCE 
MCPE 
Carbon-fibre 
microelectrodes 
Grapliite carbon 
fibre 
microelectrode 
Rotating dislc 
GCE 
AuME 
DL 
-
0.02,0.01 
Mgml"' 
0.233 ppm 
3.52 ^M 
5nM 
-
• 
Down to 
10 nM 
-
References 
[103] 
[104] 
[105] 
[106] 
[107] 
[108] 
[109] 
[110] 
[111] 
Abbreviations: 
MCPE = modified carbon paste electrode, 
GCE = glassy carbon electrode, 
CV - cyclic voltammetry, 
LSV = linear sweep voltammetry, 
DCP = direct current polarography, 
ACP = alternating current polarography, 
DPP = differenfial pulsepolarography, 
AdSV= adsorptive stripping voltammetry, 
SWV = squarewave voltammetry, 
DPV = differential pulse voltammetry, 
ASV = anodic stripping voltammetry, 
FIA= flow injection analysis, 
BR = Britton- Robinson buffer 
DL = detection limit. 
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methods based on chemical reactions are still in use for the assay of bulk drug 
materials. For example, the blue tetrazolium assay was very popular in the 1950s 
and 1960s for the assay of corticosteroid drug formulations, moreover in their 
bioassay [112, 113]. However, this method is used for the assay of several bulk 
corticosteroids in the recent edition of US Pharmacopoeia (<351> "Assay for 
steroids" [18]). Representative examples of UV-visible methods of drug analysis for 
some pharmaceuticals that have been published [114-157] are given in Table 1.8. 
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Table 1.8 
Quantitative analysis of drugs in pharmaceutical formulations by UV-visible 
spectrophotonietric procedures 
Name of drug Reagents used I, max (nm) References 
Acetoaminopheii 
Amiodarone 
hydrchloride 
Amlodipine besylate 
Amoxycillin & 
ampiciilin 
Ampiciliin, amoxycillin 
& carbenicillin 
Ascorbic acid 
Benidipine hydrchloride 
Diclofenac sodium 
Diltiazem hydrchloride 
Famotidine 
Flunarizine 
dihydrochioride 
Irbesartan 
Lisinopril 
m-Cresol 
p-Chlorani)ic acid 
2,3-Dichloro 5,6- dicyano 1,4-
benzoquinone 
p-Chloranilic acid 
Ninhydrin in DMF medium 
2,3-Dichloro 5,6- dicyano 1,4-
benzoquinone 
Ascorbic acid 
Potassium lodate 
Folin ciocalteau phenol 
1 -Ch loro-2,4-d in itrobenzene 
Methanol 
Tris buffer 
Sodium metavanadate 
Bromothymol blue 
Bromophenoi blue 
Bromocresol green 
KMn04 in alkaline medium 
Ninhydrin 
Iodine 
640 
535 
575 
540 
595 
580 
530 
520 
750,770 
&750 
380 
238 
2S4, 305 
750 
415 
415 
415 
610 
590 
295,355 
114 
115 
115 
116 
117 
118 
118 
119 
120 
121 
122 
123 
124 
125 
125 
125 
126 
127 
128 
Potassium iodate and iodide in 
aqueous medium 
7,7,8,8-
tetracyanoquinodimethane 
p-Chloranilic acid 
Ninhydrin 
Ascorbic acid 
352 
743 
129 
130 
525 
595 
530 
130 
131 
131 
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Labetalol hydrchloride 
Losartan potassium 
Levodopa 
Methyldopa 
L-dopa 
Menadione 
Metoprolol tartrate 
Mometasone furcate 
Nalidixic acid 
Nicorandil 
Nifedipine 
Norfloxacin 
Carbinoxamine 
Pantoprazole sodium 
Perindopril erbumine 
Ramipril 
Roxatidine acetate 
hydrochloride 
Silymarin 
Sodium nitroprusside & 
hydroxylamine hydrochloride 
KMn04 in alkaline medium 
Ce(IV) nitrate in H2SO4 medium 
Ce(IV) nitrate in H2SO4 medium 
NaOH 
NaOH in the presence of amine 
Ninhydrin 
Methanol 
Persulfate in alkaline medium 
Brucine-sulfanilic acid in H2SO4 
medium 
3-Methyl-2-benzothiazoline 
hydrazone HCl-metol 
KMn04 in neutral medium 
4-Methyl amino phenol and 
K2Cr207 
Bromocresol green 
Bromophenol blue 
Bromothymol blue 
Eriochrome Black T 
KOH in dimethylsulphoxide 
Ammonium molybdate 
KMn04 in alkaline medium 
Cu (II) & eosin 
Potassium ferricyanide and 
Ammonium ferric sulfate 
l-Chloro-2,4-dinitrobenzene in 
dimethyl sulfoxide 
Potassium iodate and potassium 
iodide in aquous medium 
2,3-Dichloro-5,6-dicyano-l ,4-
benzoquinone 
p-Chloranilic acid 
KMn04 in neutral medium 
3-Methyl-2-benzothiazoline 
695 
/ • ' '"• 
603 
510 
550 
300 
450 
595 
248 
320,390 
410 
560 
530 
525 
415 
415 
415 
520 
430 
830 
603 
538 
725 
420 
352 
530 
530 
530 
430 
132 
133 
134 
134 
135 
136 
137 
138 
139 
140 
140 
141 
142 
143 
143 
143 
143 
144 
144 
145 
146 
147 
148 
149 
150 
150 
151 
152 
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Trimethoprim 
Tliyroxine 
Verapamil HCI 
hydrazone HCI 
PersLilfate in alkaline medium 
Nitrous acid 
Chloramine T 
N-Bromosuccinimide 
Potassium metaperiodate 
Tropaeolin 000 No.! 
355 
420 
425 
415 
425 
400 
153 
154 
155 
156 
157 
157 
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Derivative spectrophotometry 
Derivative spectropliotometry (DS), which consists in the differentiation of a 
normal spectrum, offers a useful means for improving the resolution of mixtures, 
because it enhances the detectability of minor spectral features. DS is an analytical 
technique of great utility for extracting both qualitative and quantitative information 
from spectra composed of unresolved bands by using the first or higher derivatives 
of absorbance with respect to wavelength. The derivative spectra are always more 
complex than the zero - order spectrum. The first derivative is the rate of change of 
absorbance against wavelength. It starts and finished at zero, passes through zero at 
the same wavelength as X,max of the absorbance band with first a positive and then a 
negative band, with the maximum and minimum at the same wavelengths as the 
inflection points in the absorbance band. This bipolar function is characteristic of all 
the odd- order derivatives. The most characteristic feature of the second - order 
derivative is a negative band with the minimum at the same wavelength as the 
maximum on the zero - order band. It also shows two additional positive satellite 
bands on either side of the main band. The fourth derivative shows a positive band. 
The presence of a strong negative or positive band, with the minimum or maximum 
at the same wavelength as Xmax of the absorbance band, is characteristic of the even-
order derivatives. 
Compared with conventional spectrophotometric determination, DS has 
proved to be a great value in eliminating the interference from excipients and co-
formulated drugs. The DS represents an elegant approach to the problem of 
resolving spectral overlap in pharmaceutical analysis. DS permits the simple, rapid, 
sensitive and direct determination of mixtures of drugs having closely overlapping 
spectra. In pharmaceutical application, DS has led to significant developments in the 
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analysis of drugs in the presence of their degradation products or in multi-
component mixtures. 
Derivative UV- spectrophotometry was also successfully applied to the 
analysis of steroid hormone formulations. In simple cases (single- component 
formulations) only the spectral background caused by excipients should be 
eliminated. For this purpose first- derivative spectra are usually sufficient. An 
example for this is the determination of triamcinolone acetonide in an ointment 
[158]. The same technique using the "zero - crossing" method was found to be 
suitable for the simultaneous determination of the components of the dual-
component drug formulations such as creams and tablets containing triamcinolone 
acetonide and terbinafine hydrochloride [159] and oral contraceptives containing 
ethinylestradiol and levonorgestrel [160,161] as well as ethinylestradiol and 
gestodene [162]. A zero- crossing second- derivative method was used for the 
determination of fluorometholone and tetrahydrozoline hydrochloride [163] as well 
as estradiol and medroxyprogesterone acetate [164] in formulations. Another 
possibility to improve the selectivity of the method is the use of "ratio spectrum 
(zero - cross) derivative spectroscopic" method. Examples for this are the 
determination of spironolactone and hydrochlorothiazide [165], hydrocortisone, 
nystatin and oxytetracycline [166], cyproterone acetate and estradiol valerate [167] 
in pharmaceutical formulations. DS has wide applications in the field of drug 
analysis as represented in Table 1.9 [168 - 174]. 
Table 1.9 
Analysis of compounds in pharmaceutical formulations 
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Compounds Remarks References 
Angiotensin-converting 
enzyme (ACE) inhibitor 
Antihypertensive drugs: 
alprenolol-
hydrochlorothiazide; 
hydrochlorothiazide-
ramipril; 
metoprolol- nifidipine 
Amlodipine—its pyridine 
photodegradation product 
Hydrochlorothiazide-
irbesarton 
Hydrochlorothiazide-
losartan potassium 
Hydrochlorothiazide-
losartan 
Hydrochlorothiazide-
metoprolol or propranolol 
Hydrochlorothiazide-
ramipril or spironolactone 
Ramipril (third), benazepril (second), 
enalapril maleate (second), lisinopril 
(first and second) ,and quinapril (first), 
in pharmaceutical dosage forms 
Use of derivative and derivative 
compensation techniques to determine a 
weakly absorbing minor component in 
the presence of a strongly absorbing 
major component 
Third derivative, the method could 
usefully be applied to routine quality 
control of pharmaceutical formulations 
containing amlodipine 
Three methods: (1) compensaUon 
technique using ratios of the derivative 
maxima or the derivative minimum. (2) 
First derivative of the ratio spectra and 
(3) the absorbance ratio method in the 
zero- order spectra 
Two methods: (1) the amplitude in the 
first derivative of the ratio spectra at 
230.423 and 238.360 nm, respectively 
and (2) based on compensation 
technique 
Fourth derivative 
First and second derivatives, 
combined formulations 
m 
Vierordt's method and ratio-
zero- crossing derivative 
[168] 
[169] 
[170] 
[171] 
[172] 
[173] 
[174] 
spectra [165] 
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Fluorlmetry 
Fluorimetry finds wide applications in quantitative studies of rates of 
degradation, metabolism, and excretion of drugs where other analytical techniques 
are not sufficiently sensitive. The native fluorescence of estrogens enables their 
direct fluorimetric determination, e.g. the determination without a preliminary 
separation of estradiol valerate in an injection formulation in the presence of 
hydroxyprogestrone caproate [175]. However, the main application field of this is 
their sensitive HPLC detection. 
Measurement based on the fluorescence induced by non-stoichiometric 
reactions with various strongly acidic reagents [113,176,177] has almost completely 
lost their importance in modern pharmaceutical analysis. However, methanol-
sulphuric acid is still an important spray reagent in the thin-layer chromatographic 
analysis of steroid drugs. An interesting, highly specific and sensitive flow injection 
analysis method for the determination of fluticasone propionate is based on splitting 
with sodium hydroxide of its -CO-S-CH2F side chain to form fluoromethylthiol 
which is further reacted with glycine and o-phthalaldehyde. The strongly fluorescent 
isoindole derivative is formed in the reaction coil of the FIA apparatus [178]. 
Infrared spectroscopy 
Infrared (IR) spectroscopy is the most generally used method for the 
identification of bulk drugs in modern pharmacopoeias [17, 34,179]. In addition to 
this, IR spectroscopy, especially fourier- transform IR (FTIR) is one of the most 
important methods, together with X-ray powder diffractometry, differential scanning 
calorimetry (DSC), thermogravimetry (TGA) and thermomicroscopy to characterize 
the solvates and polymorphic modifications frequently occurring among steroid 
hormone drugs [180], Conventional IR spectrometry using fused KBr discs is not 
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suitable for their differentiation due to the easy transformation of the polymorphs 
under pressure. On the basis of diffuse reflectance infrared fourier transform 
spectroscopy (DRIFTS) and fourier transform Raman spectroscopic investigations 
supported by DSC and TGA measurements [181] four different polymorphic forms 
[182] and five solvates [183] were identified and characterized. FT-IR studies 
combined with all of the above-mentioned solid-phase techniques revealed the 
existence of three polymorphs of fluocinolone acetonide [184] as well as two 
polymorphs and a hemihydrate of flunisolide [185]. 
Near-infrared (NIR) spectroscopy and imaging are fast and nondestructive 
analytical techniques that provide chemical and physical information of virtually any 
matrix. In combination with multivariate data analysis these two methods open 
many interesting perspectives for both qualitative and quantitative analysis. In recent 
years, NIR spectroscopy has gained wide acceptance within the pharmaceutical 
industry for raw material testing, product quality control and process monitoring. 
The growing pharmaceutical interest in NIR spectroscopy is probably a direct resuh 
of its major advantages over other analytical techniques, namely, an easy sample 
preparation without any pretreatment, the possibility of separating the sample 
measurement position and spectrometer by use of fiber optic probes, and the 
prediction of chemical and physical sample parameters from one single spectrum. 
Actually, the major pharmacopoeias have generally adopted NIR techniques. 
The European [186] and United States Pharmacopoeia [187], both contain a general 
chapter on near-infrared spectrometry and spectrophotometry, respectively. These 
chapters address the suitability of NIR instrumentation for use in pharmaceutical 
analysis focusmg mainly on operational qualification and performance verification 
comprising scale and repeatibility, response repeatibility, photometric linearity and 
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photometric noise. Only some limited guidance is provided in terms of developing 
and validating an application. 
Fast and non destructive identification of active ingredients and excipients in 
whole tablets, even through the blister packaging, is certainly a domain of NIR 
spectroscopy [188 -190]. Generally, the measuring mode is not as critical as with 
quantitative applications, except for very thick, highly absorbing tablets and sugar 
coated tablets, for which the reflectance mode is recommended to overcome 
problems of low analyte signal intensity or even total absorption in transmittance. 
Quantitative NIR analysis of active ingredients in tablets has been widely 
reported and reviewed in the literature. Within the last 10 years, the number of 
publications describing quantitative NIR measurements of active ingredients in 
intact tablets has increased tremendously [191 - 205]. 
Mass spectrometry 
In the majority of cases, mass spectrometry is applied in pharmaceutical 
analysis associated with various chromatographic techniques. For example, time- of-
flight secondary ion mass spectrometry was successfully applied for the 
characterization and imaging of a controlled- released drug delivery system 
containing prednisolone sodium metasulphobenzoate. Cross sections of the device 
containing a multi- polymer- layer system were proved for the distribution of the 
active ingredient [206]. 
Nuclear magnetic resonance spectroscopy 
The process of preclinical drug discovery consists of two steps; finding of 
initial hits (binding ligands to a medicinal relevant target, usually a protein) and lead 
optimization. Nuclear magnetic resonance (NMR) spectroscopy is a powerful tool 
that can provide valuable information to every step of drug development. NMR is 
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commonly used for characterizing the structure and molecular dynamics of target or 
ligand molecules. During the structure-based lead optimization, NMR provides 
insight into the structural and dynamical properties of the target-ligand complex 
[207]. Recently NMR spectroscopy has been employed for the rapid screening and 
compositional analysis of steroid cocktails and veterinary drug formulations illegally 
used to livestock. Stanozolol, fluoxymesterone, methylboldenone, norethandrolone, 
clobestol acetate, testosterone and its cypionate and decanoate and other steroid 
were identified directly or after HPLC fractionation with the aid of a H-NMR 
database [208]. When using interrupted decoupling, solid state '^C-NMR is suitable 
not only for detecting low-dose active ingredients (among others prednisolone) in 
solid dosage forms, but also for discrimination between the two polymorphic forms 
of the latter [209]. 
Circular dichroism spectropolarimetry 
The main application field of circular dichroism (CD) spectroscopy is 
structural analysis but this technique can be successfully used also for analytical 
purposes. The application of this technique for drug analysis has been reviewed 
[210]. The profound difference between the ellipticities of ethisterone and its 5-ene 
isomer enables their selective determination (ethisterone at 348 nm at its negative 
maximum of the CD spectrum) and the isomer at 296 nm at the positive maximum 
of the CD curve. When the simultaneous determination was carried out by HPLC, 
the spectropolarimeter could act as a CD-detector [211]. The applicability of the CD 
method can be enhanced by the use of preliminary chemical reactions. 
Kinetic methods 
Kinetic automatic methods are good choices for drug analyses as they permit 
the sensitive, selective determination of many drugs within a few seconds with no 
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pretreatment. Moreover, the instrumentation required is generally very simple. 
Kinetic methods rely on measurement of concentration changes (detected via signal 
changes) in a reactant (which may be the analyte itself) with time after the sample 
and the reagents have been mixed. The sample and reagent can be mixed manually 
or automatically and the kinetic curve (variation of analytical signal with time) can 
be recorded immediately. The slope of the straight initial portion of the kinetic curve 
gives the reaction rate, which is proportional to the analyte concentration (initial-rate 
method). The fixed-time method also frequently used to derive such a concentration, 
involves measuring the signal (the value of which depend on the analyte 
concentration) at a pre-set time. The fixed-time and initial-rate methods have been 
used more frequently for the determination of drugs in pharmaceutical formulations 
and biological fluids [212-214]. Kinetic is relevant to analytical chemistry in at least 
four respects: 
• it allows the elucidation of the physical, chemical and physico-chemical 
mechanisms on which analytical processes are based and hence their rational 
optimisation. 
• it facilitates the development of new analytical methods and techniques that 
are otherwise unattainable if the dynamic aspects are not dealt with. 
• it is the foundation of reaction rate method. 
• it contributes to the improvement of significant analytical parameters such as 
sensifivity, selectivity and precision. 
Kinetic automatic techniques are generally based on open systems among the 
most popular of which are stopped flow (SF) system [215] and the continuous 
addition of reagent (CAR) technique [216-218]. Several drugs have been determined 
by using the CAR technique with photometric [219,220] and fluorimetric detection 
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[221]. The use of catalysts to accelerate analytical reactions is feasible with both 
reaction rate and equilibrium determinations. In this concern, the use of micellar 
media in kinetic method is recently encouraged to enhance the rate of reaction 
(through micellar catalysis) and may additionally improves the sensitivity and 
selectivity which in turn reduce the analysis time for the analyte [222-224], 
Multicomponent kinetic determinations, often called as differential rate methods, are 
also receiving popularity in the field of pharmaceutical research [225,226]. Two new 
approaches i.e. kinetic wavelength pair method [227] and H-point standard addition 
method [228] have been proposed for dealing with overlapping spectra of 
components in the binary mixtures. 
VALIDATION STRATEGY 
Accuracy and reliability of the analytical results is crucial for ensuring 
quality, safety and efficacy of pharmaceuticals. Consequently, analytical validation 
has been in the focus of regulatory requirements for a long time [229-236]. 
However, a sensible validation is also essential from a business perspective because 
analytical data are the basis of many decisions such as batch release, 
establishment/verification of shelf life, etc. 
ICH guidelines should be regarded as basis and philosophy of analytical 
validation, not as a check list. "// is the responsibility of the applicant to choose the 
validation procedure and protocol most suitable for their product" [230]. Suitability 
is strongly connected with the requirements and the design of the given analytical 
procedure, which obviously varies and must, therefore, be reflected in the analytical 
validation. This includes the identification of the performance parameters relevant 
for the given procedure, the definition of the appropriate acceptance criteria, and the 
appropriate design of the validation studies. In order to achieve this, the analyst must 
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be aware of the fundamental meaning of these performance parameters, calculation 
and test and their relationship to his specific application. The process for the 
development, validation and use of analytical methods is shown in Fig. 1.3. 
Parameters for method validation 
To be fit for the intended purpose, the method must meet certain validation 
characteristics.Typical validation characteristics (Tablel.lO), which should be 
considered are: selectivity/ specificity, linearity, range, accuracy, precision, limits of 
detection and quantitation, robustness / ruggedness. 
Selectivity / Specificity 
Slectivty of a method refers to the extent to which it can determine particular 
analyte(s) in a complex mixture without interference from other components in the 
mixture. The terms selectivity and specificity have often been used interchangeably. 
The term specific generally refers to a method that produces a response for a single 
analyte only, v '^hile the term selective refers to a method that provides responses for 
a number of chemical entities that may or may not be distinguished from each other. 
If the response is distinguished from all other responses, the method is said to be 
selective. Since very few analytical methods respond to only one analyte, the use of 
the term selectivity is more appropriate than specificity. The International Union of 
Pure and Applied Chemistry (lUPAC) has expressed the view that "Specificity is the 
ultimate of selectivity". The lUPAC discourages use of the term specificity and 
instead encourages the use of the term selectivity. 
The selectivity of the analytical method must be demonstrated by providing 
data to show the absence of interference with regard to the degradation products, 
synthetic impurities and the matrix (excipients present in the formulated product at 
their expected levels). 
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Calibration model, 
range and linearity 
Define performance 
specifications 
Devise development 
experiments 
Execute and evaluate 
results 
Plan method validation 
experiments 
Precision and 
accuracy 
Analyte stability 
Collate results 
Write validation report 
Apply validated 
method 
Fig.1.3. The process of development, validation and routine use of an 
analytical method. 
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Table 1.10 
Validation characteristics normally evaluated for the different types of test 
procedure and the minimum number of determinations required (if 
applicable). 
Validation 
characteristics 
Specificity'' 
Linearity 
Range 
Accuracy 
Precision 
Repeatability 
Intermediate 
Precision/ rep-
roducibility'' 
Detection limit 
Quantitation 
limit 
Minimum 
number 
-
5 concentrations 
-
9 determinations 
over 3 concen-
tration levels 
(e.g. 3 X 3) 
6 determinations 
at 100% or 
9 determinations 
over 3 concen-
tration levels 
(e.g. 3 X 3) 
2-series 
-
-
Test procedure 
Identity 
Yes 
No 
No 
No 
No 
No 
No 
No 
Impurities 
Quantitative 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No" 
Yes 
Limit 
Yes 
No 
No 
No 
No 
No 
Yes 
No 
Assay^ 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
^ Including dissolution, content potency 
Lack of specificity of one analytical procedure could be compensated by other 
supporting analytical procedure (s). 
'^  Intermediate precision sufficient for submission. 
May be needed in some cases. 
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Linearity 
The linearity is thie ability of analytical procedure to produce test results which 
are proportional to the concentration (amount) of analyte in samples within a given 
concentration range, either directly or by means of a well- defined mathematical 
transformation. Linearity should be determined by using a minimum of six standards 
whose concentration span 80 - 120% of the expected concentration range. 
The essential question to be answered is on the suitability of the calibration 
mode to be used in the test procedure. The requirements and the relevant parameters 
for the various calibrations are given in Tablel.ll. 
It should be noted that in most cases only a qualitative statement is needed. 
For example, if a single point calibration (external standard) is aimed at, the 
requirements are a linear response function and the zero intercept. If these 
prerequisites are fulfilled, the actual figures for the standard error of slope or the 
confidence interval of the intercept, for example, are not used further or referred to. 
Therefore, it makes no sense to repeat linearity investigations on other days or with 
other operators [237J. However, care should be taken to remain within the linear 
range of the individual detector used but this information can be obtained from the 
equipment qualification. 
The linearity of a method should be established by visual inspection of a plot 
of analytical response as a function of analyte concentration. If there is a linear 
relationship, test results should be evaluated by appropriate statistical methods, for 
example, by calculation of the regression line by the method of least squares. In 
some cases, the test data may need to be subjected to a mathematical transformation 
prior to regression analysis. 
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Table 1.11 
Requirements for different calibration modes with relevant parameters 
Quantitation Requirements Relevant parameters 
Single-point 
calibration 
External standard 
Multiple-point 
calibration 
Linear, unweighted 
Linear, weighted 
Linear function 
Non-significant 
ordinate intercept 
Homogenity of 
variances" 
Linear function 
Homogenity of 
variances 
Linear function 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
Inclusion of zero in confidence 
interval of the ordinate intercept, 
magnitude of the intercept (as 
percent of the signal 100% test 
concentration). 
F-test of the variances at the 
lower and upper limit of the 
range. 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
F-test of the variances at the 
lower and upper limit of the 
range. 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
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Non-linear 
100 % -method (area 
normalization for 
impurities): 
Continuous function 
For main peak: linear 
function 
Non-significant 
ordinate intercept 
Homogenity of 
variances" 
For impurities: linear 
function 
statistical tests (vs. quadratic 
regression). 
Appropriate equation 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
Inclusion of zero in confidence 
interval of the ordinate intercept, 
magnitude of the intercept (as 
percent of the signal 100% test 
concentration). 
F-test of the variances at the 
lower and upper limit of the 
range. 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
May be presumed for a limited range (factor 10-20). 
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Range 
The specified range is normally derived from the linearity studies. The range 
of an analytical procedure is the interval between the upper and lower concentration 
(amount) of analyte in the sample for which it has been demonstrated that the 
analytical method has suitable levels of precision, accuracy and linearity. This is 
illustrated in Fig. 1.4. 
Accuracy 
The accuracy of an analytical method is defined as the degree to which the 
determined value of analyte in a sample corresponds to the true value. Accuracy 
may be measured in different ways and the method should be appropriate to the 
matrix. The accuracy of an analytical method may be determined by any of the 
following ways: 
• Analysing a sample of known concentration and comparing the measured value 
to the 'true' value. However, a well characterized sample (e.g. reference 
standard) must be used. 
• Spiked- placebo (product matrix) recovery method. In the spiked- placebo 
recovery method, a known amount of pure active constituent is added to 
formulation blank [sample that contains all other ingredients except the active 
(s)], the resulting mixture is assayed, and the results obtained are compared with 
the expected result. 
• Standard addition method: In the standard addition method, a sample is assayed, 
a known amount of pure active constituent is added, and the sample is again 
assayed. The difference between the results of the two assays is compared with 
the expected answer. 
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[y] 
Instrumental 
response (signal) 
Signal blank 
Dynamic Range 
< • , 
Concentration [X] 
Fig.1.4. Useful range of an analytical method: LOQ = Limit of quantitative 
measurement and LOL = Limit of linear response 
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• Accuracy may also be determined by comparing test results with those 
obtained using another validated test method. 
In both method (spiked- placebo recovery and standard addition method), 
recovery is defined as the ratio of the observed result to the expected result 
expressed as a percentage. 
The accuracy of a method may vary across the range of possible assay values 
and therefore, must be determined at several different fortification levels. The 
accuracy should cover at least three concentrations in the expected range. 
Precision 
According to ICH, the precision is the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple sampling of the 
same homogeneous sample under the prescribed conditions and may be considered 
at three levels: 
• repeatability 
• intermediate precision 
• reproducibility 
Repeatability 
Repeatability is the precision obtained by independent test results with the 
same method on identical test material in the same laboratory by the same operator 
using the same equipment within short interval of time. It is also termed as intra-
assay precision [238, 239]. Sometimes it is also termed as within run or within day 
precision. 
Intermediate precision 
Intermediate precision expresses within-laboratories variations: different 
days, different analysts, different equipment etc. [240]. The International 
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Organization for Standardization (ISO) definitions used the term "M-factor different 
intermediate precision" where the M-factor expresses the number of factors 
(reference standard, operator, equipment, laboratory or time) that differ between 
successive determinations [241]. Intermediate precision is.sometimes also called 
between-run, between-day or inter-assay precision. ^ l-r- /^/^/^Z~~^^^'-
Reproducibility 
* • • " ^ , > " ' 
Reproducibility is the precision obtained within the same mfethod on identical 
test material in different laboratories with different operators using different 
equipments [242]. 
Limits of detection and quantitation 
Limit of detection (LOD) determines the lowest amount of analyte that can be 
detected, as it (the analyte) yields instrumental response greater than a blank, but 
cannot be quantified. It is a parameter of "limit test" and expected to produce a 
response, which is significantly different fi-om that of a blank. On the other hand 
limit of quantitation (LOQ) is a parameter of "determination test" and can be defined 
as the lowest concentration of the analyte that can be measured and quantified with 
acceptable precision and accuracy. 
The most common definition of LOD and LOQ is the analyte concentration 
for which the signal exceeds that for a realistic analytical blank by three and ten 
times of the standard deviation, respectively. Several approaches have been given in 
the ICH guidelines to determine the detection and quantitation limits (Tablel.l2). 
Robustness/Ruggedness 
ICH [243] defines the "robustness/ruggedness" of an analyfical procedure as 
a measure of its capacity to remain unaffected by small, but deliberate variation in 
method parameters and provides an indication of its reliability during normal usage. 
Table 1.12 
Approaches for determining the detection and quantitation [242] 
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Approach Detection limit Quantitation limit 
Visual evolution Minimum level detection Minimum level 
quantifiable 
Signal-to-noise 3:lor2:l 10: 
Standard deviation of 
the response (So) and -; -^  x CS Vb 
the slope(b) 
10.0 X (So)/b 
'^Verification with suitable number of samples. 
^ Standard deviation of the blank, residual standard deviation of the calibration line, 
or standard deviation of the intercept. 
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Ruggedness is a measure for the susceptibility of a method to small changes 
that might occur during routine analysis like small changes of pH values, mobile 
phase composition, temperature etc. Full validation must not necessarily include 
ruggedness testing; it can, however, be very helpful during the method development 
/ prevalidation phase, as problems that may occur during validation are often 
detected in advance. Ruggedness should be tested, if a method is supposed to be 
transferred to another laboratory [244]. 
STATISTICAL ANALYSIS 
Recent trend [245-248] in the pharmaceutical analysis emphasizes the use of 
statistical analysis and evaluation of the method against statistical parameters like 
correlation coefficient, variance, errors and confidence limits, limit of detection and 
sensitivity, standard deviation, 7' and 'F' values, standard deviation of slope and 
intercept etc. A brief discussion is given here. 
Correlation coefficient 
When using instrumental methods, it is often necessary to carry out a 
calibration process by using a series of samples (standard) each having a known 
concentration of analyte. Two statistical procedures should be applied to the 
calibration curve: 
• test whether the graph is linear or in the form of a curve 
• find the best straight line (or curve) through the data points 
Linearity is often tested by correlation coefficient, 'r', which can be 
calculated for a calibration curve to ascertain the degree of correlation between the 
measured instrumental variable and the sample concentration. 
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riLx^y.-Ix^y.^ 
^5p?F(ioWFfe^ 
where, 
X = mean of all the values of Xj 
y - mean of all the values of >'i 
n = number of data points. 
The maximum value of 'r' is 1. When this occurs there is exact correlation 
between the two variables (x and y). When the value of 'r' is zero (xy = 0), there is 
complete independence of the variables. The minimum value of 'r' is - 1 , indicates 
that the assumed dependence is opposite to what exists. As a general rule, 
0.90<r<0.95 indicates a fair curve, 0.95<r<0.99 as a good curve, and r>0.99 includes 
excellent linearity. 
Linear least squares 
The best straight line through a series of experimental points is that line for 
which the sum of the squares of the deviation of the points from the line is 
minimum. Besides, determining a straight line, uncertainties in the use of calibration 
graph for analysis of unknown samples can be specified by this method of least 
squares. The equation of the straight line is 
A = a + bC 
where 
A= instrumental response (i.e. absorbance) 
b=slope 
a=intercept 
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C= concentration of the standards in the spectrophotometric calibration. 
To obtain the regression Vine A on C, the sJope 'b' of the line and the 
intercept 'a' on the y-axis are given by the following equations 
b 
a -
Zx,'-[(Zx,)V«] 
Y.y, -bY^x. 
n 
where 
X\ = individual value of concentration 
_>'i =individual value of absorbance corresponding to Xj 
X = mean value of concentration 
y - mean value of absorbance 
n = number of data points in the calibration line 
Errors in the slope and intercept 
s _ \ny,~yy 
n-2 
Once the value So has been obtained, both the standard deviation of the 
intercept Sa and the slope Sb can be calculated from the following equations: 
S a = S , , Ix! 
s = 'b 
a , ^ 
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w h e r e ^ — 1 ^ ^ ] 
n 
Error in the concentration 
n l /2 
s 
' b 
i . i . ^y-yy 
n b'I.ix-xy 
vv'here x and y are the average concentration and absorbance values, 
respectively, for 'n' standard solutions. 
Confidence limit for the slope and intercept 
It determines whether the slope and/or intercept of a line differ significantly 
from a particular or predicted value. It can be calculated as, 
b ± / Sb (for slope) 
and/or 
a ± ? Sa (for intercept) 
where 
/= tabulated't' value at desired confidence level for (n-2) degrees of freedom. 
Limits of detection and quantitation 
Limit of detection (LOD)/ Limit of quantitation (LOQ) are defined as the 3.3 
and 10 fold, respectively of the standard deviation of the calibration line. The values 
are converted to a concentration by the slope of a corresponding calibration line. 
s 
LOD = 3.3 X — 
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s 
L O Q = 10 X 
Equilance testing 
An important property of an analytical method is that it should be free from 
the systematic error (bias). Determining bias involves analyzing one or more 
standard reference materials whose analyte concentration is known. However, 
random errors make it unlikely that, the measured amount will equal to the known 
amount even v/hen no systematic errors are present. In order to decide whether the 
difference between the observed and standard values can be accounted for by 
random variation, a statistical test i.e. a significance test is used for the interpretation 
of analytical data. 
• Student's /-test: Here comparison is made between two sets of replicate 
measurements made by two different methods; one is the test method while 
other is accepted (reference method). 
where, 
X1 = mean from the test method 
X2 = mean from the accepted (reference) method 
«1 & «2 = number of measurements 
Sp=pooled standard deviation of the individual measurements of two sets 
is given by 
s = 
I E ( X , -X^f +Z(X2 -X^)' 
^ V «, +^2 ~ 2 
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A statistical /-value is calculated and compared with a tabulated value for the 
given number of tests at the desired confidence level. If /^ cai>Aab then there is 
significant difference between the results obtained by the two methods at the given 
confidence level, but if /cai<'^ tab then there is no significant difference between the 
methods. It is an accuracy-indicating test. 
• F-Test: This test indicates whether there is a significant difference between 
the two methods (i.e. the new method and the accepted reference method). It 
can be represented as, 
where 
Si and 82= standard deviation of method 1&2. 
The calculated value of 'F' is compared with the tabulated standard value at 
the selected confidence level and degrees of freedom. If Fcai>Ftab then there is 
significant difference between the two methods. It is a precision indicating test. 
Interval hypothesis 
For pharmaceutical analysis, a bias of ± 2.0 % is acceptable [234] and can be 
calculated statistically [249]. 
For example, a test method (method 2) is considered acceptable if its true mean 
value is within that of the reference method (method 1), i.e. 
-0.02 ^i< ((12-|ii)< 0.02^1 
this can be written as 
0.98 <^2 / | i i< 1-02 
which can be generalised to 
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0L < \x.2l\i^ < Ou 
where 9L and 9u represents the lower and the upper acceptance limits, 
respectively when \X2 is expressed as the proportion of the reference mean |ii. 
Statistically, OL and 9u can be calculated from the relation 
G' 
c2 .2 A 
— 2 p tab 
X, 
V n 
20X|X2 + 
J 
g2,2 ^ 
— 2 '-^p''tab 
X2 
V n 
= 0 
2 ; 
The lower limit (0L) and the upper limit (0u) of confidence interval are obtained 
as 
0L = 
0u = 
- b -
- b -
-Vb^ 
2a 
fVb^ 
-4ac 
-4ac 
2a 
where, a = X, 
"^ p *• tab 
-2x,x. 
c = X2 -
2 '-'p'-tab 
n-
where x, and Xj estimates of \i\ and )i2 based on ni and n2 measurements 
respectively. Sp is the pooled standard deviation and /tab is the tabulated one sided t-
value, with ni+n2-2 degrees of freedom at the specified level of significance. 
Testing for outliers 
When a series of replicate measurements of same quantity are made, one of 
the results will appear too different markedly from the other. There is then a great 
temptation to discard this "outliers" before calculating the mean and the standard 
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deviation of tlie data or applying statistical tests to compare the data with other 
measurements. The best known method for this purpose is Dixon's Q-test. 
_ I Suspected value - Nearest value | 
[Largest value - Smallest value] 
If Qcai^ Qtab at a given confidence level, then the outliers can be rejected. 
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CLASSIFICATION OF DRUGS 
All the drugs according to their chemical nature can be divided into organic 
and inorganic compounds. They can be prepared synthetically or reconstituted from 
natural sources product. All the drugs having medicinal importance can be broadly 
divided into tv/o classes. 
Chemical classification 
The drugs are classified according to their chemical structure and properties 
without taking the pharmacological action. In this class most of the drugs are having 
at least an organic substrate; further classification is done in the relevant manner. 
Pharmacological classification 
In this class the drugs are divided according to their action on the organism's 
organ (viz. heart, brain, lymphatic system, respiratory system, endocrine system, 
central nervous system etc.) Hence these drugs are called cardiovascular, narcotics, 
analgesics, antibiotics, diuretics, and anaesthetics etc. Further classification of each 
group is done according to the therapeutic/pharmacological specificity with the 
relevant organ. A detailed classification of drugs based on pharmacological action 
on human orga.ns has been given in Scheme 1.1. 
Antihypertensive drugs 
Anti-hypertensive drugs are used to help control blood pressure in people 
whose blood pressure is too high. Blood pressure is a measurement of the force with 
which blood moves through the body's system of blood vessels. Although everyone's 
blood pressure goes up and down in the course of a typical day-getting higher when 
they are active and going down when they sleep. Some people have blood pressure 
that stays high all the time. This condition is known as hypertension. Hypertension 
is not the same as nervous tension. People who have high blood pressure are not 
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necessarily tense, high-strung or nervous. They may not even be aware of their 
condition. 
Being aware of high blood pressure and doing something to control it are 
extremely important. However, untreated, high blood pressure can lead to diseases 
of the heart and arteries, kidney damage, or stroke, and can shorten life expectancy. 
Treatments for high blood pressure depend on the type of hypertension. Most cases 
of high blood pressure are called Essential or Primary Hypertension, meaning that 
the high blood pressure is not caused by some other medical condition. For most 
people with primary hypertension, it is difficult to figure out the exact cause of the 
problem. However, such hypertension usually can be controlled by some 
combination of anti-hypertensive drugs and changes in daily habits (such as diet, 
exercise, and v/eight control). 
In people with Secondary hypertension, the high blood pressure may be due to 
medical problems such as kidney disease, narrowing of certain arteries, or tumors of 
the adrenal glands. Correcting these problems often cures the high blood pressure, 
and no further treatment is needed. Controlling primary hypertension, on the other 
hand, is usually a life-long commitment. Although people may be able to reduce the 
amount of medicine they take as their blood pressure improves, they usually must 
continue taking it for the rest of their lives. Many different types of drugs are used, 
alone or in combination with other drugs, to treat high blood pressure. The major 
categories are: 
• Angiotensin-converting enzyme inhibitors (ACE): ACE inhibitors work by 
preventing a chemical in the blood, angiotensin 1, from being converted into a 
substance that increases salt and water retention in the body. These drugs also 
make blood vessels relax, which further reduces blood pressure. 
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• Angiotensin II receptor antagonists: These drugs act at a later step in the 
same process that ACE inhibitors affect. Like ACE inhibitors, they lower 
blood pressure by relaxing blood vessels. 
• Beta blockers: Beta blockers affect the body's response to certain nerve 
impulses. This, in turn, decreases the force and rate of the heart's contractions, 
which lowers blood pressure. 
• Blood vessel dilators (Vasodilators): These drugs lower blood pressure by 
relaxing muscles in the blood vessel walls. 
• Calcium channel blockers: Drugs in this group slow the movement of 
calcium into the cells of blood vessels. This relaxes the blood vessels and 
lowers blood pressure. 
• Diuretics: These drugs control blood pressure by eliminating excess salt and 
water from the body. 
• Nerve blockers: These drugs control nerve impulses along certain nerve 
pathways. This allows blood vessels to relax and lowers blood pressure 
The present thesis deals with the determination of some antihypertensive drugs such 
as Metoprolol tartrate; Labetalol hydrochloride; Ramipril and Perindopril erbumine 
in pharmaceutical formulations. 
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METOPROLOL TARTRATE ((CisHjsNOa):- C4H6O6) 
Metoprolol tartarate, 2-Propanol l-[4-(2-methoxyethyl) phenoxy]-3-[(l-
methyIethyl)amino]-, (±)-, [ R-( R*, R*)]-2,3-dihydroxybutanedioate (2:1) (salt) 
[CAS No. 56392-17-7] is a P- selective adrenoceptor antagonist. , It is used in the 
treatment of cardiovascular disorders such as hypertension, angina pectoris, cardiac 
arrhythmias and myocardial infarction. Metoprolol tartrate is commercially available 
as 50 and 100 mg. tablets for oral administration and ampoules for intravenous 
administration. Metoprolol tartrate is a white, practically odourless, crystalline 
powder with a molecular weight of 684.81. It is very soluble in water, freely soluble 
in methylene chloride, chloroform and alcohol; slightly soluble in acetone and 
insoluble in ether. The (S)- enantiomer of this agent exhibits 33- times more potency 
than (R) - enantiomer in the heart [250]. However, a recemic form of this agent is 
used for the treatment of the disease [251]. It is mainly eliminated by hepatic 
oxidative metabolism. About 85% of an administered dose is excreted in the urine as 
metabolites, with a small amount of the unchanged parent compound [252]. In 
human the metabolic pathways of metoprolol are a-hydroxylation, o-dimethylation, 
(Fig, 1.5) and oxidative deamination. The a-hydroxylation pathways contributes to 
the elimination of only 10% of the dose but it results in the formation of the 
pharmacologically a-hydroxy-metoprolol, with 1/10 of the potency of metoprolol in 
reducing exercise heart rate [252,253]. The formation of a-hydroxy metoprolol has 
the potential to yield diastereomeric products because a new chiral center is formed 
upon benzylic hydroxylation [254]. 
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Fig. I.f5, Major pathways of metoprolol metabolism in man 
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LABETALOL HYDROCHLORIDE (C,9H24N203 • HCI) 
Labetalol hydrochloride is chemically known as 2-hydroxy-5-[l-hydroxy-2-
[(l-methyl-3-phenylpropyl) amino] ethylj-benzamide hydrochloride (CAS No. 
32780-64-6, M.W. 364.87). It is a white or almost white powder and soluble in 
water and alcohol; insoluble in dichloromethane and ether. A 1.0% solution (w/v) in 
water is clear and its pH varies between 4.0 and 5.0.Labetalol is unique drug with 
complex pharmacological properties exhibiting combined ai and P- adrenoceptor 
antagonist properties and partial [ii- agonist activity [255-257]. Labetalol, an 
antihypertensive, has been used in the management of pregnancy-induced 
hypertension or pre-eclampsia. 
Labetalol has two asymmetric centers resulting in four stereoisomers, 
designated RR, SS, SR and RS (Fig. L6). The drug is supplied as an approximately 
equicomponent mixture of all four isomers, Labetalol is a weak base (pKa= 8.3) and 
is administered as the hydrochloride salt. Labetalol exerts reversible and competitive 
ai- and ji- blocking activity [258,259] and is approximately one- fourth as potent as 
propranolol in blocking y5-receptors and one- tenth as potent as phentolamine in 
blocking a\- receptors. 
Labetalol is metabolized predominantly in the liver, the metabolites being 
excreted in the urine together with only small amounts of unchanged labetalol; its 
major metabolite has not been found to have significant a- or ^-adrenoceptor 
blocking effects. Excretion also occurs in the feaces via the bile. The elimination 
half-life at steady state is reported to be 8 hours. Following intravenous infusion, the 
elimination of half- life is about 5.5 hours. Labetalol is not removed by dialysis. 
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Fig. 1.6, Structure of labetalol and proposed pharmacological activity of 
its 4 stereoisomers 
b- Non- selective beta-adrenoceptor blocking activity 
b2- Selective beta2- adrenoceptor agonist activity 
aj - Selective betal- adrenoceptor blocking activity 
* Denotes chiral center 
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In hypertension labetalol hydrochloride is usually given in an initial dose of 
] 00 mg twice daily by mouth with food, gradually increased if necessary according 
to the response of the patient and standing blood pressure, to 200 to 400 mg twice 
daily; total daily doses of 2.4 g have occasionally been required. An initial dose of 
50 mg twice daily has been recommended for elderly patients. 
RAMIPRIL(C23H23N2 05) 
Ramipril, 2-[N-[(S)-l-ethoxy carbonyl-3-phenyl propyl]-L-alanyl]-(lS, 3S, 
5S)-2-azabicyclo [3,3,0]-octane-3-carboxylic acid [CAS No. 87333-19-5, M.W. 
416.51] is an angiotensin-converting enzyme inhibitor (ACE).It is a prodrug, which 
is rapidly hydrolysed after absorption to form the active metabolite ramiprilat (Fig. 
1.7). Ramipril itself is a poor inhibitor of ACE. Ramiprilat exerts all known 
haemodynamic effects by inhibiting ACE, thereby decreasing circulating levels of 
angiotensin II and leading to a reduction in vasopressor activity and a decrease in 
peripheral vascular resistance (Fig. 1.8). 
It is used in the treatment of hypertension, heart failure and following 
myocardial infarction to improve survival in patients with clinical evidence of heart 
failure. It is also used to reduce the risk of cardiovascular events in patients with 
certain risk factors. In the treatment of hypertension an initial dose of 1.25 mg once 
daily is given by mouth. Since there may be a precipitous fail in blood pressure 
when starting therapy with an ACE inhibitor, the first dose should preferably be 
given at bed time. The usual maintenance dose is 2.5 to 5.0 mg daily as a single 
dose, although upto 10 mg daily may be required. Following myocardial infarction, 
treatment with ramipril may be started in hospital 3 to 10 days after the infarction at 
a usual initial dose of 2.5 mg twice daily, increased after two days to 5 mg twice 
daily. The usual maintenance dose is 2.5 to 5 mg daily. 
1 ^ 
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Fig. 1.7. Structural formula of (A) Ramipril and (B) Ramiprilat 
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Fig. 1.8. Simplified representation of the renin-angiotensin-system. 
AT 1= angiotensin 11 receptor subtype 1; 
AT2= angiotensin II receptor subtype 2; 
BK= bradykinin receptor. 
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PERINDOPRIL ERBUMINE (CgHjiNzOs • C4H„N) 
Perindopril erbumine is the tert-butylamine salt of perindopril, the ethyl ester 
of non-sulphhydryl angiotensin-conerting enzyme (ACE) inhibitor. It is chemically 
described as (2S,3aS,7aS)-l-[(S)-N-[(S)-l-Carboxy-butyl]alanyl]hexahydro-2-
indolinecarboxyilc acid, 1-ethyl ester , compound with tert-butylamine(l:-l). Its 
molecular formula is Ci9H32N20fi • C4H11N. Its structural formula is: 
HOOC. 
• H2N-C(CH3)3 
Perindopril erbumine is a white, crystalline powder with a molecular weight of 
368.47 (free acid) or 441.61 (salt form). It is freely soluble in water (60% w/w), 
alcohol and chloroform. 
Perindopril, a free acid form of perindopril erbumine, is a pro-drug and 
metabolized in vivo by hydrolysis of the ester group to form perindoprilat, the 
biologically active metabolite. Perindopril has five asymmetric centers. The drug is 
synthesized stereoselectively so that it is a single enantiomer (all S stereochemistry). 
Perindopril erbumine is commercially availabe in 2 mg, 4 mg and 8 mg tablets 
for oral administration. In addition to perindopril erbumine, each tablet contains the 
following inactive ingredients: colloidal silica (hydrphobic), lactose, magnesium 
stearate and microcrystalline cellulose. The 4 mg and 8 mg tablets also contain iron 
oxide. 
Perindopril erbumine is a pro^drug for perindoprilat, which inhibits ACE in 
human subjects and animals. The mechanism through which perindoprilat lowers 
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blood pressure is believed to be primarily inhibition of ACE activity. ACE is a 
peptidyl dipeptidase that catalyzes conversion of the inactive decapeptide, 
angiotensin I, to the vasoconstrictor, angiotensin II. Angiotensin II is a potent 
peripheral vasoconstictor, which stimulates aldosterone secretion by the adrenal 
cortex, and provides negative feedback on renin secretion.Inhibtion of ACE results 
in decreased plasma angiotensin II, leading to decreased vasoconstriction, increased 
plasma renin activity and decreased aldosterone secretion. The latter results in 
diuretics and natriuresis and may be associated with a small increase of serum 
potassium. 
Perindopril is extensively metabolized following oral administration, with 
only 4 to 12% of the dose recovered unchanged in the urine. Six metabolites 
resulting from hydrolysis, glucuronidation and cyclization via dehydration have 
been identified. These include the active ACE inhibtor, perindoprilat (hydrolyzed 
perindopril) perindopril and perindoprilat glucuronides, dehydrated perindopril and 
the diastereoisomers of dehydrated perindoprilat. In human, hepatic esterase appears 
to be responsible for the perindopril. 
Perindopril erbumine is indicated in patients with stable coronary artery 
disease to reduce the risk of cardiovascular mortality or non-fatal myocardial 
infarction. It can be used with conventional treatment for management of coronary 
artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. 
Perindopril erbumine is also indicated for the treatment of patients with essential 
hypertension. It may be used or given with other classes of antihypertensive, 
especially thiazide diuretics. 
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CHArTER-2 
VALIDATED KINETIC 
SPECTROPHOTOMETRIC METHOD FOR THE 
DETERMINATION OF METOPROLOL 
TARTRATE IN PHARMACEUTICAL 
FORMULATIONS 
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INTRODUCTION 
Metoprolol tartrate is a selective P-adrenergic antagonist, which is used in the 
treatment of cardiovascular disorders such as hypertension, angina pectoris, cardiac 
arrhythmias and myocardial infarction. The drug is quite sensitive, even a small dose 
of the drug gives sufficient blockade. Since the P-blockers are also misused as 
doping agents in sports and therefore these drugs have been added to the list of 
forbidden drugs by the International Olympic Committee (IOC) [1]. Therefore, the 
development of an analytical method for the determination of metoprolol tartrate is 
of great significance. 
The assay of the drug is listed in the monograph of British Pharmacopoeia, 
which describes a potentiometric titration method [2]. Several analytical methods 
have been developed for the determination of metoprolol in biological fluids and 
pharmaceutical formulations based on high performance liquid chromatography [3-
11], gas chromatography [12,13], capillary electrophoresis [14], thin layer 
chromatography [15,16], infrared spectroscopy [17], and electrochemical methods 
[18,19]. The above mentioned techniques are sensitive but expensive and require 
laborious clean up procedure prior to analysis. Spectrophotometry is the technique 
of choice even today due to its inherent simplicity and therefore, frequently used in 
the laboratories of the developing countries to overcome versatile analytical 
problem. The drug has been determined in the visible region based on ion-pair 
formation between drug and reagents like oxidized quercetin [20]; bromophenol 
blue, bromocresol purple, bromocresol green [21]; benzyl orange [22]; bromothymol 
blue [23]; and carbon disulfide-copper chloride [24]. The charge transfer 
complexation reactions of metoprolol tartrate with a and 7c-acceptors [24, 25] have 
also been utilized for its quantification in pharmaceutical formulations. Shingbal and 
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Bhangle [26] have reported a spectrophotometric method based on the reaction of 
drug with 2, 4-dinitrofluorobenzene in HCl / dioxan medium to form a coloured 
chromophore, which absorbs maximally at 380 nm. The quantification of metoprolol 
tartrate was done on treatment of the drug with ammonium metavanadate [27], FeCls 
[28], N-bromosuccinimide [29], and a mixture of KNO3 and H2SO4 followed by 
addition of alkali to get coloured chromophore [30]. The literature is still poor in 
analytical procedures based on kinetic spectrophotometry for the determination of 
drug in pharmaceutical preparations. There is, therefore, a need for a simple and 
sensitive kinetic spectrophotometric method for the determination of metoprolol 
tartrate in pharmaceutical formulations. It was found that potassium permanganate 
oxidizes the metoprolol in alkaline medium and this reaction has not been used 
before to quantify the drug spectrophotometrically. 
This chapter describes a simple and sensitive kinetic spectrophotometric method 
for the determination of metoprolol tartrate in drug formulations. The method 
involves the oxidation of drug with alkaline potassium permanganate at 25 ± 1°C 
and subsequent measurement of absorbance at 610 nm. The initial rate and fixed 
time methods are adopted for its determination in pharmaceutical formulations. 
EXPERIMENTAL 
Apparatus 
A Shimadzu UV-visible spectrophotometer (model-1601, Japan) with matched 
quartz cells was used to measure absorbance. 
A water bath shaker (NSW 133, New Delhi, India) was used to control the heating 
temperature for colour development. 
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Reagents and standards 
All reagents and chemicals used were of analytical or pharmaceutical grade. 
Aqueous solutions of 0.6 M sodium hydroxide and 0.015M potassium permanganate 
(GR Grade, Merck Limited, Mumbai, India) were prepared in doubly distilled water. 
Potassium permanganate (GR Grade, Merck Limited, Mumbai, India) solution 
should be freshly prepared and its apparent purity was assayed by titrimetric method 
[31]. 
The standard test solution of metoprolol tartrate (0.01%) was prepared in 
doubly distilled water. The formulated dosage forms of metoprolol tartrate such as 
betaloc (AstraZeneca Pharma India Ltd., Bangalore, India), metapro (Cardicare, 
Bangalore, India) and metolar (Cipla, Mumbai, India) were purchased from the local 
market. 
Determination procedures for metoprolol tartrate 
Initial-rate method: Aliquots of 0.1-0.6 ml of 0.01% metoprolol tartrate were 
pipetted into a series of 10 ml standard flasks. To each flask, 2.0 ml of 0.60 M 
NaOH was added followed by 2.0 ml of 0.015 M potassium permanganate and then 
diluted with doubly distilled water at 25 ± 1°C, The contents of each flask were 
mixed well and the increase in absorbance was recorded as a function of time at 610 
nm. The initial rate of the reaction (v) at different concentrations was obtained from 
the slope of the tangent to the absorbance-time curve. The calibration graph was 
constructed by plotting the logarithm of the initial rate of reaction (logv) versus the 
logarithm of the molar concentration of the metoprolol tartrate (log C). The amount 
of the drug was computed either from the calibration graph or the regression 
equation. 
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Fixed-time method: The absorbance of each drug sample solution was measured at 
610 nm against a reagent blank prepared similarly at a preselected fixed time of 15 
min. The calibration curve was constructed by plotting the absorbance against the 
final concentration of the drug. The amount of the drug was computed either from 
calibration curve or regression equation. 
Determination procedure for metoprolol tartrate in pharmaceutical formulations 
Five tablets were weighed and powdered. The powder equivalent to 50 mg of 
active ingredient was weighed accurately, stirred well with doubly distilled water 
and filtered through Whatmann No. 42 filter paper (Whatmann International 
Limited, Kent, UK). The residue was washed well with doubly distilled water for 
complete recovery of the drug. The content of the drug was then diluted to 250.0 ml 
with doubly distilled water. It was further diluted according to the need and 
subjected to the determination procedures for metoprolol tartrate. The percent 
recovery of the metoprolol tartrate was calculated from the corresponding linear 
regression equations or calibration graphs. 
Procedure for reference method 
Into a series of 10 ml standard volumetric flask, different volumes (0.25-2.5 
ml) of 0.01% drug (0.1 mg ml"') solufion were pipetted and diluted to volume with 
doubly distilled water. The absorbance was measured against the solvent blank at 
224 nm. The amount of the drug in a given sample was computed from the 
calibration equation. 
RESULTS AND DISCUSSION 
Spectral studies 
The absorption spectrum of metoprolol tartrate solution in doubly distilled 
water shows two absorption bands peaking at 194 and 224 nm while that of 
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potassium permanganate solution in the alkaline medium exhibits an absorption 
band peaking at 530 nm. The addition of potassium permanganate to the solution of 
pure drug produces a new characteristics band at 610 nm. (Fig. 2.1) This band is 
attributed to the formation of manganate ion, which resulted on reduction of 
potassium permanganate in alkaline medium. The intensity of the coloured product 
increases with time and therefore, a kinetic method was developed for the 
determination of metoprolol tartrate in drug formulations. Moreover, potassium 
permanganate also oxidizes metoprolol in acid medium resulting in the formation of 
a-hydroxy metoprolol and Mn (II). In the presence of acid such as H2SO4, HCl and 
H3P04^  a-hydroxy metoprolol gives a violet colour which has not been utilized for 
quantitative analysis. 
Stoichiometry and reaction mechanism 
The stoichiometric ratio between metoprolol tartrate and potassium 
permanganate was established using limiting logarithmic method [32] by performing 
two sets of experiments. In the first set, the concentration of metoprolol tartrate was 
varied keeping a constant concentration of KMn04. In the second set of experiment, 
concentration of metoprolol tartrate was kept constant while varying the 
concentration of KMn04. The logarithm of the absorbance was plotted against the 
logarithm of the respective varied concentration of metoprolol tartrate or KMn04 
(Fig. 2.2 a and b). It is evident from the slopes of the two straight lines that the 
combining molar ratio between metoprolol tartrate and KMn04 is 1:1. 
Horai et al. have suggested that the metoprolol tartrate undergoes oxidation [33] 
resulting in the formation of a- hydroxy metoprolol. In this study, the potassium 
permanganate oxidizes the metoprolol tartrate in alkaline medium producing a-
hydroxy metoprolol and itself reduced loMnO]". The reaction product gives violet 
102 
1.4 
1,2 
1.0 
0.8 
0.6 
0.4 
200 240 280 320 360 400 440 480 520 560 600 640 680 720 760 
Wavelength (nm) 
Fig. 2.1. Absorption spectra of (a) 1 ml of 0.01% metoprololol tartrate (b) 2.0 
ml of 0.015 M. potassium permanganate in alkaline medium (c) coloured 
product (0.6 ml of metoprolol tartrate (0.01%) + 2.0 ml of 0.015 M KMn04 + 
2.0 ml of 0.6 M NaOH) versus blank diluted with doubly distilled water in 10 
ml standard flask. 
lo; 
-1.0 
-6.0 -5.6 -5.2 -4.8 -4.4 -4.0 -3.6 -3.2 -2.8 -2.4 -2.0 
Log [Drug] or [KMnOJ 
Fig. 2.2, Limiting logaritlimic plot for stoichiometric ratio between metoproloi 
tartrate and ]KMn04 (a) log A vs. log [drug] and (b) log A vs. log [KMn04]. 
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colour on treating with formaidchyde-sulphuric acid reagent, which confirmed the 
formation of a- hydroxy metoprolol [34]. 
Optimization of variables 
The influence of the concentration of NaOH solution on the rate of reaction 
was studied by keeping the constant concentrations of metoprolol tartrate (8.76x10' 
M) and KMn04 (3.00x10'^ M) and varying the concentration of NaOH (1.20x10"^-
1.32x10"' M) in a final volume of 10 ml solution. Fig. 2.3 shows that the initial rate 
of reaction increased up to 8.4x10'^ M NaOH; beyond this concentration the initial 
rate of reaction remained constant. Therefore, a concentration of 1.20x10"' MNaOH 
was used throughout the experiment. The effect of the concentration of KMn04 
solution on the initial rate of the reaction was studied in the range of 7.50x10"''-
3.30x10"^ M. The inifial rate of reaction (Fig. 2.4) increased with increasing the 
concentration of KMn04 and became constant at 2.40x10'"' M. Thus, a concentration 
of 3.00x10'^ M KMn04 in the final solution proved to be sufficient for the 
maximum concentration of metoprolol tartrate used in the determination process. 
The effect of temperature on reaction rate was studied in the range of 298-308 K. 
The absorbance-time curves showed the temperature dependence of the reaction 
rate. It was observed that metoprolol tartrate reacts faster with potassium 
permanganate within the short period of 3-15 min, 3-10 min and 3-7 min. at 298, 
303 and 308 K, respectively. At temperatures > 308 K, the decomposition of the 
reaction product may take place. To avoid this and for the sake of good results, the 
opfimum temperature of 298 K is selected for the determination process. 
Analytical data and method validation 
Under the optimized experimental conditions, a pseudo-order reaction 
condition was worked out by using a large excess of KMn04 and NaOH solution 
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Fig. 2.3. Effect of the molar concentration of NaOH solution on the initial rate 
of reaction with 60.0 i^ g per 10 ml metoprolol tartrate in doubly distilled 
water. 
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Fig. 2.4. Effect of the molar concentration of KMn04 solution on the initial rate 
of reaction with 60.0 ^g per 10 ml metoprolol tartrate in doubly distilled water. 
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with respect to the initial concentration of metoprolol tartrate. As a result, a pseudo 
zero order condition was obtained with respect to the reagents, the overall 
concentration change of KMn04 and NaOH during the course of reaction would be 
negligible. The initial rates of the reaction were determined from the slopes of the 
initial tangent to the absorbance-time curves (Fig. 2.5) and are summarized in Table 
2.1. The reaction would obey the following rate equation: 
Rate = kt C" 
where k^ is the pseudo-order rate constant, C is the concentration of metoprolol 
tatrate, n is the order of the reaction. The logarithm form of the above equation is 
written as: 
Log (rate) = log kn/ + n log C 
The linear regression analysis using the method of least square treatment of 
calibration data was made to evaluate slope, intercept and correlation coefficient. 
Under the working experimental conditions, a calibration graph was constructed by 
plotting log of initial rate of reaction (log u) versus log of metoprolol tartrate 
concentration (log C), which showed a linear relationship over the concentration 
range of 10.0 - 60.0 |.ig per 10 ml. The regression of log rate versus log C gave the 
following linear regression equation: 
Log (rate) = 3.634 + 0.999 log C 
with a correlation coefficient (r) of 0.9999. The value of n in regression equation 
confirmed that the reaction is first order with respect to metoprolol tartrate. The 
confidence limits for the slope of the line of regression and intercept were computed 
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Fig. 2.5. Absorbance-time curves for the reaction between metoprolol tartrate 
and KMn04 in aqueous medium: 2.0 ml of 0.015 M KMn04 and metoprolol 
tartrate: (a) 1.0, (b) 1.5, (c) 2.0, (d) 3.0, (e) 4.0, (f) 5.0 and (g) 6.0 ^g ml ' . Each 
set is diluted in 10 ml standard flask with doubly distilled water. 
Table 2.1 
Summary of data of the Initial rate of reaction at different concentration 
of metoprolol tartrate and KMn04 
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[Drug] (mol T') 
1.460 X lO"" 
2.190 X IQ-" 
2.920 X 10"^ ' 
4.380 X lO"" 
5.840 X 10-' 
7.300 X 10"' 
8.760 X 10-' 
8.760 X 10-" 
8.760 X 10-" 
8.760 X IQ-" 
8.760 X 10"" 
8.760 X lO"" 
8.760 X 10-" 
[KMn04] (mol P') 
3.000 X 10-' 
3.000 X 10"^  
3.000 X 10-' 
3.000 X 10-' 
3.000 X 10"' 
3.000 X 10-' 
3.000 X 10-' 
7.500 X 10-' 
9.000 X 10-^  
1.200 X 10-' 
1.800 X 10-' 
2.100 X 10"' 
2.400 X 10 ' 
Initial rate of reaction, u 
(mol r' min-') 
6.250 X 
9.375 X 
1.270 X 
1.880 X 
2.500 X 
3 . 1 0 0 ^ 
3.800 X 
8.000 X 
1.130X 
1.860 X 
2.660 X 
2.830 X 
3.800 X 
10-' 
10-' 
10-^  
10-^  
10-^  
10-^  
10-^  
10-' 
10-^  
10-^  
10-^  
10-^  
10-^  
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using the relation b ± tSb and a ± tSa [35] at 95% confidence level and found to be 
0.999 ± 1.45 X 10"^  and 3.634 ± 2.60 x 10"', respectively. This indicated the high 
reproducibility of the proposed method. The limits of detection (LOD) and 
quantitation (LOQ) were evaluated using the following equation: 
LOD = 3 .3xSo/b and L O Q = 1 0 x S o / b 
where So is the standard deviation of the calibration line and b is the slope and found 
to be 1.3x10'^ and 4.0x10'^ [ig ml'', respectively. The variance was calculated 
using the equation: 
n-2 
and found to be 1.576 x 10'^  f.ig ml"'. The low value of variance indicated negligible 
scattering of the experimental data points around the line of regression. 
In the fixed-time method, the absorbance of green coloured solution obtained 
on interaction of different concentration of metoprolol tartrate with alkaline 
potassium permanganate was measured at a preselected fixed time. Calibration plots 
of absorbance versus initial concentrations of metoprolol tartrate were established at 
a fixed time of 3, 6, 9, 12 and 15 min. The molar absorptivity, regression equations, 
coefficient of correlation, limits of detection and quantitation and variance are given 
in Table 2.2. It is clear from Table 2.2 that the most acceptable values of molar 
absorptivity, limit of detection and quantitation were obtained at a fixed time of 15 
min. Therefore, the fixed time of 15 min was adopted as the optimum time for the 
determination of metoprolol tartrate in pharmaceutical formulations. The important 
analytical parameters of conventional UV spectrophotometric method have been 
summarized in Table 2.2. It can be seen that the molar absorptivity of the fixed time 
method is higher than that of conventional UV spectrophotometric method 
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whereas the limits of detection and quantitation of the proposed method are smaller. 
The performance of the initial rate method is better since the values of LOD and 
LOQ are smaller than that of the fixed time method and analysis can be completed in 
a shorter time. 
Solution stability and selectivity 
The solution stability of metoprolol tartrate was checked by observing UV 
spectra of metoprolol tartrate for five days. The aqueous solution of the drug having 
two Xynax- 194 and 224 nm, shov/ing no change in the absorption spectra of standard 
and sample solutions of drug for at least five days, when the solution were stored 
at room temperature. To identify the metoprolol and a-hydroxy metoprolol, thin 
layer chromatography was performed. The standard solution, sample solution and 
reaction product were applied on TLC plates coated with silica gel and developed in 
ethyl acetate-methanol-ammonia (40:5:5 v/v/v) solvent system. The plates were air-
dried and spots were detected in the iodine chamber. In the case of standard and 
sample solutions, a single spot was observed with Rf = 0.50 corresponding to 
metoprolol, whereas reaction product also showed one spot with Rf = 0.65. This 
corresponds to a-hydroxy metoprolol [34]. Thus, the proposed methods are selective 
as the major metabolite, a-hydroxy metoprolol does not interfere in the 
determination. However, other P-adrenergic antagonists such as propranolol, 
atenolol and labetalol react with potassium permanganate in alkaline medium 
resulting in the formation of green coloured solution, which absorbs maximally at 
610 nm. 
Accuracy and precision 
The accuracy and precision of the proposed methods was established by measuring 
the content of metoprolol tartrate in pure form at three different concentration 
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levels (low, medium and high). The short-term (intra day assay) and the daily 
precisions (inter day assay) were performed by measuring five independent analyses 
at 1.5, 3.0 and 6.0 |ig ml'' concentration levels within one day and on five 
consecutive days, respectively (Table 2.3). The standard deviation, relative standard 
deviation and mean percent recoveries obtained by both the initial rate and fixed 
time methods can be considered to be very satisfactory. 
The validity of the proposed methods was also checked by performing recovery 
experiments through standard addition method. For this, a known amount of the pure 
drug was added to preanalysed dosage forms and then the total amount of 
metoprolol tartrate was determined following the recommended procedures and 
reference method. The results are summarized in Table 2.4, which showed 
recoveries in the range of 100.02-100.13%, 99.99-100.15 % and 99.94-100.11% for 
initial rate, fixed time and reference methods, respectively. No interference from the 
common excipients was observed. 
Robustness 
The conditions are very robust for the application of the proposed methods to 
determine the active drug in pharmaceutical formulations. Each operational 
parameter was checked and challenged for the robustness of the method. The 
operational parameters investigated were: 
• volume of0.015MKMnO4(± 0.2 ml) 
• volume of 0.60 M NaOH (± 0.2 ml) 
Under these conditions a sample solution containing 6.0 \xg ml'' (Metalor 25, 
Cipla) of active metoprolol tartrate was assayed five times by the initial rate and 
fixed time methods. The values of mean recovery, standard deviafion and relafive 
standard deviation represent good reliability of the proposed methods. 
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Table 2.3 
Test of precision of the proposed methods by Intra day and Inter day assays 
Proposed methods 
Initial rate method 
Intra day assay 
Inter day assay 
Fixed time method 
Intra day assay 
Inter day assay 
Amount 
(Mgml-') 
Taken 
1.5 
3,0 
6.0 
1.5 
3.0 
6.0 
1.5 
3.0 
6.0 
1.5 
3.0 
6.0 
Found iSD" 
1.50 ±0.04 
3.00 ±0.06 
6.01 ±0.06 
1.50 ±0.04 
2.99 ±0.06 
6.00 ±0.06 
1.50 ±0.04 
2.99 ±0.05 
6.01 ±0.05 
1.50 ±0.06 
2.99 ±0.06 
6.00 ±0.07 
Recovery 
(%) 
100.03 
100.06 
100.13 
100.14 
99.95 
100.07 
100.21 
99.93 
100.15 
100.01 
99.93 
100.04 
SAE 
0.02 
0.03 
0.03 
0.02 
0.03 
0.03 
0.02 
0.02 
0.02 
0.03 
0.03 
0.03 
C.L. 
0.05 
0.07 
0.07 
0.05 
0.07 
0.07 
0.06 
0.06 
0.06 
0.07 
0.07 
0.08 
^ Mean for five independent analyses. 
'' SAE, standard analytical error. 
C.L., confidence limit at 95 % confidence level and four degrees of freedom (t = 2.776). 
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The effect of temperature on reaction rate is well known and important in 
understanding the various activation parameters of the reaction products. In order to evaluate 
the apparent activation parameters, the reaction rate was studied at 298, 303, and 308 K at 
[metoprolol] = 1.46 x 10"''-8.76 x 10'^ ' M, [KMn04] = 3.00 x 10"^  M and [NaOH] = 1.20 x 10" 
' M. 
Arrhenius curve (Fig. 2.6) was constructed by plotting log k versus 1/ T and found to 
be linear. Activation energy (Ea) can be calculated from the slope (-Ea / 2.303R) and A from 
the intercept of the Arrhenius curve and found to be 90.73 KJmol"' and 4.75 xlO", 
respectively. The other activation parameters such as enthalpy, entropy and free energy of 
activation of the reaction product were calculated using Eyring equation: 
AH* 1 
\og- = \log{kJh) + -
2.303/? T T I 2.303 R 
The plot of log k'T versus 1/T (Fig 2.7) was linear with correlation coefficient of 0.9999. 
A H* was evaluated from the slope (-A H ' / 2.303 R) and AS* from the intercept [log (kb /h) + 
AS* / 2.303 R] of the compiled Eyring plot. The values of AH* and AS* were found to be 
88.20 KJ mof' and 84.54 JK^'mol"', respectively. The Gibbs free energy of activation was 
determined by AG* = AH* - TAS* at 298 K and found to be -63.01 K J mol"'. 
Applicability of the proposed methods 
The proposed methods (initial rate and fixed time methods) were successfully applied 
to the determination of metoprolol tartarte in pharmaceutical formulations. The results of the 
proposed methods were statistically compared with those of the reference method using point 
hypothesis test. Table 2.5 shows that the calculated t- (paired) and F-values at 95% 
confidence level are less than the theoretical ones, confirming no significant differences 
between the performance of the proposed methods and the reference method. The previous 
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T 1 ' r 
0.00324 0.00326 0.00328 0.00330 0.00332 0.00334 0.00336 0.00338 
1/T(K) 
Fig. 2.(5. Arrhenius plot: log k versus 1/T for activation energy. 
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The previous investigations were also checked and confirmed by interval hypothesis tests 
[36]. The Canadian Health Protection Branch has recommended that a bias, based on 
recovery experiments, of ± 2 % is acceptable [37]. It is evident from Table 2.5 that the true 
bias of all samples of drug is smaller than ± 2 %. 
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CHAPTER 
DETERMINATION OF LABETALOL 
HYDROCHLORIDE IN DRUG FORMULATIONS 
BY SPECTROPHOTOMETRY 
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INTRODUCTION 
Labetalol hydrochloride i.e. Benzamide, 2-hydroxy-5-[l-hydroxy-2-[(l-methyl-
3-phenylpropyl)amino]ethyl]-, monohydrochloride (CAS No. 32780-64-6, M.W. 
364.87) is an adrenergic P-receptor blocking agent used in the treatment of 
hypertension, which exhibits both a and P-adrenoceptor blocking activity and because 
of its use as doping agent in sports, this drug has been added to the list of forbidden 
substances issued by the International Olympic Committee [1]. The drug is used to 
induce hypotension during surgery as it decreases blood pressure more rapidly than 
other beta blockers. The drug is quite sensitive, even a small dose of the drug gives 
sufficient blockade, thus indicating that the drug is very much confined with the 
cardio protective effects. Hence, it is must to determine the amount of labetalol 
hydrochloride in drug formulations. The drug is official in Martindale, The Extra 
Pharmacopoeia [2]. The assay procedure is cited in the monographs of British 
Pharmacopoeia [3] and United States Pharmacopoeia [4], which describe a 
potentiometric titration method and a liquid chromatographic method, respectively. 
Several analytical methods such as thin layer chromatography (HPTLC) [5, 6], high 
performance liquid chromatography (HPLC) [7, 8], liquid chromatography (LC) [9, 
10], liquid chromatography coupled with mass spectrometry (LC-MS) [11,12], gas 
chromatography coupled with mass spectrometry (GC-MS) [13] capillary 
electrophoresis (CE) [14], electrochemical method [15] and flourimetry [16] are 
reported for the estimation of labetalol hydrochloride. The determination in biological 
fluids normally requires the use of trace analysis techniques, higher instrumentation 
such as HPLC, LC, CE, cyclic voltammetry, flourimetry and hyphenated techniques 
like LC-MS, GC-MS, inductively coupled plasma-mass spectrometry which normally 
makes the method much more expensive. In addition to this, these methods require 
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long and tedious pretreatment of the samples and laborious clean up procedures prior 
to analysis. UV-visible spectrophotometry is the technique of choice even today in the 
laboratories of research, hospitals and pharmaceutical industries due to its low cost 
and inherent simplicity. The analytical procedures based on spectrophotometry [17-
22] were frequently published in reputed journals. Few spectrophotometric methods 
have been developed for the determination of labetalol hydrochloride in bulk drug and 
pharmaceutical formulations. The quantification of the drug was done based on the 
reaction of labetalol hydrochloride with Folin Ciocalteau's reagent, 4-
aminophenazone, 2,6-dichloroquinone chlorimide and ferric alum [23]; benzocaine 
and p-nitroaniline in presence of triethylamine and sodium carbonate, respectively 
[24]; p-N, N-dimethylphenylenediamine, and 3-methyl 2-benzothiazolinone 
hydrazone hydrochloride in the presence of sodium hypochlorite and eerie ammonium 
sulphate to form intensely coloured products with Xmax at 685 and 545 nm, 
respectively [25]. The estimation of drug was done in the visible region based on ion-
pair formation between drug and reagents like suprachen violet 3 B [25] and wool fast 
blue BL [26]. 
This chapter describes a selective and sensitive spectrophotometric method for 
the determination of labetalol in drug formulations. The method is based on the 
reaction of 4-aminobenzenesulphonic acid with dilute HCl and NaN02 in a 
temperature range of 0 - 3 °C to form an electrophile i.e positive diazonium ion, 
which immediately couples at ortho to the hydroxyl group of the benzene ring of 
labetalol in Na2C03 medium forming a yellow azo product having Xmax at 395 nm. 
The proposed method is carefully optimized and validated as per the International 
Conference on Hormonisation (ICH) guidelines [27]. 
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EXPERIMENTAL 
Apparatus and reagents 
The absorbance measurements were made on a Shimadzu UV-visible 1601 
spectrophotometer (Kyoto, Tokyo, Japan) with matched quartz cells. 
All chemicals and reagents were of analytical grade. Aqueous solutions of 4-
aminobenzenesulphonic acid (0.029 M; Fluka Chemie AG, Switzerland), NaN02 
(0.29 M; Otto Chemie, Mumbai, India) and sodium carbonate (0.28 M; GR grade, 
Merck Limited, Mumbai, India) were freshly prepared. A 0.2 M HCl was also 
prepared by diluting 1.77 ml of pure HCl (35 %, GR grade, Merck Limited, Mumbai, 
India) in 100 ml, distilled water. 
Drug standard and commercial dosage forms 
Labetalol hydrochloride as a reference standard was obtained from Sigma 
Chemical Company (St. Louis, MO, USA). Standard solution of Labetalol 
hydrochloride (0.04 %) was prepared in distilled water. Commercial dosage forms of 
labetalol hydrochloride such as Lobet-100 mg tablet (Samarth Pharma Pvt. Ltd., 
Mumbai, India) and Normadate -50 mg capsule (Glaxo Smithkline, Mumbai, India), 
were obtained from local drug store. 
Spectrophotometric procedure for the determination of labetalol hydrochloride 
Into a series of 25 ml standard volumetric flasks, 1.5 ml of 0.029 M 4-
aminobenzenesulphonic acid, 1.5 ml of 0.29 M NaNOa and 2.0 ml of 0.2 M HCl were 
pipetted and kept in an ice-bath (0 - 3 °C) for 10.0 min to complete diazotization 
reaction. To each flask, aliquot of 0.04% labetalol hydrochloride reference standard 
solution (0.05 -1.1 ml) was added followed by 4.0 ml of 0.28 M sodium carbonate and 
then diluted to volume with distilled water at room temperature (25 ± 1 °C). The 
contents of each flask were mixed well and the absorbance was measured at 395 nm 
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against the reagent blank prepared similarly except drug. The colour was stable up 
to 2 h. The amount of the drug was computed either from the calibration graph or the 
regression equation. 
Procedure for the determination oflabetalol hydrochloride in drug formulations 
The powdered contents of 2 capsules of 50 mg strength (or 1 tablet of 100 mg 
strength) were taken in 50 ml distilled water and left for 10 min for complete 
dispersion and then filtered through Whatmann No. 42 filter paper (Whatmann 
International Limited, Kent, UK) in a 250 ml standard volumetric flask. The residue 
was washed well with distilled water for complete recovery of the drug and then 
diluted up to the mark with distilled water. The assay was completed following the 
recommended spectrophotometric procedure for the determination of labetalol 
hydrochloride 
Preparation of degraded labetalol 
Labetalol hydrochloride was oxidized by treating 100 mg of the drug in 10 ml 
distilled water with 0.5 ml saturated sodium carbonate solution and 2.5 ml of 0.3 M 
sodium metaperiodate for 10 min at room temperature (25 ± 1°C). The excess of 
sodium carbonate was neutralized with the corresponding volume of HCl and then the 
products were isolated. The hydrolyzed solution was treated with methyl isobutyl 
ketone. The two layers were formed and the organic layer was separated out. The 
extract was then evaporated to dryness at room temperature and the residue as 
compound 1 (2-hydroxy-5-formylbenzamide) was crystallized from distilled water. 
Compound 2 (l-methyl-3-phenylpropylamine), which was in aqueous layer, was 
extracted with dichloromethane. The extract was evaporated to dryness and the 
residue was crystallized in ether. Thin layer chromatography was applied using silica 
gel G plate and a mixture of n -propanol - 1 % ammonia (4:1, v/v) as mobile phase. 
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The bands corresponding to labetalol, compound 1 (2-hydroxy-5-formylbenzamide) 
and compound 2 (l-methyl-3-phenylpropylamine) were located under UV lamp at 
254 nm and the Rf values were found to be 0.70, 0.80 and 0.35, respectively. The 
spots of compound 1 and 2 were too detected by spraying with 2, 4-
dinitrophenylhydrazine in 2M HCl and ninhydrin to give yellow and purple spots, 
respectively, thus indicating the presence of carbonyl group in compound 1 and amine 
group in compound 2. The literature has confirmed [28] that the two major products 
of labetalol were 2-hydroxy-5-formylbenzamide (I, compound 1) and l-methyl-3-
phenylpropylamine (II, compound 2) (Scheme 3.1) thus confirming the above 
findings. 
Validation 
The proposed method has been validated for specificity, linearity, precision, 
accuracy, and recovery. 
Specificity 
The sample solutions of labetalol tablet and capsule were subjected to stress 
conditions of light, heat, acid, base and oxidants. All stressed samples were analyzed 
for labetalol content and compared to an unstressed time zero reference solution. The 
reference assay value for the unstressed product was evaluated and the content of 
degradation in the stressed and control samples was calculated relative to this assay 
value. 
Linearity 
The linearity was evaluated by determining labetalol at ten concentration levels: 
0.8, 1.6, 3.2, 4.8, 6.4, 8.0, 11.2, 14.4, 16.0 and 17.6 ^g ml''. Each concentration was 
analyzed for five times. 
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'^V^  
0 
II 
H—C 
CONH2 
, -OH 
sodium metaperiodate 
in Na2C03 medium 
li 
Scheme 3.1.0xidative degradation of labetalol through N-dealkylation: 
1.2-hydroxy-5-formyIbenzamide and II. l-methyI-3-phenylpropylamine. 
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Accuracy and precision 
Three concentrations within the Hnearity range were selected: 1.6, 8.0, and 16.0 
jig ml' for evaluating accuracy and precision. Five independent analyses at each 
concentration level was performed within one day (intra day assay) and repeated for 
five consecutive days (inter day assay). 
Recovery studies 
To study the accuracy of the proposed method and to check the interference 
from excipients used in the formulations, recovery experiments were carried out by 
standard addition method. For this, 1.2 ml (or 2.0 ml) of sample solution (0.4 mg ml') 
was transferred into a 100.0 ml standard volumetric flask followed by 0.8 ml (or 2.0 
ml) of reference standard solution (0.4 mg ml'') and volume was completed to the 
mark with distilled water. The nominal value was determined by the recommended 
procedure. 
RESULTS AND DISCUSSION 
Spectral studies 
The aqueous solutions of pure labetalol and 4-aminobenzenesulphonic acid 
(sulphanilic acid) exhibit absorption maxima at 208 and 249 nm, respectively. The 
addition of NaN02 and HCl to 4-aminobenzenesuIphonic acid causes diazotization 
and the resulting product absorbs maximally at 270 nm. The blank solution is 
prepared similarly on addition of sodium carbonate to this diazotized solution, which 
causes no shift in the absorption maximum. The blank solution when added to the 
drug solution causes a remarkable shift in the absorption maximum due to the 
formation of coupling product, which exhibits absorption band peaking at 395 nm 
(Fig, 3.1), This reaction is exploited to develop a spectrophotometric method for the 
determination of labetalol hydrochloride in drug formulations by measuring the 
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Fig. 3.1. Absorption spectra of (a) pure drug solution: 10.0 jxg ml' of labetalol 
hydrochloride in distilled water; (b) 8.67x10"^  M 4-aminobenzenesulphonic acid 
in distilled water; (c) blank solution: diazotized solution (2 ml of l.TSxlO""* M 4-
aminobenzenesulphonic acid + 1.5 ml of 0.29 M NaNO: + 1.8 ml of 0.2 M HCl) 
with 4.0 ml of 0.28 M NaiCOj in 25 ml distilled water and (d) sample solution: 
440.0 |ig labetalol hydrochloride and 4.0 ml of 0.28 M NajCOs with diazotized 
solution (1.5 ml of 0.029 M 4-aminobenzenesulphonic acid + 1.5 ml of 0.29 M 
NaN02+ 1.8 ml of 0.2 M HCl) in 25 ml distilled water. 
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concrete absorbance at 395 nm. 
Mechanism of the colour reaction 
It has been reported that primary aromatic amines such as 4-nitroaniline and 4-
aminobenzenesulphonic acid on treatment with HCl and NaN02 in a temperature 
range of 0-3 °C, yield diazonium salt [29]. However, only strongly nucleophilic 
electron-rich aromatic or heteroaromatic compounds such as phenol can be coupled 
with diazonium salts to yield coloured azo compounds [30]. The diazocoupling 
reaction can be considered as a proton eliminating condensation of a positive 
diazonium ion with another compound possessing an active hydrogen atom. 
The substitution of electrophile usually proceeds para to the active group or ortho if 
para position is already substituted. In the similar manner, 4-aminobenzenesulphonic 
acid was diazotized to form a positive diazonium ion. Labetalol is a water-soluble 
antiadrenergic P-blocker possessing -OH group attached to the benzene ring (phenol) 
and forms phenolate ion in sodium carbonate medium [31]. The phenolate ion 
undergoes coupling reaction with positive diazonium ion to form a yellow azo 
compound, which absorbs maximally at 395 nm. In this case the coupling of 
diazonium ion proceeds ortho to the hydroxyl group of the benzene ring of labetalol 
because the para position in the drug is already occupied. The reaction sequence is 
shown in Scheme 3.2. 
Optimization of variables 
The different parameters responsible for the formation of diazocoupling 
coloured product were extensively studied. The optimum conditions for the 
proposed method were established by conducting a series of experiments. 
V/^ 
labetalol 
Na2C03 in H2O 
OH 
phenolate anion 
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HO3S -.r\ NH, 
4-aminoben2enesulfonic acid 
NaN02 + 2HC1 
0-3°C 
HO3S- V-N- NCI 
+ NaCl + 2H2O 
HO3S—< Ch N = N 
positive diazonium ion 
diazo coupling 
V 
N=N \ / 
SO,H 
Azo coupling product (colored) 
Scheme 3.2. Azo compound of labetalol (yellow coloured) formed due 
to union between the positive diazonium ion and a phenolate anion 
in sodim carbonate medium. 
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Effect of time 
To optimize the reaction time for colour development, 1.74 x 10'^  M 4-
aminobenzenesulphonic acid was treated with 1.74 x 10"^  M NaN02 and 1.60 x 10"^  
M HCl in a 25 ml standard volumetric flask. The content of the mixture was 
maintained in an ice bath (0 - 3 °C) for varied time of 2 - 14 min and then the flask 
was taken out. To each flask, 1.0 ml of 0.04% labetalol hydrochloride and 4.48 x 10' 
^ M Na2C03 were added and diluted to volume with distilled water at room 
temperature (25 ± TC). The maximum intensity of colour was obtained at 7 min of 
cooling and remained constant up to 14 min. Therefore, 10 min of reaction time was 
used throughout the determination process. 
Effect of 4-aminobenzenesulphonic acid concentration 
The influence of the concentration of 4-aminobenzenesulphonic acid on the 
development of colour was investigated by treating varied concentration (1.16 x 10' 
- 2.32 X lO"-' M) of 4-aminobenzenesulphonic acid with 1.74 x 10'^  M NaNOa and 
1.60 X 10-^  M HCl in a 25 ml standard volumetric flask and was cooled in an ice 
bath for 10 min. After cooling, 400.0 |Lig labetalol hydrochloride and 4.48 x 10'^  M 
NaaCOj were added and diluted to volume with distilled water at room temperature 
o 
(25 ± 1 C). It was observed that the absorbance measured at 395 nm increased with 
increasing concentration of 4-aminoben2enesulphonic acid and became constant at 
1.16x10" M, above this concentration absorbance remained constant (Fig. 3.2 a). 
Therefore, the concentration of 1.74 x lO'"* M 4-aminobenzenesulphonic acid proved 
to be sufficient for the maximum concentration of labetalol hydrochloride. 
Effect ofNaN02 concentration 
The effect of the concentration of NaNOa on the colour development was 
investigated in the range of 1.16 x 10"^  - 2.32 x IQ"^  M. The absorbance (Fig. 3.2 
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b) increased with increasing concentration of reagent and became constant at 1.16 x 
10" M, above which up to 2.32 x 10" M, absorbance remained constant. Therefore 
1,74 X 10"^  M; NaNOo was chosen as an optimum value for the determination 
process. 
Effect ofHCl concentration 
The influence of the concentration of HCl on the colour development has been 
investigated in the range of 1.60 x lO'-^  M - 1.84 x IQ'-^  M and the results are shown 
in Fig. 3.2 c. The highest absorbance was obtained with 1.04 x 10'^  M HCl, above 
this concentration up to 1.84x10'^  M, the absorbance remained constant. Therefore, 
the concentration of 1.44x10"^  M HCl was used in all measurements. 
Effect ofNa2C03 concentration 
The effect of the concentration of NaaCOs was studied in the range of 5.60 x 10' -
5.04 X 10"2 M. As can be seen from Fig. 3.2 d, the absorbance of the coloured 
product incretised with increasing concentration of Na2C03 and remained constant at 
3.36 X 10" M. Further increase in concentration of the reagent up to 5.04 x 10' M 
caused no change in the absorbance. Thus, 4.48 x lO''^  M NaiCOs was used as an 
optimum value for the determination of iabetalol. 
Analytical data and calibration graph 
The calibration graph between the absorbance at 395 nm and the Iabetalol 
hydrochloride concentration was found to be linear over the concentration range of 
0.8 - 17.6 \ig mf' with molar absorptivity and sandeli's sensitivity of 2.874 x IC* 1 
mol" cm" and 0.013 jig cm" per 0.001 absorbance unit, respectively. The linear 
regression equation of the proposed method has been evaluated by the least square 
treatment of the calibration data (n = 10). The linear regression equation and 
coiTelation coefficient are A = 4.84 x lO""* + 7.864 x 10"^  C where A is the 
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CD 
n 
L. 
o 
CO 
< 
.000 0.006 0.012 0.018 0.024 0.030 0.036 0.042 0.048 0.054 0.060 
Concentration of labetalol hydrochloride, M 
Fig. 3.2. Effect of the molar concentration of reactants: (a) 4-
aminobenzenesulphonic acid; (b) NaNO:; (c) HCI; and (d) Na2C03 with 16.0 jig 
ml' labetalol hydrochloride on the absorbance of the coloured product. 
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absorbance and C is the concentration of iabetalol hydrochloride in |j,g ml'' and r = 
0.9999, respectively, which indicated an excellent linearity. Table 3.1 summarizes 
Beer's law limit; linear regression equation; correlation coefficient; confidence 
limits and standard deviations for slope and intercept at 95% confidence level; 
variance; detection limit and quantitation limit [32] for the proposed method. 
The statistical analysis of the calibration data has made possible to calculate 
error (Sc) in the determination of a given concentration of Iabetalol hydrochloride 
using the following equation [33]; 
^•-T 
1/2 
, 1 (A-A)' 
1 + - + n b'Y.(C.-C)' 
where A and C are average values of the absorbance and concentration, respectively, 
for n standard samples. The plot of Sc versus concentration of Iabetalol 
hydrochloride (Fig. 3.3) indicates that the minimum error is obtained when the 
analysis is carried out at 8.40 jig ml"'. The value of Sc can be used to establish the 
confidence limit at the selected level of significance for the determination of 
unknown concentrations of Iabetalol hydrochloride using the relation Cj ± tSc. The 
resuhs are presented graphically (Fig. 3.4) by plotting the relative uncertainty 
(%AC/C) against the concentration of Iabetalol hydrochloride [34] at 95 and 99 % 
confidence levels for n-2 degrees of freedom. Thus, the confidence limit can be 
established and the relative uncertainty can be estimated directly on the 
concentration over the full range of the concentration tested. 
Specificity 
The specificity of the proposed method was evaluated by estimating the 
amount of Iabetalol in the presence of varying amounts of degraded products of 
139 
Table 3.1 
Optical performance and regression characteristics of the proposed method 
Parameters 
>^max (nm) 
Stability (h) 
Beer's law limit (}j,g ml"') 
Molar absorptivity (1 mol"' cm"') 
Linear regression equation 
Sa 
±tSa 
Sb 
±tSb 
Correlation coefficient (r) 
Detection limit (fig ml"') 
Quantitation limit (|J,g ml"') 
Proposed method 
395 
02 
0.8- 17.6 
2.87 X 10' 
A = 4.84x 10"'+7.86 X 10"^C 
1.02 X 10"^  
2.35 X 10"^  
9.99 X 10"^  
2.30 X 10"' 
0.9999 
0.08 
0.23 
Sa and Sb are standard deviation of intercept and slope, respectively. 
\40 
O 
L_ 
LU 
0.0275 
0.0270 
0.0265 -
0.0260 -
0.0255 
0.0250 -
0.0245 
0.0240 — I \ 1 1 1 1 \ — — 1 1 — • — I 1 1 1 1 1 1 1 — ' — I — 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Concentration of labetalol hydrochloride (j^ g mf^) 
Fig. 3.3. Plot of error (Sc) versus concentration of labetalol 
hydrochloride in the determination process. 
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0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Concentration of labetalol hydrochloride (^ ig nril'^ ) 
Fig. 3.4. Plot showing variation in the confidence limit at (a) 95% confidence 
and (b) 99 %confidence level: relative uncertainty percentage (% AC/C) versus 
concentration of labetalol hydrochloride. 
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labetalol such as 2-hydroxy-5-formylbenzamide and l-methyl-3-phenylpropylamine, 
which were the major degradants of labetalol. It was found that l-methyl-3-
phenylpropylamine did not interfere with the proposed method whereas 2-hydroxy-
5-formylbezamide interferes seriously. 
The various excipients commonly used in dosage forms such as sodium stearyl 
fumarate, magnesium stearate, starch, lactose and talc did not interfere with the 
proposed method. The samples were stressed by light, acid and base for 2, 2 and 5-
day-time points, respectively at room temperature (25 ± 1°C). It was observed that 
stress by such conditions did not cause significant degradation. There was no change 
in the absorption spectra of the pure drug and stressed (light, acid and base) sample 
solutions. The two reported metabolites of labetalol such as 0-sulphate (I, major) 
and 0-glucuronide (11, minor) (Scheme 3.3) were not interfering with the proposed 
method because of denature of the phenolic group in these metabolites [35]. The 
proposed method is specific and selective as not giving reaction with compounds, 
which lack phenol group in the moiety. 
Robustness 
The robustness of the proposed method relative to each operational parameter 
was challenged. The operational parameters investigated were as follows: 
• volume of 0.029 M 4-aminobenzenesulphonic acid, 1.5 ml (± 0.5 ml) 
• volume of 0.29 M NaN02, 1.5 ml (± 0.5 ml) 
• volume of 0.2 M HCl, 2.0 ml (± 0.5 ml) 
• volume of 0.28 M Na2C03,4.0 ml (± 1.0 ml) 
• cooling time of 10 min (± 3.0 min) 
Under these conditions quality control sample solution containing 8.0 fig 
ml" (Lobet 100, Samarth Pharma) of labetalol hydrochloride was assayed five times. 
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hepatic metabolism 
CONH2 
-OSO2O' 
Scheme 3.3 Metabolites of labetalol: I by sulphation and II by glucuronidation 
process. 
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The results obtained by the quality control sample represent good recovery with 
acceptable bias of OL >0.98 and BU < 1.02. 
Ruggedness 
The method ruggedness was evaluated by a second analyst using a different 
spectrophotometer (Spectronic 20D"^ , Milton Roy Company, USA) and freshly 
prepared standard sample solutions. The quality control tablet and capsule samples 
of labetalol hydrochloride were analyzed five times at one concentration level (8.0 
l^ g ml'') by the ruggedness chemist and developing chemist following the 
recommended procedure. The % recovery ± RSD resulted from ruggedness chemist 
(tablet: 99.97 ± 0.63%; capsule: 100.06 ± 0.58) and developing chemist (tablet: 
99.98 ± 0.52%; capsule; 99.97 ± 0.53%) were compared. The % recovery and RSD 
results agreed well within the acceptable limits with permissible bias of all samples 
within ± 2.0%). 
Accuracy and precision of the proposed methods 
The accuracy and precision of the proposed method was established by 
determining the content of labetalol in pure and pharmaceutical formulations at three 
different concentration levels (1.6, 8.0, and 16.0 j^ g ml''). The intra day and inter 
day precisions of the proposed method in pure form was evaluated by carrying out 
five independent analyses at each concentration level within one day and on five 
consecutive days (Table 3,2). In the same manner, the intra and inter day precisions 
was also performed in drug formulations by measuring the amount of labetalol at 
each concentration level (Table 3.3). The results presented in Table 3.2 and 3.3 can 
be considered to be very satisfactory. 
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Table 3.2 
Intra day and Inter day assays: Test of accuracy and precision of the proposed method 
in pure form 
Intra day Assay 
Amount (p.g 
Taken 
1.6 
8.0 
16.0 
Found :: 
1.60 ± 
8.00 ± 
16.01 ± 
ml"') 
hSD' 
0.04 
0.04 
0.04 
SAE'' 
0.019 
0,019 
0.019 
C.L' 
0.053 
0.052 
0.053 
Inter day Assay 
Amount 
Taken 
1.6 
8.0 
16.0 
(^gml-') 
Found ± SD' 
1.60 ±0.05 
8.01 ±0.05 
16.01 ±0.05 
SAE'' 
0.021 
0.021 
0.022 
C.L' 
0.059 
0.058 
0.061 
Mean for five independent analyses. 
'' SAE, standard analytical error. 
'^ C.L., confidence limit at 95% confidence level and four degrees of freedom (t = 2.776). 
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The validity of the proposed method was evaluated by recovery studies using 
the standard addition method. For this purpose, a known amount of reference drug 
was added to formulated tablets and capsules at two different concentration levels 
and the nominal amount of drug was determined by the proposed method. Each 
concentration level was analyzed five times and the results (Table 3.4) show good 
recovery with low SD and RSD. No interference from the common excipients was 
observed. 
The applicability of the proposed method has been tested for the determination 
of labetalol in drug formulations. The results of the proposed method were compared 
with those obtained by the Bilal's spectrophotometic method [24] using point and 
interval hypothesis tests [36]. The student's t and F-values at 95% confidence level 
did not exceed the tabulated t- and F-values, confirming no significant difference 
between the performance of the proposed method and the reference method (Table 
3.5). Once it is ensured that the proposed method is not significantly different from 
the reference method, it is necessary to check the bias of each drug sample based on 
recovery experiments using the interval hypothesis test. In pharmaceutical analysis, 
The Canadian Health Protection Branch has recommended a bias of ± 2 % with 
lower limit (BL) of 0.98 and upper limit (0u) of 1.02 [37]. It is evident from Table 3.5 
that the true bias of all samples is < ± 2 %. The interval hypothesis test has 
confirmed that the accuracy and precision are within the acceptable limits and 
indicated no significant difference between the performances of the proposed 
method and the reference method at 95% confidence level. 
The proposed method for the determination of labetalol hydrochloride in drug 
formulations was compared favourably with other existing spectrophotometric 
methods (Table 3.6). The molar absorptivity of the proposed method is higher than 
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Table 3.4 
Standard addition method: Evaluation of the validity of the proposed method 
for the recovery of labetaloi hydrochloride 
Formulations^ 
Tablet 
Lobet 100 
(Samarth Pharma) 
Capsule 
Normadate 50 
(Glaxo Smithline) 
Concentration 
(^gml"') 
Taken Added 
4.8 3.2 
8.0 8,0 
4.8 3.2 
8.0 8.0 
Found ± SD'' 
7.99 ±0.04 
16.01 ±0.05 
7.99 ±0.04 
16.01 ±0.04 
Recovery ± RSD^ 
(%) 
99.90 ±0.52 
100.09 ±0.27 
99.97 ±0.53 
100.07 ±0.27 
SAE 
0.018 
0.019 
0.019 
0.019 
C.L. 
0.051 
0.053 
0.053 
0.053 
^Mean for five independent analyses 
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Table 3.5 
Point and interval hypothesis tests: Evaluation of the applicability of the 
proposed method at 95yo confidence level 
Formulations^ Proposed method Reference method t & F- 9L' BU*^  
Recovery RSD' Recovery RSD'' values'' 
(%) (%) (%) (%) 
Tablet 
99.97 Lobet 100 
(Samarth Pharma) 
Capsule 
'Normadate 50 100.03 
(Glaxo Smithkline) 
0.63 99.89 0.8! t = 0.21I 0.991 l.OI 
F= 1.626 
0.52 99.98 0.86 t = 0.148 0.987 1.014 
F = 2.722 
*Mean for five independent analyses. 
''Theoretical t-value (v = 8) and F-value (v = 4, 4) at 95 % confidence level are 2.306 and 
6.39, respectively. 
'^ In pharmaceutical analysis, a bias, based on recovery experiments, of ± 2% is acceptable. 
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Table 3.6 
Comparison of the proposed method with existing spectrophotometric methods 
for the determination of labetalol hydrochloride in drug formulations 
Reagents 
2,6-dichloroquinone chlorimide 
Folin Ciocalteau's reagent 
4-aminophenazone 
Ferric ammonium sulfate 
p-N,N-dimethylphenylene-
diamine hydrochloride & sodium 
hypochlorite 
'^niiix 
(nm) 
670 
650 
510 
530 
685 
Beer's 
law limit 
(Mgml-') 
5-25 
8-40 
2,5-15 
50-250 
-
RSD 
(%) 
-
-
-
-
0.35-0.52 
Molar 
absoptivity 
(1 moP' cm"') 
1.39x10' 
5.88x10' 
2.09x10' 
1.05 xIO'^  
References 
[23] 
[23] 
[23] 
[23] 
[25] 
3-methyl 2-benzothiazolinone 545 
hydrazone hydrochloride & eerie 
ammonium sulfate 
0.35-0.52 [25] 
Suprachen violet 3B" 
Wool fast blue BL' 
Diazotized 
4-aminobenzenesulfonic acid 
565 
600 
395 
-
1-6 
0.8-17.6 
0.35-0.52 
0.64 
0.34-0.52 2.87x10' 
[25] 
[26] 
This work 
'Extractive method. 
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that of other methods indicating its greater sensitivity. It has the advantage of 
determining labetalol as low as 0.8 |.ig ml"'. Moreover, the proposed method is fast 
with respect to analysis time and directly applicable to the drug sample without prior 
extraction needed in other methods [25, 26]. The method is versatile and useful due 
to independence from pH and high tolerance limit from common excipients present 
in drug formulations. 
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CHAPTER-4 
KINETIC SPECTROPHOTOMETRIC METHODS 
FOR THE DETERMINATION OF RAMIPRIL IN 
COMMERCIAL DOSAGE FORMS 
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INTRODUCTION 
Ramipril, 2-[N-[(S)-l-ethoxy carbonyl-3-phenyl propyl]-L-alanyl]-(lS, 3S, 
5S)-2-azabicyclo [3.3, 0]-octane-3-carboxylic acid [M.W. 416.51] is an angiotensin-
converting enzyme inhibitor (ACE). It is used in the treatment of hypertension, heart 
failure and following myocardial infarction. It is also used to reduce the risk of 
cardiovascular events in patients with certain risk factors. Ramipril acts as a prodrug 
of diacid ramiprilat. Ramipril owes its activity to ramiprilat to which it is converted 
after oral administration [1,2]. This drug is officially listed in British Pharmacopoeia 
[3] which describes a potentiometric titration procedure for its assay in tablets. In 
order to assure the quantity of ramipril in dosage forms, several methods have been 
reported which include LC-MS [4], HPLC [5-8], capillary electrophoresis [9], 
atomic absorption spectrophotometry [10,11], voltammetry [12], ion selective 
electrode potentiometry [13], and radioimmunoassay [14]. 
The literature revealed that several spectrophotometric methods have been 
reported for the quantitative analysis of ramipril in pharmaceutical preparations and 
biological fluids. The estimation of ramipril in a binary mixture was carried out by 
derivative compensation technique [15] as well as zero crossing derivative technique 
[16, 17]. The determination of ramipril was carried out based on ion-pair complex 
of the drug with picric acid and bromocresol green [18], formation of ternary 
complex of the drug with Cu (II) and eosin [10], and Fe (III) and ammonium 
thiocyanate [11]. The charge transfer complexation reaction has also been utilized 
for its quantification using 7,7,8,8,tetracyanoquinodimethane, p-chloranilic acid and 
2,3-dichloro-5,6-dicyano-p-benzoquinone [19]. Potassium permanganate oxidizes 
ramipril in alkaline medium and itself reduces to manganate ion, which was 
157 
measured at 610 nm [20]. The estimation of ramipril has been done by 
spectrophotometry and fluorinietry utilizing the reaction of the drug with 7-fluoro-4-
nitrobenzo-2-oxo-l,3-diazole, which exhibits maximum absorbance at 460 nm, and 
maximum fluorescence intensity at 530 nm after excitation at 465 nm [21]. The 
reaction of ramipril with a mixture of potassium iodide and potassium iodate has 
been utilized for its assay in commercial dosage forms [22]. 
This chapter describes a simple and sensitive spectrophotmetric method for the 
determination of ramipril in bulk and dosage forms. The method is based on the 
reaction of ramipril with 1- chloro 2, 4- dinitrobenzene (CDNB) in 
dimethylsulphoxide (DMSO) at 100 ± Tc. The absorbance (kmax = 420 nm) of the 
coloured product increases as a function of heating time. Therefore, two calibration 
procedures i.e. fixed time (AA) and equilibrium methods are adopted for the 
determination of ramipril in bulk and commercial dosage forms. 
EXPERIMENTAL 
Apparatus 
Spectral runs were made on a Shimadzu UV-visible 1601 spectrophotometer 
(Model no. 1601, Kyoto, Japan). All other spectrophotometric measurements were 
made on Spectronic 20 D"*' spectrophotometer (Milton Roy Company, USA). A 
water bath shaker (NSW 133, New Delhi, India) was used for heating. 
Material and reagents 
Ramipril reference standard (Batch No. TR001FO2 ) was kindly provided by 
Dr. Reddy's Laboratories Limited (Andhra Pradesh, India). CDNB and DMSO were 
purchased from Merck Limited, Mumbai, India. The pharmaceutical preparations of 
ramipril such as Ramipres-2.5 (Cipla, Mumbai, India), Ramace-2.5 (AstraZeneca, 
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Mumbai, India) and Hopace-2.5 (Cardicare, Bangalore, India) were obtained from 
local market. 
Standard solutions: 
• 0.7% CDNB (3.46 x 10'^  M) was prepared in DMSO. 
• 0.1% ramipril (2.40 x 10'^  M) was also prepared in DMSO. 
Procedure for determination 
Accurately measured aliquots of standard solution of ramipril corresponding 
to 0.1 - 1.1 mg were transferred into a series of 5 ml standard volumetric flasks. To 
each flask, 2.2 ml of 3.46 x 10'^  M CDNB was added and diluted to volume with 
DMSO. The content of the mixture was kept on water bath at 100 ± 1°C for a 
preselected fixed time. The absorbance of the yellow coloured product was 
measured at 420 nm against the reagent blank as a function of time. The following 
two procedures were adopted for constructing the calibration graphs: 
• Fixed-time method (l^A): The change in absorbance (AA) between the times, ti 
(3 min) and t2 (6 min) was computed and plotted against the initial 
concentration of ramipril. 
• Equilibrium method: The equilibrium was attained at 30 min of heating. The 
absorbance measured at 32 min of heating was plotted against the initial 
concentration of ramipril. 
Alternatively, regression equations were also developed for estimation of the 
content of ramipril. 
Analysis of commercial dosage forms 
To determine the amount of ramipril in pharmaceutical preparations (label 
claim: 2.5 mg / tablet or capsule), the contents of 20 tablets or capsules were 
weighed and finely powdered. A portion of the powder equivalent to 50 mg ramipril 
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was stirred with 20 ml DMSO and let stand for 10 min. The residue was filtered on 
Whatmann No, 42 filter paper (Whatmann International Limited, Kent, UK) and 
washed with DMSO. The filtrate and washings were diluted to 30 ml with DMSO. 
This solution was fiarther diluted as necessary to complete the analysis following the 
recommended procedures. 
Procedure for reference method [10] 
An aliquot of standard solution containing 0.1 - 1.0 mg of ramipril was 
transferred into a series of 50.0 ml separating funnels. The volume of each solution 
was adjusted to 10.0 ml with distilled water and 3.0 ml of 0.2% Cu (II) sulphate and 
1.0 ml of 0.1% eosin were added with swirling. The funnels were shaken vigorously 
with 3.0 X 3.0 ml portions of chloroform for 1.0 min, and then allowed to pass the 
organic layer through anhydrous sodium sulphate into a 10.0 ml standard volumetric 
flask. The volume of chloroform layer was made up to 10.0 ml and the absorbance 
was measured at 535 nm against the reagent blank prepared similarly and a 
calibration graph was constructed. 
Validation Parameters 
Specificity 
The specificity of the proposed method was evaluated by determining the 
ramipril concentration in the presence of varying amounts of degraded product of 
ramipril (ramipril diketopiperazine) and common excipients (sodium stearyl 
fumarate, magnesium stearate, starch, lactose and talc). 
Recovery studies 
Recovery experiments were carried out by standard addition method. For this, 
4.0 ml (or 8.0 ml) of reference ramipril solution (1.0 mg ml"') was transferred into a 
100.0 ml volumetric flask followed by 6.0 ml of sample solution (I.O mg ml'') and 
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volume was completed up to the mark with DMSO. The total amount was 
determined by the recommended procedure. 
Limits of detection and quantitation 
The limits of detection (LOD) and quantitation (LOQ) were calculated using 
the following equations [23]: 
LOD = 3.3 xSo/bandLOQ=\OxSo/b 
where So and b are the standard deviation and slope of the calibration line, 
respectively. 
RESULTS AND DISCUSSION 
A yellov*/ coloured product with maximum absorption at 420 nm was formed 
when ramipril was allowed to react with CDNB in DMSO while the reagent, CDNB, 
exhibited absorption band at 350.5 nm. (Fig. 4.1) At room temperature, the reaction 
did not take place, hence the reaction was carried out at 100 ± 1°C to increase the 
rate of reaction and decrease the time for attaining equilibrium. At this temperature, 
the intensity of the coloured product increased with time and attained equilibrium in 
30 min. The increase in absorbance as a function of time was utilized to develop a 
kinetically based spectrophotometric method for the quantitation of ramipril. 
Optimization of reaction conditions 
The optimum conditions affecting the formation of Meisenheimer complex 
were studied and maintained throughout the experiment to determine the quantity of 
ramipril in bulk and drug formulations. 
Effect of heating time 
To optimize the reaction time for colour development, 2.2 ml of 3.46 x 10" M 
CDNB and 1.0 ml of 2.40 x lO''^  M ramipril were added and kept on water bath at 
0 
100±1 C for varied time. The maximum intensity of colour was obtained at 30 min 
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280 320 360 400 
Wavelength (nm) 
520 
Fig. 4.1. Absorption Spectra of (a) 4. 80 x lO'^  M ramipril (b) 3.46 x 10'^  M 
CDNB versus DMSO (c) Complex (4. 80 x 10 ^  M ramipril and 1.73 x 10 ^  M 
CDNB) versus Blank (1.73 x 10 ^  M CDNB). 
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of heating and remained constant up to 34 min. Therefore, 32 min of reaction time 
was used in equihbrium method (Fig. 4.2). 
Effect of the concentration ofCDNB 
The effect of the concentration of CDNB on the coloured product was studied 
using the equilibrium procedure in the range 1.38 x 10'^  - 1.66 x 10'^  M. The 
absorbance increased with increase in concentration of CDNB. The maximum 
absorbance was obtained with 1.38x10'^  M; above this concentration absorbance 
remained constant (Fig 4.3). Thus, 1.52 x 10'^  M was used for subsequent studies. 
Stoichiometry 
The stoichiometry of the reaction was established by limiting logarithmic 
method [25]. The slopes of the plots of logarithm of absorbance versus logarithm of 
respective varied molar concentration were calculated and found to be 1:1 between 
ramipril and CDNB (Fig 4.4). The mole ratio method was also employed to evaluate 
the combining ratio. The plot of absorbance versus mole ratio (ramipril/ CDNB) has 
also confirmed that one mole of ramipril reacted with 1 mole of CDNB (Fig 4.5). 
The apparent formation constant and Gibbs free energy (A G*) were calculated and 
found to be 7.20 xlO^ and -56.12 KJ mol"', respectively. 
Mechanism of the reaction 
A literature survey revealed that brightly coloured products are formed when 
polynitroaromatic and halopolynitroaromatic compounds react with bases. The 
formation of coloured products is due to various interactions depending upon the 
degree to which the base participates through its unshared electron pair with the 
nitro compounds [25]. Ramipril possesses -NH group in its structure thus behaves 
as a base. The addition of CDNB to ramipril in DMSO yielded the 1-substituted 
Meisenheimer complex, which absorbs maximally at 420 nm. On the basis of our 
163 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 
Time of heating (min) 
Fig. 4.2. Effect of heating time on the absorbance of the coloured product 
(ramipril 200.0 ^g ml'). 
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-^ 1 1 1 1 1 1 r 
0.000 0.002 0.004 0.006 0.008 0.010 0.012 0.014 0.016 0.018 0.020 
Concentration of CDNB (M) 
Fig. 4.3. Effect of the concentration of CDNB on the absorbance of the coloured 
product (ramipril 200.0 |j,g ml"'). 
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a, -2S 
o 
TO 
o -3.2 
m 
n 
< 
o -3.6 
-4.0 
-4.4 
-4.8 
log A = -3.422 ±0.002 
(r = 0.99904) 
.002 ± 0.003 log [ramipril 
log A = -2,063 ± 0.007 + 0.995 ± 0.016 log [CDNB] 
(r = 0.99999) 
-1.0 -0.8 -0.6 -0.4 -0.2 
Log [Ramipril] or [CDNB] 
0.0 0.2 
Fig. 4.4. Limiting logarithmic plots for molar combining ratio between 
ramipril and CDNB: (a) log Absorbance versus log [Ramipril]; (b) log 
Absorbance versus log [CDNB]. 
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0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 
Mole ratio (Ramipril / CDNB) 
Fig, 4,5. Mole ratio plot for the reaction between ramipril and CDNB in DMSO 
([Ramipril] = [CDNB]) - 3,46x10"^  M). 
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experimental findings and literature background [26] the reaction mechanism is 
proposed and given in Scheme 4.1. 
Solution stability 
The solution stability was ascertained from UV spectra of reference standard 
and quality control samples. The reference standard of the drug showed an 
absorption peak at 260 nm. The standard and quality control sample solutions were 
kept at room temperature for five days and it was observed that there was no change 
in the absorption spectra of these solutions. The solution stability was also 
ascertained by applying the standard and quality control samples on TLC plates 
coated with silica gel G (Merck Limited, Mumbai, India) and developed in 
methanol-chloroform (2:8 v/v) solvent system. The plates were air-dried and spots 
were detected in the iodine chamber. In both the cases, a single spot was observed 
with Rf = 0.80 corresponding to ramipril. 
Analytical performance 
Under the optimized experimental conditions mentioned above, the 
absorbance of each solution was recorded as a function of time at a regular interval 
of 3 min. The change in absorbance (AA) between the times ti (3 min) and t2 (6 or 9, 
12, 15 min) was computed and plotted against the initial concentration of ramipril. 
The corresponding linear regression equations with coefficient of correlations are 
summarized in Table 4.1. As can be seen from the table that the most acceptable 
linearity was obtained when the change in absorbance between 3 and 6 min (i.e. AA 
= Ae - A3) was plotted against the initial concentration of ramipril. This fixed time 
was adopted for the assay procedure. 
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CDNB 
Ramipril 
DMSO 
At 100°C 
.„n\\\H 
C OH 
+ HCl 
C OH 
Meisenheimer yellow complex 
Scheme 4.1 
Table 4.1 
Calibration equations at different fixed times 
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AA Calibration equation 
A6-A3 AA= 6.30X 10""+1.54x 10"-^ C 0.9999 4.14x10"" 3.14x10"" 
A9-A3 AA = -1.43 X 10-' + 2.04x 10"^C 0.9998 1.81x10"' 1.37x10"^ 
A,2-A3 AA = -3.36x 10--' + 2.62x 10"'C 0.9998 2.17x10" ' 1.64x10"' 
A,5-A3 AA = -6.90x 10"' + 3.16x 10"'C 0.9997 4.18x10"^ 3.16x10"' 
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The reaction between ramipril and CDNB required 30 min to complete. 
Therefore, in equilibrium procedure, the calibration curve was constructed by 
plotting absorbance measured after attaining the equilibrium (32 min) against the 
initial concentration of ramipril. The linear dynamic range, molar absorptivity, 
regression equation, correlation coefficient, confidence limits for slope and 
intercept, limits of detection and quantitation, and variance of calibration line for 
both the procedures are summarized in Table 4.2. The high values of correlation 
coefficient indicated the excellent linearity of the calibration curves. The small 
values of confidence limit of slope and intercept pointed towards good 
reproducibility of the proposed procedures. 
The accuracy and precision of the fixed time and equilibrium methods were 
evaluated by performing five successive measurements within one day at three 
different concentration levels (40, 120 and 220 |.ig ml"'). The inter day precision was 
measured by assaying the bulk sample on five consecutive days. The results are 
summarized in Table 4.3. The results showed that the RSD (< 0.22%) and standard 
analytical error (< 0.04) found in intra and inter day assays can be considered to be 
very satisfactory. 
To test the applicability of the proposed methods, recovery experiments were 
performed using the standard addition method. For this purpose, a known amount of 
pure ramipril was spiked to its formulated preparations and the total amount of the 
drug was estimated. The results are summarized in Table 4.4. As can be seen from 
the table that the mean recovery ranged from 99.98 - 100.03% with low RSD values. 
Moreover, it was also found that the degraded product of ramipril and common 
excipients such as sodium stearyl fumarate, magnesium stearate, starch, lactose and 
talc did not interfere with quantitation process. 
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Table 4.3 
Evaluation of accuracy and precision of the proposed methods 
Proposed methods 
Fixed time (A A) 
Intra day assay 
Inter day assay 
Equilibrium method 
Intra day assay 
Inter day assay 
Amount 
(^g ml-') 
Taken 
40.0 
120.0 
220.0 
40.0 
120.0 
220.0 
40.0 
120.0 
220.0 
40.0 
120.0 
220.0 
Found ± SD' 
40.01 ±0.06 
119.99 ±0.06 
219.99 ±0.07 
39.97 ±0.08 
119.99 ±0.06 
219.94 ±0.07 
39.99±0.08 
119.98 ±0.07 
219.98±0.07 
40,01 ±0.09 
120.01 ±0.08 
220.03 ±0.08 
RSD 
(%) 
0.15 
0.05 
0.03 
0.20 
0.05 
0.03 
0.20 
0.06 
0.03 
0.22 
0.07 
0.04 
SAE'' 
0.026 
0.026 
0.032 
0.036 
0.029 
0.033 
0.036 
0.031 
0.032 
0.039 
0.035 
0.036 
C.L.' 
0.072 
0.071 
0.088 
0.099 
0.080 
0.092 
0.100 
0.085 
0.089 
0.107 
0.097 
0.101 
'^ Mean for 5 independent analyses. 
^ SAE, standard analytical error. 
•"CL., confidence limit at 95 % confidence level and 4 degrees of freedom (t = 2.776). 
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The proposed methods have been applied for the analysis of ramipril in 
commercial dosage forms. The analysis of the same batch of samples was also 
completed by Abdellatefs spectrophotometric method [10]. The results of the 
proposed method (fixed time or equilibrium method) were compared with those 
obtained by the Abdellatefs spectrophotometric method. The student's t- and F-
values at 95% confidence level did not exceed the tabulated t- and F- values. The 
interval hypothesis test [27] has also been performed to compare the results at 95% 
confidence level. The results presented in Table 4,5 showed that the true bias of all 
samples is smaller than ±2% indicating the compliance of the regulatory authorities 
[28]. These tests have confirmed that there is no significant difference between the 
performances of the methods compared. 
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Table 4.5 
Comparison of the proposed methods with the reference method 
Formulations 
Tablets 
Ramipres 
(Cipla) 
Fixed time method 
Recovery RSD 
(%) (%) 
100.03 0.05 
eL= 0.986 eu= 1.012 
Equilibrium method 
Recovery RSD 
(%) (%) 
99.99 0.07 
eL= 0,986 eu = 1.013 
Reference method 
Recovery RSD 
(%) (%) 
99.98 0.09 
Ramace 100.01 0.06 100.00 0.07 99.98 0.08 
(AstraZeneca) eL=0.987 0u= 1.012 0L=O.987 eu= 1.013 
t = 0.063 F= 1.889 t =0.038 F= 1.443 
Capsule 
Hopace 99.95 0.06 99.98 0.09 100.00 0.10 
(Cardicare) eL= 0.986 Gu = 1.014 91=0.983 80 = 1.016 
t = 0.081 F = 2.819 t = 0.029 F= 1.217 
Theoretical t- (v = 8) and F-values (v = 4, 4) at 95 % confidence level are 2.306 and 6.39, 
respectively. 
9L and Gyare within the acceptable limits of ± 2%. 
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SPECTROPHOTOMETRIC METHODS FOR 
THE DETERMINATION OF PERINDOPRIL 
ERBUMINE IN PHARMACEUTICAL 
PREPARATIONS VIA TERNARY COMPLEX 
FORMATION WITH Zn ( I I ) AND EOSIN AND 
CHARGE TRANSFER COMPLEXATION WITH 
IODINE 
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INTRODUCTION 
Perindopril erbumine is chemically known as, tert-butyl-amine salt of [[2S-1-
(R, R) 2a, 3aP, 7aP]-l-[2-(l-ethoxy carbonyl butyl] amino]-oxopropyl, octa-lH 
indole-2 carboxylic acid [CAS No. 107133-36-8, MW. 441.6], It is used for 
management of hypertension and congestive heart failure. The effectiveness of 
perindopril as an antihypertensive drug has been demonstrated in various clinical 
trials [1,2]. The prodrug is transformed in vivo by hydrolysis into pharmacologically 
active perindoprilat. It is thought that perindopril reduces blood pressure by 
inhibiting the enzyme which catalyses the conversion of angiotensin I to angiotensin 
II. Decreased plasma angiotensin II leads to increase plasma rennin activity and a 
decrease in aldosterone. Studies in animals and humans suggest that specific and 
competitive suppression of the rennin-angiotensin-aldosterone system is the main 
mechanism by which blood pressure is reduced. 
The drug is officially listed in the monograph of British Pharmacopoeia [3], 
which describes a potentiometric titration procedure for its assay in formulations. In 
order to assure the quantity of perindopril in pharmaceutical preparations, several 
methods have been reported in the literature for the determination of perindopril 
such as GC [4], GC-MS [5], HPLC [6], capillary electrophoresis [7], atomic 
absorption spectrophotometry [8 ], and radioimmunoassay [9,10]. 
Few spectrophotometric methods have also been reported for its quantification 
in commercial dosage forms using eosin and copper [8], bromothymol blue at pH 
5[11], FeCls in the presence of potassium thiocyanate [11]. TT- acceptors [12] such as 
2,3- dichloro- 5,6- dicyano-p-benzoquinone, 7,7,8,8- tetracyanoquinodimethane, 
tetracyanoethylene, chloranil and p-chloranilic acid as chromogenic reagents. 
Kinetic spectrophotometric method was also utilized based on the reaction with 1-
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chloro 2,4- dinitrobenzene and measuring the rate of change of absorbance at 420 
nm [13]. The assay of perindopril was carried out by UV-spectrophotometry using 
zero crossing method [14]. 
This chapter reports two simple, sensitive and accurate spectrophotometric 
methods for the determination of perindopril in commercial dosage forms. Method 
A is based on the ternary complex formation with Zn (II) and eosin which is 
quantitatively extracted into chloroform and measured at 510 nm whereas Method B 
is based on the formation of charge transfer complex between perindopril and iodine 
in dichloromethane at room temperature. 
EXPERIMENTAL 
Apparatus 
Spectral runs were made on a Shimadzu UV-visible 1601 spectrophotometer 
(Kyoto, Tokyo, Japan). All other spectrophotometric measurements were made on 
Spectronic 20 D"^  spectrophotometer (Milton Roy Company, USA). 
Materials and reagents 
All chemicals and reagents were of analytical or pharmaceutical grade. 
Perindopril erbumine was kindly provided by Glenmark Pharmaceuticals Ltd. 
Mumbai, India. 
Pharmaceutical formulations of perindopril erbumine such as Coversyl (Serdia 
Pharmaceuticals Ltd., India) and Perigard (Glenmark Pharmaceuticals Ltd., India) 
were purchased from local drug stores. 
(I) 1.39x10"^  M zinc sulphate (Merck limited, Mumbai, India) solution was prepared 
in doubly distilled water 
(II) 1.45xl0"'M eosin (Fluka Chemie AG, Switzerland) solution was also prepared 
in doubly distilled water. 
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(111) 2.36x10"" M iodine resublimed (Merck limited Munibai, India.) solution was 
prepared in dichloromethane (Merck limited, Mumbai, India.). 
Standard test solutions 
Standard perindopril (Img ml"') (Batch No. K32002003, Glenmark 
Pharmaceuticals Ltd, Mumbai) solutions were prepared in doubly distilled water and 
dichloromethane for methods A and B, respectively. The solutions were stable for at 
least five days if stored at room temperature and dark place. 
Proposed procedures 
Method A 
Appropriate volumes (0.05-1.00 ml) of the standard perindopril solution (1 mg 
ml"') were placed into a series of 100 ml separating funnels. To each funnel, 2.2 ml 
of zinc sulphate (1.39 xlO"' M) solution was added followed by 2.0 ml of eosin 
(1.45 X10"''M) solution and shaken well. The complex was extracted with 2 x 2.5 ml 
portions of chloroform and chloroform layer was passed over anhydrous sodium 
sulphate. The absorbance of the resulting complex was measured at 510 nm against 
blank in which the drug is omitted. The nominal content of the drug was determined 
from the calibration graph or corresponding regression equation. 
Methods 
Appropriate volumes of standard solution of perindopril (1 mg ml"') 
corresponding to 50- 900 \xg were transferred into a series of 5 ml volumetric flasks. 
To each flask, 2.0 ml of 2.36 xlO""^  M iodine was added and diluted to volume with 
dichloromethane. The contents of each flask were mixed well and absorbance of the 
yellow coloured product was measured at 365 nm against a reagent blank in which 
drug is omitted. The absorbance was plotted against the initial concentration to get 
the calibration curve. Alternatively, regression equation was derived. 
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Determination procedure for perindopril in pharmaceutical formulations 
Twenty five tablets of perindopril (label claim: 2.0 mg/tablet) were powdered 
and perindopril was extracted separately by shaking with 20 ml doubly distilled 
water and dichloromethane for methods A and B, respectively., followed by another 
two extractions, each with 10 ml of distilled water and dichloromethane. The 
extracts were filtered through Whatmann No 42 filter paper (Whatmann 
International Limited, Kent, UK) into a 50 ml volumetric flask and then diluted to 
volume with appropriate solvent. An aliquot of the diluted solution was analysed for 
perindopril content following the proposed procedures. 
Limits of detection and quantitation 
According to International Conference on Harmonisation (ICH) guidelines 
[15], the following expressions are used to evaluate LOD and LOQ. 
LOD = 3 ,3xSo/bandLOQ=10xSo/b 
where So and b are standard deviation and slope of the calibration line, respectively . 
Evaluation of bias 
The point and interval hypothesis tests [16] have been performed to compare 
results of the proposed methods with those of the reference method at 95% 
confidence level. The test method is considered acceptable when its true mean is 
within ± 2.0 % of that of the reference method. This can be written as 
0.98<^2/lii <1.02 
which can be generalized to 
9L < 1^7/HI <9U 
where 9L and 6u are lower and upper acceptance limits, respectively which were 
calculated from the following quadratic equation [16]. 
e'\x',-Syin,]-297,7-,^e\xl~Syin^]=^ 
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RESULTS AND DISCUSSION 
Method A 
Ternary complexes of general formula (LnMxSy) have been widely used in 
spectrophotometric analysis [17-23]. In the present study, the ternary complex was 
utilized for the determination of perindopril in which main ligand L is perindopril, 
the second ligand S is eosin and M is Zn (II). The ternary complex is extractable 
with chloroform, whereas the binary system (zinc- drug and zinc - eosin) cannot be 
extracted in that way. In the ternary complex, the interaction of Zn (II) (X), 
perindopril (Y) and eosin (Z) may be considered as 
either XY+Z<^ XZ+Y 
or XY +Z ^ XYZ 
The absorption spectra have been recorded for each component, separately, and to 
their mixture under the experimental conditions discussed above in both aqueous 
and organic solvent. The spectra revealed (Fig. 5.1) that aqueous solution of eosin 
(Z) absorbed maximally in the visible region at 470 nm and there are no significant 
changes in colour and absorption spectrum in the presence of Zn (II) or perindopril, 
while neither Zn (II) nor the perindopril shows any absorption in the visible region, 
However, when Zn (II) solution is mixed with a mixture containing perindopril and 
eosin, the orange - yellow colour changes to red. The absorption spectrum of the 
reaction mixture exhibited a new band peaking at 510 nm. The later spectrum is 
attributed to the formation of ternary complex. 
Optimization of the experimental condition 
The different experimental parameters affecting the colour development and 
its stability were carefully studied and optimized. Such factors were changed 
individually while the others were kept constant. 
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Fig. 5.1. Absorption spectra of (a) 4.34x10''' M eosin; (b) 4.34x10"^  M eosin and 
8.35x10"* M Zn (II); (c) 4.34x10"'' M eosin and 50.0 ng ml' perindopril against 
doubly distilled water (d) 200.0 jig ml' perindopril with 6.12xl0''' M Zn (II) 
and 5.78 xlO'^ M eosin extracted into chloroform against blank (6.12x10"^  M Zn 
(II) and 5.78 x l O ^ eosin ) treated similarly. 
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colour changes to red. The absorption spectrum of the reaction mixture exhibited a 
new band peaking at 510 nm. The later spectrum is attributed to the formation of 
ternary complex. 
Optimization of the experimental condition 
The different experimental parameters affecting the colour development and 
its stability were carefully studied and optimized. Such factors were changed 
individually while the others were kept constant. 
Effect ofZn (II) concentration 
The effect of concentration of Zn (II) on the absorbance of the ternary 
complex was studied over the concentration range 2.78xlO'V- 6.68xlO'^M; 
keeping the concentrations of the drug (4.53XI0"' 'M) and eosin (5.78X10' ' 'M) 
constant. It was observed that increasing the concentration of Zn (II) would result in 
a gradual increase in the absorbance of the ternary complex up to5.56x10' M and 
remained constant up to 6.68xlO"-^ M. Thus 6.12xlO'^M of Zn (II) was used as an 
optimum concentration (Fig. 5.2). 
Effect of eosin concentration 
The effect of eosin concentration on the absorbance of the ternary complex 
was examined in the concentration range of 2.89xlO"^M- 6.36X10' ' 'M; keeping the 
concentration of the drug (4.53xlO"'*M) and Zn (II) (6.12xlO''^M) constant. It was 
found that increasing the concentration of eosin resulted in a subsequent increase in 
the absorbance value of the ternary complex up to 5.20X10'' 'M and remained 
constant up to 6.36 X10"''M. Therefore, a concentration of 5.78X10"''M was used as 
the optimum concentration of eosin (Fig. 5.3). 
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2+ Concentration of Zn *M 
Fig. 5.2. Effect of molar concentration of Zn (II) on the formation of ternary 
complex 
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Fig. 5.3. Effect of molar concentration of eosin on the formation of ternary 
complex 
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Effect of shaking time 
In order to examine the effect of shaking time on the complex formation and 
the absorbance of the drug- Zn (II) - eosin ternary complex, experiment was 
performed for the periods ranging from 1-3 min. A constant absorbance was 
obtained from one min. shaking and remained constant up to three min. Therefore, 
two min. shaking time was recommended for the determination process. 
Stoichiometry of the ternary complex 
The stoichiometrty of the reaction was studied adopting the limiting 
logarithmic method [24]. For this, three sets of experiments were performed. In the 
first set, the concentration of perindopril was varied; keeping excess concentrations 
of Zn (II) (6.12 xiO"^M) and eosin (2.89 xlQ-^M). In the second set, the 
concentration of Zn (II) was varied while keeping high concentrations of perindopril 
(4.53 xlO'^M) and eosin (2.89 xlO"-^ M). In the last experiment, excess 
concentrations of Zn (II) (6.12 x\Q'^M) and perindopril (4.53 xiO'-^ M) were 
employed and the effect on the absorbance was observed on varying the 
concentration of eosin. A plot of log absorbance vs. log [perindopril] or log [Zn (II)] 
or log [eosin] gave straight lines; the values of the slopes are 0.97, 1.02 and 1.01, 
respectively. (Fig. 5.4 a, b and c) Hence, it is concluded that the reaction proceeds 
in the ratio 1: 1:1, confirming that one molecule of the drug denses with one 
molecule of Zn (II) and one molecule of eosin. Based on the obtained molar 
reactivity, and literature background, the possible reaction pathway is proposed and 
shown in Scheme 5.1. 
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2+1 log[Drug] or [Eosin] or [Zn ] 
Fig. 5.4. Limitting logarithmic plot for molar combining ratio between 
perindopril, Zn (II) and eosin: (a) log Absorbance vs log [Perindopril]; (b) log 
.2+ Absorbance vs log [Zn ]; (c) log Absorbance vs log [eosin]. 
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Scheme 5.1 
Method B 
The absorption spectrum of iodine in dichloromethane showed only one peak 
with maximum absorption at 500 nm. The colour of iodine changes to yellow upon 
reaction with perindopril. This is due to charge transfer complexation reaction 
between the n- donor amine and the a- acceptor iodine followed by the formation of 
tri- iodide ion pair (Scheme 5.2) that exhibited strong absorption maxima at 290 and 
365 nm (Fig. 5.5). 
Optimization of the experimental condition 
Effect of concentration of iodine 
The influence of concentration of iodine on the absorbance of the complex 
was investigated by treating varied concentration (4.73 xlO'^M- 1.04 xlO' M) of 
iodine with 0.75 ml of 2.26 x]0"^M perindopril into a series of 5 mi flasks. The 
contents were diluted with the same solvent at room temperature. The highest 
absorbance was achieved with 8.51 xlO''' M iodine. Further addition of iodine 
caused no change in the absorbance and therefore, 9.44x10''' M iodine was selected 
as an optimum concentration for determination process (Fig. 5.6). 
Stoichiometric relationship 
Job's Method [25] was applied to determine the molar combining ratio for 
charge transfer complex, perindopril- iodine. It is apparent from Fig. 5.7 that the 
molar combining ratio between perindopril and iodine is 1:1. 
The spectrophotometric data were used to calculate the association constant 
and apparent molar absorptivity of the perindopril- iodine charge transfer complex 
using the Ross and Labs equation [26]: 
MHO) , ± , J , , 1 , ' 
[A] + ID] A, Ke, [A] + [D] c, 
Stepl-
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200 250 300 350 400 450 500 550 600 650 700 
V\^ve length (nm) 
-3 Fig. 5.5. Absorption spectra of (a) 1.5 ml of 2.36 x 10" M iodine in 
-3 dichloromethane and (b) 750,0 ng perindopril and 2.0 ml of 2.36 x 10 M 
iodine in dichloromethane. In both cases, the solutions were diluted to 5 ml. 
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Concentration of iodine,M 
Fig. 5.6. Effect of the molar concentration of iodine on the absorbance of 
coloured product (perindoprii 150.0 |ag ml"') 
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mole fraction of drug 
Fig. 5,7, Job's plot for the reaction between perindopril and iodine in 
dichlorometane ([Perindopril] = [Iodine] = 1,00x10'^  M). 
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where [A] and [D] are the initial molar concentration of iodine and perindopril, 
respectively. Aj,^ and f ^  are the absorbance and apparent molar absorptivity of the 
charge transfer complex at the wavelength X. K is the association constant of the 
complex. 
The values of -^—^—— x — were plotted against which yielded a 
[A] + [D] A, [A] + [D] 
•• 1 1 
straight line (Fig. 5.8) with the slope of and intercept — . This straight line is 
described by the following regression equation: 
i i l i ^ x — = 7.62x10^'X ^ + 2.69x10^" (r =0.9999) 
[A]^[D] A, [A]^-{D] 
From the above equation, the association constant and apparent molar 
absorptivity of the charge transfer complex were found to be 3.53x10'and 3.71 xlO' 
1 mol" cm' , respectively. The standard free energy of complexation, AG , was 
calculated using the relation: AG = -RTln K and found to be - 20,25 KJmol" . 
Validation parameters 
Selectivity 
The selectivity of the method was ascertained by analyzing standard 
perindopril in presence of excipients such as lactose, magnesium stearate, cellulose 
and silicon dioxide. It was observed that both methods are free from interferences. 
Analytical data 
Standard calibration curves for both the procedures were constructed by 
plotting absorbance against concentration of perindopril (^g ml"'). Beer's law range 
and molar absorptivity are given in Table 5.1. Regression equations were derived 
using the method of least squares. The correlation coefficients, standard 
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Fig. 5.8. Plot of 1/A X ([D] [A] / [D] + [A]) Vs. 1/[D] + [A] 
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Table 5.1 
Optical characteristics and statistical data of the regression equations 
Parameters Method A Method B 
Beer's law limit (jLig ml"') 10.0-200.0 10.0- 180.0 
Molar absorptivity (I mol"'cm') 2.25x10^ 3.71x10^ 
Linear regression equation A = 4.15x 10"V 5.10x1 Q-'^ C A = -4.43x 10"'' +4.50x 1 Q'^ C 
Sa 4.51x10"' 7.58x10"' 
tSa 1.07x10'^ 1.79x10"^ 
Sb 3.71x10"' 6.93X10-' 
tSb 8.77x10"' 1.64x10"^ 
Correlation coefficient (r) 0.9999 0.9999 
Variance (So^) 2.25x10"' 1.49x10"' 
Detection limit (^g ml"') 0.49 0.90 
Quantitation limit (f^ g ml"') 1.48 2.71 
± t Sa, Confidence limit for intercept. 
± t Sb, Confidence limit for slope. 
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deviation of slope and intercept, variance of calibration line and detection and 
quantitation limits were calculated and listed in Table 5.1. The values of correlation 
coefficient and variance clearly indicated the excellent linearity of calibration graph 
and negligible scattering of the experimental data points around the calibration line, 
respectively. 
Accuracy and precision 
In order to determine accuracy and precision of the proposed procedures 
quality control sample solutions containing three different concentrations (20.0, 
100.0 and 180.0 \x% ml'') were prepared and analyzed in five replicates within one 
day as well as for five consecutive days. The standard deviations (SD), relative 
standard deviations (% RSD), standard analytical error (SAE) and confidence limit 
(CL) were calculated and summarized in Table 5.2. 
Recovery studies 
Recovery experiments were carried out by standard addition method. The 
concentration of perindopril was determined in tablets (Coversyl-2.0, Perigard-2.0) 
after spiking with 50 and 200% of additional drug. It was observed from Table 5.3 
that the methods A and B afforded recoveries in the range of 99.97% - 100.05%. 
Application 
The applicability of the proposed methods for the assay of perindopril in drug 
formulations has been tested on commercially available tablets. The results of the 
proposed methods were statistically compared with those of the reference method 
[12] using point and interval hypothesis tests. Table 5.4 shows that the calculated t-
(paired) and F-values at 95% confidence level are less than the theoretical ones, 
confirming no significant difference between the methods compared. For 
pharmaceutical analysis, a bias of ±2.0% is acceptable and the limit of acceptance 
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Table 5.2 
Evaluation of the accuracy and precision of the two proposed methods 
Proposed methods 
Method A 
Intra day assay 
Inter day assay 
Method B 
Intra day assay 
Inter day assay 
Amount 
(Mgml-') 
Taken 
20.0 
100.0 
180.0 
20.0 
100.0 
180.0 
20.0 
100.0 
180.0 
20.0 
100.0 
180.0 
Found ± SD" 
19.99 ±0.22 
99.96 ±0.16 
180.04±0.26 
19.99 ±0.33 
99.99 ±0.22 
179.88±0.29 
20.01 ±0.30 
100.05 ±0.19 
179.97 ±0.34 
19.97 ±0.46 
100.01 ±0.34 
180.05 ±0.43 
Recovery ± RSD' 
(%) 
99.99± 1.12 
99.96 ±0.16 
100.02±0.15 
99.99 ± 1.64 
99.99 ±0.22 
99.93 ±0.16 
100.05 ± 1.49 
100.05 ±0.19 
99.98 ±0.19 
99.83 ±2.3! 
100.00 ±0.34 
100.03 ±0.24 
SAE" 
0.10 
0.07 
0.12 
0.15 
0.10 
0.13 
0.13 
0.08 
0.15 
0.21 
0.15 
0.19 
C.L."^  
0.28 
0.20 
0.33 
0.41 
0.28 
0.36 
0.37 
0.23 
0.42 
0,57 
0,42 
0.53 
^Mean for five independent analyses. 
SAE, standard analytical error. 
•^ C.L., confidence limit at 95% confidence level and four degrees of freedom (t = 2.776). 
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Table 5.4 
Determination of perindopril in pharmaceutical preparations by the proposed 
methods and reference method [12] 
Formulations Method A Method B 
Recovery RSD 
(%) (%) 
Recovery RSD 
(%) (%) 
Reference method [ 12] 
Recovery RSD 
(%) (%) 
Coversyl2.0 99.93 0.101 100.09 0.165 
(Serdia) eL=0.983 eu=1.016 eL=0.982 00=1.016 
99.92 
t=0.02 F= 1.387 t=0.27 F=1.08 
Perigard2.0 99.80 0.146 100.02 0.093 
(Glenmerck) eL=0,983 eu=1.0]9 eL=0.987 eu=1.011 
t=0.20 F=1.88 t=0.11 F=1.67 
99.94 
0.172 
0.201 
203 
interval is within 9L= 0.98 and 0u= 1.02. It is observed from the Table 5.4 that the 
true bias is well within the acceptance limit at 95 % confidence level. 
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Validated Kinetic Spectrophotometric Metliod for the Determination of 
Metoprolol Tartrate in Pharmaceutical Formulations 
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A kinetic spectrophotometric mettiod lias been described for the determination of metoprolol tartrate in 
pharmaceutical formulations. The method is based on reaction of the drug with alkaline potassium perman-
ganate at 25±1°C. The reaction is followed spectrophotometrically by measuring the change in absorbance at 
610 nm as a function of time. The initial rate and fixed time (at 15.0 min) methods are utilized for constructing 
the calibration graphs to determine the concentration of the drug. Both the calibration graphs are linear in the 
concentration range of 1.46x10"'—8.76x10"'vi (10.0—60.0/ig per 10ml). The calibration data resulted In the 
linear regression equations of log (rate)=3.634+0.999 logC and /l = 6.300xl0"''+6.49lx|0"^ C for initial-rate 
and fixed time methods, respectively. The limits oi quantitation for initial rate and fixed time methods are 0.04 
and O.lO^gmP', respectively. The activation parameters such as £,, 4//*, AS* and 4 0 ' are also evaluated for 
the reaction and found to be 90.73 kJmor' , 88.20 kJmor' , 84.54 JK~'moP' and 63.01 kJmol"', respectively. 
The results are validated statistically and through recovery studies. The method has been successfully applied to 
the determination of metoprolol tartrate in pharmaceutical formulations. Statistical comparison of the results 
with the reference method shows excellent agreement and indicates no significant difference in accuracy and pre-
cision. 
Key words spectrophotometry; metoprolol tartrate; validation parameters; pharmaceutical formulation 
Metoprolol tartrate is a iBciective /3-adrenergic antagonist, 
which is used in the treatment of cardiovascular disorders 
such as hypertension, angina pectoris, cardiac arrhythmias 
and myocardial infarction. The drug is quite sensitive, even a 
small dose of the drug gives sufficient blockade. Since the /?-
blockers are also misused as doping agents in sports and 
therefore these drugs have been added to the list of forbidden 
drugs by the International Olympic Committee (IOC)." 
Therefore the development of an analytical method for the 
determination of metoprolol tartrate is of great significance. 
The assay of the drug is listed in the monograph of British 
Pharmacopoeia, which describes a potentiometric titration 
method.^ ^ Several analytical methods have been developed 
for the determination of metoprolol in biological fluids and 
pharmaceutical formulations based on high performance liq-
uid chromatography,-'"'" gas chromatography,'^''^' capillary 
electrophoresis,'"*' thin layer chromatography,"'" infrared 
spectroscopy,'"and electrochemical methods."'" The above 
mentioned techniques are sensitive but expensive and require 
laborious clean up procedure prior to analysis. Spectropho-
tometry is the technique of choice even today due to its in-
herent simplicity and therefore frequently used in the labora-
tories of the developing countries to overcome versatile ana-
lytical problem. The drug has been determined in the visible 
region based on ion-pair formation between drug and 
reagents like oxidized quercetin^"'; bromophenol blue, 
bromocresol purple, bromocresol green^"; benzyl orange^^'; 
bromothymol blue^^'; and carbon disulfide-copper chloride.^''' 
The charge transfer complexation reactions of metoprolol 
tartrate with a and ;r-acceptors^'*'"' have also been utilized 
for its quantification in pharmaceutical formulations. Shing-
bal and Bhangle^*' have reported a spectrophotometric 
method based on the reaction of drug with 2,4-dinitrofluo-
robenzene in HCl/dioxan medium to form a colored chro-
mophore, which absorbs maximally at 380 nm. The quantifi-
cation of metoprolol tartrate was done on treatment of the 
drug with ammonium metavanadate,"' FeClj,^ **' A/-bromosuc-
cinimide,^" and a mixture of KNO3 and H2SO4 followed by 
addition of alkali to get colored chromophore.-"" The litera-
ture is still poor in analytical procedures based on kinetic 
spectrophotometry for the determination of drug in pharma-
ceutical preparations. There is, therefore, a need for a simple 
and sensitive kinetic spectrophotometric method for the de-
termination of metoprolol tartrate in pharmaceutical formu-
lations. It was found that potassium permanganate oxidizes 
the metoprolol in alkaline medium and this reaction has not 
been used before to quantify the drug spectrophotometrically. 
This paper describes a simple and sensitive kinetic spec-
trophotometric method for the determination of metoprolol 
tartrate in drug formulations. The method involves the oxida-
tion of drug with alkaline potassium permanganate at 
25±1°C and subsequent measurement of absorbance at 
610nm. The initial rate and fixed time methods are adopted 
for its determination in pharmaceutial formulations. 
Experimental 
Apparatus A Shimadzu UV-visible spectrophotometer (model-1601, 
Japan) with matched quartz cells was used to measure absorbance. 
A water bath shaker (NSW 133, New Delhi, India) was used to control the 
heating temperature for color development. 
Reagents and Standards All reagents and chemicals used were of ana-
lytical or pharmaceutical grade. Aqueous solutions of 0.6 M sodium hydrox-
ide and 0.015 M potassium permanganate (GR Grade, Merck Limited, Mum-
bai, India) were prepared in doubly distilled water. Potassium permanganate 
(GR Grade, Merck Limited, Mumbai, India) solution should be freshly pre-
pared and its apparent purity was assayed by titrimetric method."' 
The standard test solution of metoprolol tartrate (0.01%) was prepared in 
doubly distilled water. The formulated dosage forms of metoprolol tartrate 
such as betaloc (AstraZeneca Pharma India Ltd., Bangalore, India), metapro 
(Cardicare, Bangalore, India) and metolar (Cipla, Mumbai, India) were pur-
chased from the local market. 
Determination Procedures for Metoprolol Tartrate Initial-Rate 
Method: Aliquots of 0.1—0.6ml of 0.01% metoprolol tartrate were pipetted 
into a series of 10 ml standard flasks. To each flask 2,0 ml of 0.60 M NaOH 
followed by 2.0ml of 0.015M potassium permanganate were added and then 
diluted with doubly distilled water at 25± 1 °C. The contents of each flask 
* To whom correspondence shou,ld be addressed, e-mail: nrahman05@yahoo.com ) 2005 Pharmaceutical Society of Japan 
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were mixed well and the increase in absorbance was recorded as a function 
of time at 610nm. The initial rate of the reaction (v) at different concentra-
tions was obtained from the slope of the tangent to the absorbance-time 
curve. The calibration graph was constructed by plotting the logarithm of the 
initial rate of reaction (log v) versus the logarithm of the molar concentration 
of the metoprolol tartrate (logC). The amount of the drag was computed ei-
ther from the calibration graph or the regression equation. 
Fixed-Time Method: The absorbance of each drug sample solution was 
measured at 610 nm against a reagent blank prepared similarly at a prese-
lected fixed time of 15min. The calibration curve was constructed by plot-
ting the absorbance against the final concentration of the drug. The amount 
of the drug was computed either from calibration curve or regression equa-
tion. 
Determination Procedure for Metoprolol Tartrate in Piiarmaceutical 
Formulations Five tablets were weighed and powdered. The powder 
equivalent to 50 mg of active ingredient was weighed accurately, stirred well 
with doubly distilled water and filtered through Whatman No. 42 filter paper 
(Whatman International Limited, Kent, U.K.). The residue was washed well 
with doubly distilled water for complete recovery of the drug. The content of 
the dmg was then diluted to 250.0 ml with doubly distilled water. It was fur-
ther diluted according to the need and subjected to the determination proce-
dures for metoprolol tartrate. The percent recovery of the metoprolol tartrate 
was calculated from the corresponding linear regression equations or cali-
bration graphs. 
Procedure for Reference Method Into a series of 10 ml standard volu-
metric flask, different volumes (0.25—2.5 ml) of 0.01% drug (0.1 mgml ') 
solution were pipetted and diluted to volume with doubly distilled water. 
The absorbance was measured against the solvent blank at 224 nm. The 
amount of the drug in a given sample was computed from the calibration 
equation. 
Results and Discussion 
Spectral Studies The absorption spectrum of metopro-
lol tartrate solution in doubly distilled water shows two ab-
sorption bands peaking at 194 and 224 nm while that of 
potassium permanganate solution in the alkaline medium ex-
hibits an absorption band peaking at 530 nm. The addition of 
potassium permanganate to the solution of pure drug pro-
duces a new characteristics band at 610 nm. This band is at-
tributed to the formation of manganate ion, which resulted 
on reduction of potassium permanganate in alkaline medium. 
The intensity of the colored product increases with tirne and 
therefore, a kinetic method was developed for the determina-
tion of metoprolol tartrate in drug formulations. Moreover, 
potassium permanganate also oxidizes metoprolol in acid 
medium resulting in the formation of a-hydroxy metoprolol 
and Mn(II). In the presence of acid such as H2SO4, HCl and 
H3PO4, a-hydroxy metoprolol gives a violet color which has 
not been utilized for quantitative analysis, 
Stoichiometry and Reaction Mechanism The stoichio-
metric ratio between metoprolol tartrate and potassium per-
manganate was established using limiting logarithmic 
method^ '^ by performing two sets of experiments. In the first 
set, the concentration of metoprolol tartrate was varied keep-
ing a constant concentration of KMn04. In the second set of 
experiment, concentration of metoprolol tartrate was kept 
constant while varying the concentration of KMn04. The 
logarithm of the absorbance was plotted against the loga-
rithm of the respective varied concentration of metoprolol 
tartrate or KMn04 (Figs. 1 a, b). It is evident from the slopes 
of the two straight lines that the combining molar ratio be-
tween metoprolol tartrate and KMn04 is ] : 1. 
Horai et al. have suggested that the metoprolol tartrate un-
dergoes oxidation^^' resulting in the formation of a-hydroxy 
metoprolol. In this study, the potassium permanganate oxi-
dizes the metoprolol tartrate in alkaline medium producing 
-4.8 -AA -40 -3.6 -32 
Log IDrugl or [KMnO,] 
Fig, 1. Limiting Logarithmic Plot for Stoichiometric Ratio between 
Metoprolol Tartrate and KMn04 (a) log A vs. log[drug] and (b) log/f vs. 
loglKMnOJ 
0 04 0.06 0 08 0 10 
Molar concentration of NaOH 
Fig. 2. Effect of the Molar Concentration of NaOH Solution on the Initial 
Rate of Reaction with 60,0/tg per 10 ml Metoprolol Tartrate in Doubly Dis-
tilled Water 
a-hydroxy metoprolol and itself reduced to Mn04", The re-
action product gives violet color on treating with formalde-
hyde-sulfuric acid reagent, which confirmed the formation of 
a-hydroxy metoprolol.^''' 
Optimization ofVariables The influence of the concen-
tration of NaOH solution on the rate of reaction was studied 
by keeping the constant concentrations of metoprolol tartrate 
(8.76X1 0"^M) and KMn04 (S.OOXIO-^M) and varying the 
concentration of NaOH (1.20X 10^^—1.32X 10"'M) in a 
final volume of 10 ml solution. Figure 2 shows that the initial 
rate of reaction increased up to 8 ,4X10"^M NaOH; beyond 
this concentration the initial rate of reaction remained con-
944 Vol. 53, No, 8 
0.0005 0.0010 0.0015 0.0020 0 0025 0.0030 0 0035 
Molar ooncentration of KMnO^ 
Fig. 3. Effect of the Molar Concentration of KMn04 Solution on the Ini-
tial Rate of Reaction with 60.0/ig per 10 ml Metoprolol Tartrate in Doubly 
Distilled Water 
stant. Therefore, a concentration of 1.20X10"' M NaOH was 
used throughout the experiment. The effect of the concentra-
tion of KMn04 solution on the initial rate of the reaction was 
studied in the range of 7.SOX 10""—3.30x 10'^ M. The initial 
rate of reaction (Fig. 3) increased with increasing the concen-
tration of KMn04 and became constant at 2 . 4 0 X 1 0 ~ ' M . 
Thus, a concentration of 3 .00X10~^M KMnO^ in the final 
solution proved to be sufficient for the maximum concentra-
tion of metoprolol tartrate used in the determination process. 
The effect of temperature on reaction rate was studied in the 
range of 298—308 K. The absorbance-time curves showed 
the temperature dependence of the reaction rate. It was ob-
served that metoprolol tartrate reacts faster with potassium 
permanganate within the short period of 3—15min, 3— 
lOmin and 3—7min. at 298, 303 and 308 K, respectively. At 
temperatures >308K, the decomposition of the reaction 
product may take place. To avoid this and for the sake of 
good results, the optimum temperature of 298 K is selected 
for the determination process. 
Analytical Data and Method Validation Under the op-
timized experimental conditions, a pseudo-order reaction 
condition was worked out by using a large excess of KMn04 
and NaOH solution with respect to the initial concentration 
of metoprolol tartrate. As a result, a pseudo zero order condi-
tion was obtained with respect to the reagents, the overall 
concentration change of KMn04 and NaOH during the 
course of reaction would be negligible. The initial rates of 
the reaction were determined from the slopes of the initial 
tangent to the absorbance-time curves (Fig. 4) and are sum-
marized in Table 1. The reaction would obey the following 
rate equation: 
r a t e = * ^ 
where k^ is the pseudo-order rate constant, C is the concen-
tration of metoprolol tatrate, n is the order of the reaction. 
The logarithm form of the above equation is written as: 
04 -
0.3 • 
02 • 
01 -
no 1 
- • - a 
^^d 
I^r 
- ^ 9 
^ ^ 
Time (min) 
Fig. 4. Absorbance-Time Curves for the Reaction between Metoprolol 
Tartrate and ICMnO^ in Aqueous Medium: 2.0 ml of 0 . 0 1 5 M KMnO, and 
Metoprolol Tartrate: (a) 1.0, (b) 1.5, (c) 2.0, (d) 3.0, (e) 4.0, (f) 5.0 and (g) 
6.0^gml '. Each Set is Diluted in 10ml Standard Flask with Doubly Dis-
tilled Water 
Table I. Summary of Data of the Initial Rate of Reaction at Different 
Concentration of Metoprolol Tartrate and K.Mn04 
[Drug] (moll ') [KMnOjKmoll Initial rate of reaction, V'(mol 1 ' min ') 
1.460X10"'' 
2.190X10 ' 
2.920X10 ' 
4,380X10 ' 
5.840X10 ' 
7.300X10 ' 
8.760X10 ' 
8,760X10" 
8,760X10 ' 
8,760X10 '' 
8,760X10 ' 
8.760X10" 
8.760X10" 
3.000X10 ' 
3.000X10 ' 
3.000X10 ' 
3.000X10 •' 
3.000X10 ' 
3.000X10 ' 
3.000X10 ' 
7.500X10 " 
9.000X10 " 
1.200X10 ' 
1.800X10 -' 
2.100X10^ 
2.400X10 ' 
6.250X10 ' 
9.375X10 ^ 
1.270X10 ' 
1.880X10 ' 
2.500X10 • 
3.100X10 ' 
3.800X10" 
8.000X10 ' 
1.130X10 ' 
1.860X10 ' 
2.660X10 ' 
2.830X10 ' 
3.800X10"^ 
log(rate)=log^,p+/ilogC 
The linear regression analysis using the method of least 
square treatment of calibration data was made to evaluate 
slope, intercept and correlation coefficient. Under the work-
ing experimental conditions, a calibration graph was con-
structed by plotting log of initial rate of reaction (log v) ver-
sus log of metoprolol tartrate concentration (log Q, which 
showed a linear relationship over the concentration range of 
10.0—60.0/ig per 10 ml. The regression of log rate versus 
log C gave the following linear regression equation: 
log(rate)=3.634+0.999 log C 
with a correlation coefficient (r) of 0.9999. The value of n in 
regression equation confirmed that the reaction is first order 
with respect to metoprolol tartrate. The confidence limits for 
August 2005 
Table 2. Summary of Optical Characteristics and Statistical Data for the Fixed-Time Method 
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Parameters 
Beer's law limit (/Jg per 10 ml) 
Molar absorptivity (1 mol ' cm ') 
Regression equation 
V' 
Intercept 
5. 
-IS, 
Slope 
\ 
i ' \ 
Correlation coefficient (r) 
Variance {S^,) 
Detection limit (/igml ') 
Quantitation limit (/ig m l ' ) 
3 min 
10.0—60.0 
9.133X10' 
/(=1.0IX10 •' + 
1.324X10 'C 
5.80X10 ' 
l.OIXIO ' 
4.70X10 " 
1.208X10 ' 
1.324X10 ' 
1.30x10" 
3.342X10 ' 
0.9997 
3.364X10 ' 
0.15 
0.44 
6min 
10.0—60.0 
2.192X10' 
/(=6.9XI0 ' + 
3.178X10 'C 
7.80X10 ' 
6.9X10 * 
6.20X10 * 
1.594X10 ' 
3.178X10 ' 
1.70xi0 ' 
4.371X10 ' 
0.9999 
6.084X10 ' 
0.08 
0.25 
Fixed-lime method 
9 min 
10.0—60-0 
3.151XIO' 
/4=7.9XI0 •• + 
4,580x10 'C 
6.30X10 ' 
7.9X10 ' 
5.10X10 ' 
1.311X10 •' 
4.580X10"' 
1.40X10 ' 
3.599X10 ' 
0.9999 
3.969X10 ' 
0.05 
0.14 
12 min 
10.0—60.0 
3 973X10' 
/ (= -172X IO '-I 
5 831X10 ' C 
1.04X10 ' 
-1.72X10 ' 
8.31X10 ' 
1.697X10 ' 
5.831X10 ' 
2 30X10 ' 
5913X10 ' 
09999 
I.082XU) » 
0.06 
0.18 
15 min 
10 0—60.0 
4.453X10' 
/ I=6.3XI0 ' + 
6,491X10 ' C 
6.60X10 ' 
6.3X10 ' 
5.30X10 ' 
1.363X10 ' 
6491X10 ' 
1.50x10 ' 
3.857X10 ' 
0.9999 
4.356X10 ' 
0.03 
0.10 
Reference 
method 
25.0—250.0 
2 028X10' 
/(==107X10 ' + 
2,940X10 ' C 
7,00X10 ' 
1,07X10 ' 
5,00X10 ' 
1,286X10'' 
2,940X10 • 
4,00X10 ' 
1,03x10 ' 
0,9999 
4,900X10 ' 
0,08 
0,24 
a) Calculated t-value, which is less than the theoretical value of ((2.776) for n-l degrees of freedom. 
the slope of the line of regression and intercept were com-
puted using the relation b±lS^, and a±tS^^^'' at 95% confi-
dence level and found to be 0.999± 1.45X10"' and 
3.634±2.60XI0"^ respectively. This indicated the high re-
producibility of the proposed method. The limits of detection 
(LOD) and quantitation (LOQ) were evaluated using the fol-
lowing equation; 
LOD=3.3X5'„/i atid LOQ=10X5(/6 
where Sg is the standard deviation of the calibration line and 
b is the slope and found to be 1.3x10"^ and 
4.0X10"'^/igmr', respectively. The variance was calculated 
using the equation: 
X(i°g' • log v„.r 
and found to be 1.576X10~'^gmr'. The low value of vari-
ance indicated negligible scattering of the experimental data 
points around the line of regression. 
In the fixed-time method, the absorbance of green colored 
solution obtained on interaction of different concentration of 
metoprolol tartrate with alkaline potassium permanganate 
was measured at a preselected fixed time. Calibration plots of 
absorbance versus initial concentrations of metoprolol tar-
trate were established at a fixed time of 3, 6, 9, 12 and 
15 min. The molar absorptivity, regression equations, coeffi-
cient of correlation, limits of detection and quantitation and 
variance are given in Table 2. It is clear from Table 2 that the 
most acceptable values of molar absorptivity, limit of detec-
tion and quantitation were obtained at a fixed time of 15 min. 
Therefore, the fixed time of 15 min was adopted as the opti-
mum time for the determination of metoprolol tartrate in 
pharmaceutical formulations. The important analytical para-
meters of conventional UV spectrophotometric method have 
been summarized in Table 2. It can be seen that the molar ab-
sorptivity of the fixed time method is higher than that of con-
ventional UV spectrophotometric method whereas the limits 
of detection and quantitation of the proposed method are 
smaller. The performance of the initial rate method is better 
since the values of LOD and LOQ are smaller than that of 
the fixed time method and analysis can be completed in a 
shorter time. 
Solution Stability and Selectivity The solution stability 
of metoprolol tartrate was checked by observing UV spectra 
of metoprolol tartrate for 5 d. The aqueous solution of the 
drug having two A,^ ^^ ; 194 and 224 nm, showing no change 
in the absorption spectra of standard and sample solutions of 
drug for at least 5 d, when the solutions were stored at room 
temperature. To identify the metoprolol and a-hydroxy meto-
prolol, thin layer chromatography was performed. The stan-
dard solution, sample solution and reaction product were ap-
plied on TLC plates coated with silica gel and developed in 
ethyl acetate-methanol-ammonia (40: 5 : 5 v/v/v) solvent 
system. The plates were air-dried and spots were detected in 
the iodine chamber In the case of standard and sample solu-
tions, a single spot was observed with Rf=0.50 correspond-
ing to metoprolol, whereas reaction product also showed one 
spot with Rf=0.65. This corresponds to a-hydroxy metopro-
lol.'"'' Thus, the proposed methods are selective as the major 
metabolite, a-hydroxy metoprolol does not interfere in the 
determination. However, other /3-adrenergic antagonists such 
as propranolol, atenolol and labetalol react with potassium 
permanganate in alkaline medium resulting in the formation 
of green colored solution, which absorbs maximally at 
610nm. 
Accuracy and Precision The accuracy and precision of 
the proposed methods was established by measuring the con-
tent of metoprolol tartrate in pure form at three different con-
centration levels (low, medium and high). The short-term 
(intra day assay) and the daily precisions (inter day assay) 
were performed by measuring five independent analyses at 
1.5, 3.0 and 6 .0/ igmr ' concentration levels within 1 d and 
on 5 consecutive days, respectively (Table 3). The standard 
deviation, relative standard deviation and mean percent re-
coveries obtained by both the initial rate and fixed time meth-
ods can be considered to be very satisfactory. 
The validity of the proposed methods was also checked by 
performing recovery experiments through standard addition 
method. For this, a known amount of the pure drug was 
added to preanalysed dosage forms and then the total amount 
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Table 3. Test of Precision of the Proposed Methods by Intra Day and Inter 
Day Assays 
Proposed 
methods 
Initial rate method 
Intra day assay 
Inter day assay 
Fixed time method 
Intra day assay 
Inter day assay 
Talcen 
1.5 
3.0 
6.0 
1.5 
3.0 
6.0 
1,5 
3,0 
6.0 
1,5 
3.0 
6,0 
Amount 
( / jgml ' ) 
Found ± 5,0," 
1,50+0,04 
3.00 
6.01 
1,50 
2,99 
6,00 
t0.06 
t:0.06 
t0,04 
t0.06 
£0,06 
1,50+0,04 
2.99 + 0.05 
6.01+0.05 
1,50+0,06 
2,99+0,06 
6.00+0.07 
Recovery 
(%) 
100,03 
100,06 
100.13 
100.14 
99.95 
100,07 
100,21 
99,93 
100,15 
100,01 
99.93 
100,04 
SAE'" 
0,02 
0,03 
0.03 
0.02 
0.03 
0,03 
0,02 
0.02 
0.02 
0.03 
0,03 
0.03 
C.L.'-i 
0,05 
0,07 
0,07 
0.05 
0.07 
0.07 
0,06 
0.06 
0.06 
0.07 
0.07 
0.08 
a) Mean for five independent analyses, b) SAE, standard analytical error c) 
C,L,, confidence limit at 95% confidence level and four degrees of freedom (/ = 2,776), 
of metoprolol tartrate was determined following the recom-
mended procedures and reference method. The results are 
summarized in Table 4, which showed recoveries in the range 
of 100.02—100.13%, 99.99—100.15% and 99.94—100.11% 
for initial rate, fixed time and reference methods, respec-
tively. No interference from the common excipients was ob-
served. 
Robustness The conditions are very robust for the appli-
cation of the proposed methods to determine the active drug 
in pharmaceutical formulations. Each operational parameter 
was checked and challenged for the robustness of the meth-
ods. The operational parameters investigated were: 
• volume of 0.015 M KMnO^ (±0,2 ml) 
• volume of 0 .60 M NaOH (±0.2 ml) 
Under these conditions a sample solution containing 
6.0/ igmr ' (Metalor 25, Cipla) of active metoprolol tartrate 
was assayed five times by the initial rate and fixed time meth-
ods. The values of mean recovery, standard deviation and rel-
ative standard deviation represent good reliability of the pro-
posed methods. 
The effect of temperature on reaction rate is well known 
and important in understanding the various activation para-
meters of the reaction products. In order to evaluate the ap-
parent activation parameters, the reaction rate was studied 
at 298, 303, and 308K at [metoprolol]=1.46X lO"*"— 
8.76XI0""''M, [KMnO4] = 3.00xl0"^M and [NaOH]=l.20x 
10''M. 
Arrhenius curve (Fig. 5) was constructed by plotting logk 
versus l/fand found to be linear with coefficient of correla-
tion, r= - 0.9998, Activation energy (£J can be calculated 
from the slope (-EJ2303R) and A from the intercept of the 
Arrhenius curve and found to be 90.73 kJinoP' and 
4.75X10", respectively. The other activation parameters 
such as enthalpy, entropy and free energy of activation of the 
reaction product were calculated using Eyring equation: 
AH'-k 4S» 
log — = \og(kJh) + — 
T \ ^^ ^ > 2.303« 
0 00324 0.00326 0 00328 0.00330 0.00332 0 00334 0 00336 0 00338 
1/T(K) 
Fig. 5. Arrhenius Plot: log<r versus l/Tfor Activation Energy 
1 
2,303/; T 
The plot oi\ogklT versus l/7'(Fig, 6) was linear with cor-
0 00324 0,00326 0,00328 0 00330 0.00332 0 00334 0.00336 0 00338 
1/T{K) 
Fig, 6. Eyring Plot; logA/Z'v'crau.v 1/7" for zJW'and 4 5 ' 
relation coefficient of -0,9999, 4 / / ' was evaluated from the 
slope (-zl/-/V2,303/?) and AS^ from the intercept 
[log(V/') + ^'5''/2,303j^] of the compiled Eyring plot. The 
values of 4 / / ' and 4 5 ' were found to be 88,20 kJmol"' and 
84,54 J K ' ' moP', respectively. The Gibbs free energy of ac-
tivation was determined by AG^=AH^-TAS^ at 298K and 
foundtobe-63,01 kJiuoP', 
Applicability of the Proposed Methods The proposed 
methods (initial rate and fixed time methods) were success-
fully applied to the determination of metoprolol tartarte in 
pharmaceutical formulations. The results of the proposed 
methods were statistically compared with those of the refer-
ence method using point hypothesis test. Table 5 shows that 
the calculated t- (paired) and F-values at 95% confidence 
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Table 4. Summary of Data for the Determination of Metoprolol Tartrate in I'liarmaceutical Preparations by Standard Addition Method 
Preparations"' 
Amount 
( / rgmr ' ) 
Initial rate method Fixed time method Reference method 
FoundtS.D"' Recovery Found±S.D."' Recovery „ Found±S.D.°' Recovery 
Taken Added (/Jgml ') (%) ^ ^ ' ^ (/Jgml ') (%) ^^^ ^'^^ (/igml ') (%) ^'^^ ^ ' " 
Betaloc-25 3.0 
(AstraZeneca) 3.0 
Metapro-25 3.0 
(Cardicare) 3.0 
Metolar-25 3.0 
(Cipla) 3.0 
1.0 4.00 + 0.06 100.05 0.03 0.07 3.99i0.06 
3.0 6.00±0.08 100.02 0.04 0.10 (i.0l±0.05 
1.0 4.01+0.05 100.13 0.02 0.06 4.01 ±0.06 
3.0 6.00+0.07 100.07 0.03 0.09 6.01 ±0.05 
1.0 4.00+0.05 100.06 0.02 0.06 3.99±0.05 
3.0 6.00±0.06 100.02 0.03 0.07 6.00+0.05 
99.99 0.03 0.07 4.00±0.05 
100.09 0.02 0.06 5.99±0.05 
100.14 0.03 0.07 3.99±0.09 
100.15 0.02 0.06 6.01 ±0.06 
99.99 0.02 0.06 4.00±0.05 
100.04 0.02 0.06 6.00±0.07 
100.11 0.02 0.06 
99.94 0.02 0.06 
99.94 0.04 0.11 
100.17 0.03 0.07 
100.11 0.02 0.06 
100.05 0.03 0.09 
0) Mean for five independent analyses. 
Table 5. Comparison of the Proposed Methods Using Point and Interval Hypothesis Tests with the Reference Method at 95% Confidence Level 
Initial rate method Fixed time method 
Formulations"' Recovery RBD"' /- F-
(%) (%) value"' value'" 
Recovery RSD°' (- F-
(%) (%) value'" value'" "u 
Reference method 
Recovery R.S.D."' 
{%) (%) 
Betaloc-25 
(AstraZeneca) 
Metapro 
(Cardicare) 
Metolar 
(Cipla) 
100.02 0.99 0.23 
100.07 1.16 0.23 
100.13 0.93 0.18 
1.55 0.994 1.008 100.15 1.14 0.55 
1.53 0.988 1.010 100.04 0.82 0.37 
1.55 0.989 1.012 99.99 0.83 0.13 
2.06 0.992 1.012 99.94 0.80 
1.32 0.990 1.008 100.17 0.94 
1.92 0.986 1.013 100.05 1.15 
a) Mean for five independent analyses, h) ThcorcticaW-valuc (v=8) and f-valuc (v=4, 4) ai 95% confidence level arc 2.306 and 6.39, respectively, c) In pharmaceutical 
analysis, a bias, based on recovery experiments, of ±2% (8^=0.98 and 8^= 1.02) is acceptable. 
level are less than the theoretical ones, confirming no signifi-
cant differences between the performance of the proposed 
methods and the reference method. The previous investiga-
tions were also checked and confirmed by interval hypothesis 
tests.'^' The Canadian Health Protection Branch has recom-
mended that a bias, based on recovery experiments, of ±2% 
is acceptable."^ It is evident ft-om Table 6 that the true bias of 
all samples of drug is smaller than ±2%. 
Conclusion 
Initial rate and fixed time methods are applied for the rou-
tine quality control analysis of metoprolol tartrate in pharma-
ceutical formulations. The proposed method does not require 
any laborious clean up procedure prior to analysis and there-
fore, can be fi-equently used in the laboratories of research, 
hospitals and pharmaceutical industries. It has extremely 
high sensitivity, selectivity and low limit of detection. 
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